,Start Date,Start Price,End Date,End Price,Weekly Returns,Bin Label,News,Basics
0,2023-01-08,109.61644744873047,2023-01-15,107.1442642211914,-0.022553031822120873,D3,[],{}
1,2023-01-15,107.1442642211914,2023-01-22,104.9393310546875,-0.020579105960837896,D3,[],{}
2,2023-01-22,104.9393310546875,2023-01-29,100.58673095703125,-0.04147729982562931,D5,[],{}
3,2023-01-29,100.58673095703125,2023-02-05,98.25773620605469,-0.02315409526502521,D3,[],{}
4,2023-02-05,98.25773620605469,2023-02-12,103.63164520263672,0.05469196832819856,U5+,[],{}
5,2023-02-12,103.63164520263672,2023-02-19,104.53843688964844,0.008750142731388744,U1,[],{}
6,2023-02-19,104.53843688964844,2023-02-26,104.89160919189453,0.003378396623807456,U1,[],{}
7,2023-02-26,104.89160919189453,2023-03-05,102.01851654052734,-0.027391062769482333,D3,[],{}
8,2023-03-05,102.01851654052734,2023-03-12,102.79167938232422,0.007578652072339542,U1,[],{}
9,2023-03-12,102.79167938232422,2023-03-19,100.05579376220703,-0.026615827628823086,D3,[],{}
10,2023-03-19,100.05579376220703,2023-03-26,100.72860717773438,0.006724382369364346,U1,[],{}
11,2023-03-26,100.72860717773438,2023-04-02,102.25682830810547,0.015171669431252699,U2,[],"{""assetTurnoverTTM"": 0.5369, ""bookValue"": 46834, ""cashRatio"": 0.4196532791491937, ""currentRatio"": 1.444, ""ebitPerShare"": 1.2462, ""eps"": 1.1102, ""ev"": 291024.25, ""fcfMargin"": 0.0229, ""fcfPerShareTTM"": 4.4383, ""grossMargin"": 0.731, ""inventoryTurnoverTTM"": 2.7101, ""longtermDebtTotalAsset"": 0.2604, ""longtermDebtTotalCapital"": 0.3619, ""longtermDebtTotalEquity"": 0.5994, ""netDebtToTotalCapital"": 0.2712, ""netDebtToTotalEquity"": 0.4492, ""netMargin"": 0.1947, ""operatingMargin"": 0.2186, ""payoutRatioTTM"": 0.5464, ""pb"": 5.7647, ""peTTM"": 20.7203, ""pfcfTTM"": 23.9731, ""pretaxMargin"": 0.252, ""psTTM"": 4.6655, ""ptbv"": 10.008, ""quickRatio"": 1.1906, ""receivablesTurnoverTTM"": 5.7174, ""roaTTM"": 0.1209, ""roeTTM"": 0.2887, ""roicTTM"": 0.1714, ""rotcTTM"": 0.2045, ""salesPerShare"": 5.7013, ""sgaToSale"": 0.269, ""tangibleBookValue"": 26977, ""totalDebtToEquity"": 0.6565, ""totalDebtToTotalAsset"": 0.2852, ""totalDebtToTotalCapital"": 0.3963, ""totalRatio"": 1.7682, ""period"": ""2023-03-31""}"
12,2023-04-02,102.25682830810547,2023-04-09,107.96605682373047,0.05583224719646873,U5+,[],"{""assetTurnoverTTM"": 0.5369, ""bookValue"": 46834, ""cashRatio"": 0.4196532791491937, ""currentRatio"": 1.444, ""ebitPerShare"": 1.2462, ""eps"": 1.1102, ""ev"": 291024.25, ""fcfMargin"": 0.0229, ""fcfPerShareTTM"": 4.4383, ""grossMargin"": 0.731, ""inventoryTurnoverTTM"": 2.7101, ""longtermDebtTotalAsset"": 0.2604, ""longtermDebtTotalCapital"": 0.3619, ""longtermDebtTotalEquity"": 0.5994, ""netDebtToTotalCapital"": 0.2712, ""netDebtToTotalEquity"": 0.4492, ""netMargin"": 0.1947, ""operatingMargin"": 0.2186, ""payoutRatioTTM"": 0.5464, ""pb"": 5.7647, ""peTTM"": 20.7203, ""pfcfTTM"": 23.9731, ""pretaxMargin"": 0.252, ""psTTM"": 4.6655, ""ptbv"": 10.008, ""quickRatio"": 1.1906, ""receivablesTurnoverTTM"": 5.7174, ""roaTTM"": 0.1209, ""roeTTM"": 0.2887, ""roicTTM"": 0.1714, ""rotcTTM"": 0.2045, ""salesPerShare"": 5.7013, ""sgaToSale"": 0.269, ""tangibleBookValue"": 26977, ""totalDebtToEquity"": 0.6565, ""totalDebtToTotalAsset"": 0.2852, ""totalDebtToTotalCapital"": 0.3963, ""totalRatio"": 1.7682, ""period"": ""2023-03-31""}"
13,2023-04-09,107.96605682373047,2023-04-16,110.83028411865234,0.026528960852929107,U3,[],"{""assetTurnoverTTM"": 0.5369, ""bookValue"": 46834, ""cashRatio"": 0.4196532791491937, ""currentRatio"": 1.444, ""ebitPerShare"": 1.2462, ""eps"": 1.1102, ""ev"": 291024.25, ""fcfMargin"": 0.0229, ""fcfPerShareTTM"": 4.4383, ""grossMargin"": 0.731, ""inventoryTurnoverTTM"": 2.7101, ""longtermDebtTotalAsset"": 0.2604, ""longtermDebtTotalCapital"": 0.3619, ""longtermDebtTotalEquity"": 0.5994, ""netDebtToTotalCapital"": 0.2712, ""netDebtToTotalEquity"": 0.4492, ""netMargin"": 0.1947, ""operatingMargin"": 0.2186, ""payoutRatioTTM"": 0.5464, ""pb"": 5.7647, ""peTTM"": 20.7203, ""pfcfTTM"": 23.9731, ""pretaxMargin"": 0.252, ""psTTM"": 4.6655, ""ptbv"": 10.008, ""quickRatio"": 1.1906, ""receivablesTurnoverTTM"": 5.7174, ""roaTTM"": 0.1209, ""roeTTM"": 0.2887, ""roicTTM"": 0.1714, ""rotcTTM"": 0.2045, ""salesPerShare"": 5.7013, ""sgaToSale"": 0.269, ""tangibleBookValue"": 26977, ""totalDebtToEquity"": 0.6565, ""totalDebtToTotalAsset"": 0.2852, ""totalDebtToTotalCapital"": 0.3963, ""totalRatio"": 1.7682, ""period"": ""2023-03-31""}"
14,2023-04-16,110.83028411865234,2023-04-23,110.88796997070312,0.0005204881726101895,U1,[],{}
15,2023-04-23,110.88796997070312,2023-04-30,110.98407745361328,0.0008667079299544689,U1,[],{}
16,2023-04-30,110.98407745361328,2023-05-07,113.10822296142578,0.019139191463751315,U2,[],{}
17,2023-05-07,113.10822296142578,2023-05-14,112.58920288085938,-0.004588703340723588,D1,[],{}
18,2023-05-14,112.58920288085938,2023-05-21,111.0032958984375,-0.014085782134012126,D2,[],{}
19,2023-05-21,111.0032958984375,2023-05-28,106.7550048828125,-0.03827175563788643,D4,[],{}
20,2023-05-28,106.7550048828125,2023-06-04,108.14867401123047,0.013054836444884588,U2,[],{}
21,2023-06-04,108.14867401123047,2023-06-11,106.40900421142578,-0.016085909658254627,D2,[],{}
22,2023-06-11,106.40900421142578,2023-06-18,105.7750244140625,-0.005957952544162648,D1,[],{}
23,2023-06-18,105.7750244140625,2023-06-25,110.88379669189453,0.04829847410702026,U5,[],{}
24,2023-06-25,110.88379669189453,2023-07-02,111.64818572998047,0.006893604484069948,U1,[],"{""assetTurnoverTTM"": 0.5443, ""bookValue"": 38693, ""cashRatio"": 0.24194237838762075, ""currentRatio"": 1.2814, ""ebitPerShare"": -2.0335, ""eps"": -2.3533, ""ev"": 324045.75, ""fcfMargin"": 0.1822, ""fcfPerShareTTM"": 4.264, ""grossMargin"": 0.7345, ""inventoryTurnoverTTM"": 2.7234, ""longtermDebtTotalAsset"": 0.3261, ""longtermDebtTotalCapital"": 0.4507, ""longtermDebtTotalEquity"": 0.8806, ""netDebtToTotalCapital"": 0.4134, ""netDebtToTotalEquity"": 0.8077, ""netMargin"": -0.3974, ""operatingMargin"": -0.3434, ""pb"": 7.5671, ""peTTM"": 94.116, ""pfcfTTM"": 27.0405, ""pretaxMargin"": -0.3548, ""psTTM"": 5.0213, ""ptbv"": 15.3876, ""quickRatio"": 1.0279, ""receivablesTurnoverTTM"": 5.6413, ""roaTTM"": 0.029, ""roeTTM"": 0.0707, ""roicTTM"": 0.0408, ""rotcTTM"": 0.0716, ""salesPerShare"": 5.9216, ""sgaToSale"": 0.2655, ""tangibleBookValue"": 19028, ""totalDebtToEquity"": 0.9539, ""totalDebtToTotalAsset"": 0.3533, ""totalDebtToTotalCapital"": 0.4882, ""totalRatio"": 1.5883, ""period"": ""2023-06-30""}"
25,2023-07-02,111.64818572998047,2023-07-09,105.46540832519531,-0.05537732086160463,D5+,[],"{""assetTurnoverTTM"": 0.5443, ""bookValue"": 38693, ""cashRatio"": 0.24194237838762075, ""currentRatio"": 1.2814, ""ebitPerShare"": -2.0335, ""eps"": -2.3533, ""ev"": 324045.75, ""fcfMargin"": 0.1822, ""fcfPerShareTTM"": 4.264, ""grossMargin"": 0.7345, ""inventoryTurnoverTTM"": 2.7234, ""longtermDebtTotalAsset"": 0.3261, ""longtermDebtTotalCapital"": 0.4507, ""longtermDebtTotalEquity"": 0.8806, ""netDebtToTotalCapital"": 0.4134, ""netDebtToTotalEquity"": 0.8077, ""netMargin"": -0.3974, ""operatingMargin"": -0.3434, ""pb"": 7.5671, ""peTTM"": 94.116, ""pfcfTTM"": 27.0405, ""pretaxMargin"": -0.3548, ""psTTM"": 5.0213, ""ptbv"": 15.3876, ""quickRatio"": 1.0279, ""receivablesTurnoverTTM"": 5.6413, ""roaTTM"": 0.029, ""roeTTM"": 0.0707, ""roicTTM"": 0.0408, ""rotcTTM"": 0.0716, ""salesPerShare"": 5.9216, ""sgaToSale"": 0.2655, ""tangibleBookValue"": 19028, ""totalDebtToEquity"": 0.9539, ""totalDebtToTotalAsset"": 0.3533, ""totalDebtToTotalCapital"": 0.4882, ""totalRatio"": 1.5883, ""period"": ""2023-06-30""}"
26,2023-07-09,105.46540832519531,2023-07-16,103.85922241210938,-0.015229504522785042,D2,[],"{""assetTurnoverTTM"": 0.5443, ""bookValue"": 38693, ""cashRatio"": 0.24194237838762075, ""currentRatio"": 1.2814, ""ebitPerShare"": -2.0335, ""eps"": -2.3533, ""ev"": 324045.75, ""fcfMargin"": 0.1822, ""fcfPerShareTTM"": 4.264, ""grossMargin"": 0.7345, ""inventoryTurnoverTTM"": 2.7234, ""longtermDebtTotalAsset"": 0.3261, ""longtermDebtTotalCapital"": 0.4507, ""longtermDebtTotalEquity"": 0.8806, ""netDebtToTotalCapital"": 0.4134, ""netDebtToTotalEquity"": 0.8077, ""netMargin"": -0.3974, ""operatingMargin"": -0.3434, ""pb"": 7.5671, ""peTTM"": 94.116, ""pfcfTTM"": 27.0405, ""pretaxMargin"": -0.3548, ""psTTM"": 5.0213, ""ptbv"": 15.3876, ""quickRatio"": 1.0279, ""receivablesTurnoverTTM"": 5.6413, ""roaTTM"": 0.029, ""roeTTM"": 0.0707, ""roicTTM"": 0.0408, ""rotcTTM"": 0.0716, ""salesPerShare"": 5.9216, ""sgaToSale"": 0.2655, ""tangibleBookValue"": 19028, ""totalDebtToEquity"": 0.9539, ""totalDebtToTotalAsset"": 0.3533, ""totalDebtToTotalCapital"": 0.4882, ""totalRatio"": 1.5883, ""period"": ""2023-06-30""}"
27,2023-07-16,103.85922241210938,2023-07-23,106.8103256225586,0.02841445508555185,U3,[],{}
28,2023-07-23,106.8103256225586,2023-07-30,102.89164733886719,-0.036688197146210855,D4,[],{}
29,2023-07-30,102.89164733886719,2023-08-06,101.5951156616211,-0.01260094196933248,D2,[],{}
30,2023-08-06,101.5951156616211,2023-08-13,103.95598602294922,0.023238030154829392,U3,[],{}
31,2023-08-13,103.95598602294922,2023-08-20,105.65892028808594,0.016381300685857303,U2,[],{}
32,2023-08-20,105.65892028808594,2023-08-27,106.63616180419922,0.0092490204655582,U1,[],{}
33,2023-08-27,106.63616180419922,2023-09-03,106.27816009521484,-0.0033572261316168195,D1,[],{}
34,2023-09-03,106.27816009521484,2023-09-10,105.51377868652344,-0.007192271751849999,D1,[],{}
35,2023-09-10,105.51377868652344,2023-09-17,104.74261474609375,-0.007308656272473901,D1,[],{}
36,2023-09-17,104.74261474609375,2023-09-24,103.59309387207031,-0.010974720048854913,D2,[],{}
37,2023-09-24,103.59309387207031,2023-10-01,100.2906723022461,-0.03187878116568721,D4,"[{""date"": ""20230925002708"", ""headline"": ""Verve's New Beat: CMO Onboard, Catalysts Ahead, But We're Dancing Solo For Now"", ""summary"": ""Verve Therapeutics' Q2 2023 results show progress in their VERVE-101 trial, with a new CMO appointed. Read why we maintain a Hold rating for VERV stock.""}, {""date"": ""20230925003000"", ""headline"": ""Merck COVID drug molnupiravir linked to virus mutation transmission"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230925032500"", ""headline"": ""With Cancer Immunotherapy Market Set To Grow At Double-Digit CAGR Till 2032, This Company Plans To Ride The Wave Through Treatments For Complex Cancers"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230925054500"", ""headline"": ""3M, Merck share losses lead Dow's nearly 100-point drop"", ""summary"": ""Shares of 3M and Merck are trading lower Monday morning, sending the Dow Jones Industrial Average into negative territory. Shares of 3M and Merck are...""}, {""date"": ""20230925095607"", ""headline"": ""10 Best Ways to Prevent Type 2 Diabetes"", ""summary"": ""In this article, we shall discuss the 10 best ways to prevent type 2 diabetes. To skip our detailed analysis of the global diabetes industry and the larger pharmaceutical industry in 2023, go directly and see 5 Best Ways to Prevent Type 2 Diabetes. Diabetes is directly responsible for more than 280,000 deaths each year. [\u2026]""}, {""date"": ""20230925103900"", ""headline"": ""Merck\u2019s COVID antiviral may be linked to virus mutations, study finds"", ""summary"": ""Molnupiravir, which was granted an emergency use authorization by the FDA in December 2021, may allow mutated viruses to spread, a study has found.""}, {""date"": ""20230925120600"", ""headline"": ""Merck (MRK), Eisai Combo Therapy Fail Two Lung Cancer Studies"", ""summary"": ""Data from both late-stage studies evaluating Merck's (MRK) Keytruda and Eisai's Lenvima combination in certain types of metastatic non-small cell lung cancer, fail to achieve their primary endpoints.""}, {""date"": ""20230925123500"", ""headline"": ""Merck & Co. Inc. stock falls Monday, underperforms market"", ""summary"": ""Shares of Merck & Co. Inc. slipped 0.47% to $105.84 Monday, on what proved to be an all-around positive trading session for the stock market, with the S&P...""}, {""date"": ""20230926000000"", ""headline"": ""MilliporeSigma to Become First Provider to Offer Fully Integrated mRNA Services"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230926044000"", ""headline"": ""Unusually active option classes on open September 26th"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230926082020"", ""headline"": ""Big Pharma R&D Spending: The Secret Ingredient To Outperformance?"", ""summary"": ""High R&D spending by pharma companies does not necessarily lead to sales growth, let alone shareholder returns. See why bold M&A deals may be a different story.""}, {""date"": ""20230926123500"", ""headline"": ""Merck & Co. Inc. stock outperforms market despite losses on the day"", ""summary"": ""Shares of Merck & Co. Inc. shed 0.43% to $105.39 Tuesday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500...""}, {""date"": ""20230927064800"", ""headline"": ""Mainz Biomed To Present The Power Of mRNA That Promises To Revolutionize Medicine"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230927065300"", ""headline"": ""Dow falls nearly 100 points on losses for Walgreens Boots, Johnson & Johnson stocks"", ""summary"": ""The Dow Jones Industrial Average is falling Wednesday morning with shares of Walgreens Boots and Johnson & Johnson delivering the stiffest headwinds for the...""}, {""date"": ""20230927080600"", ""headline"": ""Johnson & Johnson, Verizon share losses contribute to Dow's 186-point fall"", ""summary"": ""Shares of Johnson & Johnson and Verizon are seeing declines Wednesday afternoon, dragging the Dow Jones Industrial Average into negative territory. Shares of...""}, {""date"": ""20230927090014"", ""headline"": ""Merck & Co., Inc.'s (NYSE:MRK) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?"", ""summary"": ""It is hard to get excited after looking at Merck's (NYSE:MRK) recent performance, when its stock has declined 6.3% over...""}, {""date"": ""20230927092700"", ""headline"": ""Dow's 270-point fall led by losses in shares of Walgreens Boots, Johnson & Johnson"", ""summary"": ""The Dow Jones Industrial Average is falling Wednesday afternoon with shares of Walgreens Boots and Johnson & Johnson facing the biggest declines for the...""}, {""date"": ""20230927102900"", ""headline"": ""Dow down nearly 175 points on losses for shares of McDonald's, Verizon"", ""summary"": ""Behind declines for shares of McDonald's and Verizon, the Dow Jones Industrial Average is falling Wednesday afternoon. The Dow was most recently trading 172...""}, {""date"": ""20230927115300"", ""headline"": ""Dow down 88 points on losses for shares of Verizon, McDonald's"", ""summary"": ""Dragged down by declines for shares of Verizon and McDonald's, the Dow Jones Industrial Average is falling Wednesday afternoon. The Dow was most recently...""}, {""date"": ""20230927123500"", ""headline"": ""Merck & Co. Inc. stock falls Wednesday, underperforms market"", ""summary"": ""Shares of Merck & Co. Inc. shed 1.38% to $103.94 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500...""}, {""date"": ""20230927164300"", ""headline"": ""Top Stock Reports for Alphabet, Exxon Mobil & Merck"", ""summary"": ""Today's Research Daily features new research reports on 16 major stocks, including Alphabet Inc. (GOOGL), Exxon Mobil Corp. (XOM) and Merck & Co., Inc. (MRK).""}, {""date"": ""20230927222100"", ""headline"": ""Amazon Web Services Now Offers Generative AI Tools For Businesses, Catches Up With Microsoft Azure, Google Cloud"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230927232300"", ""headline"": ""Mirati stock climbs 10% ahead of data presentation, FDA meeting on rival drug"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230927233300"", ""headline"": ""Teva names Novartis exec to lead US commercial business"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230928014900"", ""headline"": ""Merck's new application for sotatercept given priority review by FDA"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230928021300"", ""headline"": ""Merck wins FDA priority review for lung disease therapy"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230928031100"", ""headline"": ""Merck Gets FDA Priority Review of Sotatercept in Pulmonary Arterial Hypertension >MRK"", ""summary"": ""By Colin Kellaher Merck &amp; Co. has won U.S. Food and Drug Administration priority review of its sotatercept drug candidate for the treatment of adults...""}, {""date"": ""20230928052100"", ""headline"": ""Pharma Giants Shift Stance, Embrace Medicare Negotiations Amid Rising Drug Costs"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230928055000"", ""headline"": ""Merck, Bristol Myers, AstraZeneca agree to Medicare drug pricing talks"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230928061400"", ""headline"": ""Dow's 84-point rally led by gains for UnitedHealth, JPMorgan Chase shares"", ""summary"": ""Shares of UnitedHealth and JPMorgan Chase are posting positive momentum Thursday morning, sending the Dow Jones Industrial Average into positive territory....""}, {""date"": ""20230928064500"", ""headline"": ""Merck Receives Priority Review from FDA for New Biologics License Application for Sotatercept, an Activin Signaling Inhibitor to Treat Adults with Pulmonary Arterial Hypertension (PAH)"", ""summary"": ""RAHWAY, N.J., September 28, 2023--Merck Receives Priority Review from FDA for Biologics License Application for Sotatercept, an Activin Signaling Inhibitor to Treat Adults with PAH""}, {""date"": ""20230928073700"", ""headline"": ""The Zacks Analyst Blog Highlights Alphabet, Exxon Mobil, Merck, Abbott Laboratories and NextEra Energy"", ""summary"": ""Alphabet, Exxon Mobil, Merck, Abbott Laboratories and NextEra Energy are part of the Zacks top Analyst Blog.""}, {""date"": ""20230928123500"", ""headline"": ""Merck & Co. Inc. stock rises Thursday, still underperforms market"", ""summary"": ""Shares of Merck & Co. Inc. inched 0.35% higher to $104.30 Thursday, on what proved to be an all-around great trading session for the stock market, with the...""}, {""date"": ""20230928233600"", ""headline"": ""Merck & Co. Inc. stock underperforms Friday when compared to competitors"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230929052100"", ""headline"": ""As Merck, AstraZeneca and other drugmakers sign on, Medicare price negotiations face critical moment"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230929062000"", ""headline"": ""As Merck, AstraZeneca and other drugmakers sign on, Medicare price negotiations face critical moment\u00a0"", ""summary"": ""A deadline looms to sign drug-price negotiation agreements as industry watches for legal reprieve.""}, {""date"": ""20230929083900"", ""headline"": ""10 Health Care Stocks With Whale Alerts In Today's Session"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231001022143"", ""headline"": ""Dividend Champion, Contender, And Challenger Highlights: Week Of October 1"", ""summary"": ""A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Click here to read the update for the week of October 1.""}, {""date"": ""20231001053100"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: POINT Biopharma Global (PNT), Keros Therapeutics (KROS) and Merck & Company (MRK)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]","{""assetTurnoverTTM"": 0.5541, ""bookValue"": 41246, ""cashRatio"": 0.37260760370659046, ""currentRatio"": 1.3836, ""ebitPerShare"": 2.2569, ""eps"": 1.8637, ""ev"": 286476.8, ""fcfMargin"": 0.427, ""fcfPerShareTTM"": 5.1935, ""grossMargin"": 0.7349, ""inventoryTurnoverTTM"": 2.7183, ""longtermDebtTotalAsset"": 0.3183, ""longtermDebtTotalCapital"": 0.4464, ""longtermDebtTotalEquity"": 0.8236, ""netDebtToTotalCapital"": 0.345, ""netDebtToTotalEquity"": 0.6365, ""netMargin"": 0.2973, ""operatingMargin"": 0.36, ""payoutRatioTTM"": 0.5157, ""pb"": 6.309, ""peTTM"": 56.472, ""pfcfTTM"": 19.7633, ""pretaxMargin"": 0.3521, ""psTTM"": 4.3872, ""ptbv"": 11.8031, ""quickRatio"": 1.1182, ""receivablesTurnoverTTM"": 5.9684, ""roaTTM"": 0.0431, ""roeTTM"": 0.1067, ""roicTTM"": 0.0602, ""rotcTTM"": 0.094, ""salesPerShare"": 6.2694, ""sgaToSale"": 0.2651, ""tangibleBookValue"": 22047, ""totalDebtToEquity"": 0.8451, ""totalDebtToTotalAsset"": 0.3266, ""totalDebtToTotalCapital"": 0.458, ""totalRatio"": 1.6299, ""period"": ""2023-09-30""}"
38,2023-10-01,100.2906723022461,2023-10-08,101.19664001464844,0.009033419475662052,U1,"[{""date"": ""20231001022143"", ""headline"": ""Dividend Champion, Contender, And Challenger Highlights: Week Of October 1"", ""summary"": ""A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Click here to read the update for the week of October 1.""}, {""date"": ""20231001053100"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: POINT Biopharma Global (PNT), Keros Therapeutics (KROS) and Merck & Company (MRK)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231001220100"", ""headline"": ""Drugmakers comply with Medicare pricing talks despite lawsuits"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231001233700"", ""headline"": ""Merck & Co. Inc. stock falls Monday, underperforms market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231002071600"", ""headline"": ""Cantor Fitzgerald Reaffirms Their Buy Rating on Merck & Company (MRK)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231002082800"", ""headline"": ""This fund shows that industry expertise can help you make a lot of money in the stock market"", ""summary"": ""The managers of the Janus Henderson Global Life Sciences Fund have direct experience to help them separate promising innovators from flashes in the pan.""}, {""date"": ""20231002083400"", ""headline"": ""How Is The Market Feeling About Merck & Co?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231002083900"", ""headline"": ""10 Health Care Stocks Whale Activity In Today's Session"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231002113400"", ""headline"": ""FDA Accepts Merck's (MRK) Filing for Sotatercept in PAH Disease"", ""summary"": ""The FDA grants priority review to Merck's (MRK) FDA filing for sotatercept to treat adults with pulmonary arterial hypertension. A final decision is expected before March 2023-end.""}, {""date"": ""20231002124952"", ""headline"": ""Drugmakers sign on to negotiate Medicare prices under protest"", ""summary"": ""All the drugmakers that make the 10 prescription medicines  subject to the first-ever price negotiations for the U.S. Medicare health program, including Amgen and Novartis, said they signed on to participate in the talks by the Oct. 1 deadline.  The penalties for not doing so would have been steep: drugmakers would have to pay 65% to 95% taxes on their drug's Medicare sales or withdraw all of their products from the Medicare and Medicaid programs, which together provide health benefits to 158 million Americans.  \""Merck will sign the initial agreement with CMS under protest,\"" the U.S. company said in a statement.""}, {""date"": ""20231002213100"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Maravai Lifesciences Holdings (MRVI) and Karuna Therapeutics (KRTX)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231002233600"", ""headline"": ""Merck & Co. Inc. stock falls Tuesday, still outperforms market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231003030100"", ""headline"": ""Medicare drug price negotiations move forward with all drugmakers participating, White House says"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231003035800"", ""headline"": ""PDS Biotech updates Phase 2 data for lead asset in head and neck cancer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231003040000"", ""headline"": ""Medicare drug price negotiations move forward with all drugmakers participating, White House says\u00a0"", ""summary"": ""Novo Nordisk is latest drugmaker to challenge negotiation program in court.""}, {""date"": ""20231003041300"", ""headline"": ""Selected drugmakers agree to US government price talks - White House"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231003070600"", ""headline"": ""Merck is Oversold"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231003080000"", ""headline"": ""Drugmakers agree to US government price talks amid pushback"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231003081200"", ""headline"": ""IN BRIEF: NetScientific portfolio company updates on cancer trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231003083900"", ""headline"": ""Drugmakers Agree To Participate For Medicare Drug Price Negotiation With Biden Administration"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231003100000"", ""headline"": ""Merck Helps To Improve Diversity in Clinical Trials Through Beacon of Hope"", ""summary"": ""NORTHAMPTON, MA / ACCESSWIRE / October 3, 2023 / Merck & Co., Inc.Unique collaboration expands our clinical trials efforts to four Historically Black Medical School Clinical Trial Centers of ExcellenceIncreasing diversity in clinical trials plays ...""}, {""date"": ""20231003100806"", ""headline"": ""The 10 pharma companies participating in Medicare price negotiations"", ""summary"": ""Ten pharmaceutical manufacturers are signing the Inflation Reduction Act's Medicare drug price negotiation program. These companies are Bristol Myers Squibb (BMY), AstraZeneca (AZN), Boehringer Ingelheim, Immunex, Janssen Pharmaceuticals, Pharmacyclics, Merck & Company (MRK), Janssen Biotech, Novartis (NVS), and Novo Nordisk (NVO), according to the Biden administration. Yahoo Finance Health Care Reporter Anjalee Khemlani discusses the news. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live.""}, {""date"": ""20231003230300"", ""headline"": ""9 Analysts Have This to Say About Merck & Co"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231003233700"", ""headline"": ""Merck & Co. Inc. stock rises Wednesday, still underperforms market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231004045100"", ""headline"": ""Cancer Drug Maker 3D Medicines Inc. Trading Higher After Company Announces It Will Repurchase Up To 10% Of Outstanding Shares"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231004050011"", ""headline"": ""Gilead Sciences: A Healthy Buy With Solid Dividend"", ""summary"": ""Gilead Sciences has outperformed the S&P 500 with a 19% total return since my last Buy rating in August last year. Learn why GILD stock is a buy.""}, {""date"": ""20231004085900"", ""headline"": ""US government to stop distributing Merck's COVID-19 drug for free: report"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231004094601"", ""headline"": ""4 Factor Dividend Growth Portfolio: First Year Is Coming Down To The Wire"", ""summary"": ""Learn about the 4-factor dividend growth portfolio, utilizing the same index as the Schwab U.S. Dividend Equity ETF, with a few minor twists. Click here to read.""}, {""date"": ""20231004100604"", ""headline"": ""Cantor Fitzgerald Reiterates Merck (MRK) Overweight Recommendation"", ""summary"": """"}, {""date"": ""20231004123244"", ""headline"": ""US plans shift of Merck COVID treatment to commercial market"", ""summary"": ""The U.S. government will stop distributing free doses of Merck & Co's COVID-19 antiviral treatment molnupiravir by the middle of next month and expects it to be sold on the commercial market instead.  The Administration for Strategic Preparedness and Response (ASPR), a division of the U.S. Department of Health and Human Services, said in a statement posted on its website late last week they anticipate transition of the drug, sold under the brand name Lagevrio, from government-managed to traditional commercial distribution in November.  Merck, which developed the drug with Ridgeback Biotherapeutics, said in an emailed statement on Wednesday that it needs an updated letter of authorization from the U.S. Food and Drug Administration to allow it to start selling the drug commercially.""}, {""date"": ""20231005020700"", ""headline"": ""Merck announces AMBASSADOR trial meets one of two primary endpoints of DFS"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231005023300"", ""headline"": ""Merck posts Phase 3 win for Keytruda in muscle-invasive bladder cancer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231005031700"", ""headline"": ""Merck Keytruda Study Hits Key Goal in Advanced Bladder Cancer"", ""summary"": ""By Colin Kellaher A late-stage study of Merck &amp; Co.'s blockbuster cancer drug Keytruda has met one of its key goals in certain patients with an advanced...""}, {""date"": ""20231005032600"", ""headline"": ""Merck reports positive results in late-stage trial of Keytruda as treatment for bladder cancer"", ""summary"": ""Merck & Co. Inc. said Thursday a late-stage trial of its cancer treatment Keytruda met its main goal of disease-free survival for patients with advanced...""}, {""date"": ""20231005040200"", ""headline"": ""EMD Serono Launches New Collaboration with United Nations\u2019 Global Initiative on Ageing to Support Caregivers"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231005040400"", ""headline"": ""No Merck's COVID-19 Pill - US Government Ceases Free Distribution"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231005042700"", ""headline"": ""Merck's Keytruda improves urothelial carcinoma survival, data shows"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231005043900"", ""headline"": ""Merck's Best Selling Cancer Drug Meets One Goal In Late-Stage Bladder Cancer Study"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231005050300"", ""headline"": ""Disney Slashes Ticket Prices For Children, US Government Ceases Free Distribution Of Merck COVID Pill, UK Deep Dives Into Amazon And Microsoft's Cloud Power: Today's Top Stories"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231005064500"", ""headline"": ""Merck to Hold Third-Quarter 2023 Sales and Earnings Conference Call Oct. 26"", ""summary"": ""RAHWAY, N.J., October 05, 2023--Merck to Hold Third-Quarter 2023 Sales and Earnings Conference Call Oct. 26""}, {""date"": ""20231005070000"", ""headline"": ""Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Met Primary Endpoint of Disease-Free Survival (DFS) in Certain Patients With Muscle-Invasive Urothelial Carcinoma (MIUC) After Surgery"", ""summary"": ""RAHWAY, N.J., October 05, 2023--Merck\u2019s KEYTRUDA Met Primary Endpoint of Disease-Free Survival in Certain Patients With Muscle-Invasive Urothelial Carcinoma After Surgery""}, {""date"": ""20231005081500"", ""headline"": ""Merck is Collaborating to Address Antimicrobial Resistance"", ""summary"": ""Shared commitments like the AMR Action Fund are vital to make progress against this public health threatNORTHAMPTON, MA / ACCESSWIRE / October 5, 2023 / Antibiotics have transformed health care and saved countless lives. But rising levels of antimicrobial ...""}, {""date"": ""20231005100020"", ""headline"": ""Merck Insiders Sell US$8.3m Of Stock, Possibly Signalling Caution"", ""summary"": ""The fact that multiple Merck & Co., Inc. ( NYSE:MRK ) insiders offloaded a considerable amount of shares over the past...""}, {""date"": ""20231005103000"", ""headline"": ""EMD Serono Launches New Collaboration with United Nations-Guided Global Initiative on Ageing to Support Caregivers"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231005123500"", ""headline"": ""Merck & Co. Inc. stock outperforms market on strong trading day"", ""summary"": ""Shares of Merck & Co. Inc. rallied 1.40% to $103.60 Thursday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500...""}, {""date"": ""20231006120300"", ""headline"": ""Merck's (MRK) Meets Goal in Muscle-Invasive Bladder Cancer Study"", ""summary"": ""Data from a late-stage study shows that Merck's (MRK) Keytruda lowered the risk of disease recurrence or death when used after surgery in certain patients with urothelial carcinoma.""}, {""date"": ""20231006123500"", ""headline"": ""Merck & Co. Inc. stock rises Friday, still underperforms market"", ""summary"": ""Shares of Merck & Co. Inc. inched 0.27% higher to $103.88 Friday, on what proved to be an all-around favorable trading session for the stock market, with the...""}, {""date"": ""20231006140948"", ""headline"": ""Biotech-Pharma Trade: Buying Opportunities On The Horizon"", ""summary"": ""Concerns over interest rates, pricing erosion, and Medicare's drug price negotiation plan weigh on biotech and pharma sectors. Learn what investors need to know.""}, {""date"": ""20231006180854"", ""headline"": ""Truist Securities Reiterates Merck (MRK) Buy Recommendation"", ""summary"": """"}, {""date"": ""20231007222300"", ""headline"": ""As FDA mulls fate of Amgen drug, Sanofi could snap up rival Mirati"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]","{""assetTurnoverTTM"": 0.5541, ""bookValue"": 41246, ""cashRatio"": 0.37260760370659046, ""currentRatio"": 1.3836, ""ebitPerShare"": 2.2569, ""eps"": 1.8637, ""ev"": 286476.8, ""fcfMargin"": 0.427, ""fcfPerShareTTM"": 5.1935, ""grossMargin"": 0.7349, ""inventoryTurnoverTTM"": 2.7183, ""longtermDebtTotalAsset"": 0.3183, ""longtermDebtTotalCapital"": 0.4464, ""longtermDebtTotalEquity"": 0.8236, ""netDebtToTotalCapital"": 0.345, ""netDebtToTotalEquity"": 0.6365, ""netMargin"": 0.2973, ""operatingMargin"": 0.36, ""payoutRatioTTM"": 0.5157, ""pb"": 6.309, ""peTTM"": 56.472, ""pfcfTTM"": 19.7633, ""pretaxMargin"": 0.3521, ""psTTM"": 4.3872, ""ptbv"": 11.8031, ""quickRatio"": 1.1182, ""receivablesTurnoverTTM"": 5.9684, ""roaTTM"": 0.0431, ""roeTTM"": 0.1067, ""roicTTM"": 0.0602, ""rotcTTM"": 0.094, ""salesPerShare"": 6.2694, ""sgaToSale"": 0.2651, ""tangibleBookValue"": 22047, ""totalDebtToEquity"": 0.8451, ""totalDebtToTotalAsset"": 0.3266, ""totalDebtToTotalCapital"": 0.458, ""totalRatio"": 1.6299, ""period"": ""2023-09-30""}"
39,2023-10-08,101.19664001464844,2023-10-15,101.32329559326172,0.0012515788922926596,U1,"[{""date"": ""20231007222300"", ""headline"": ""As FDA mulls fate of Amgen drug, Sanofi could snap up rival Mirati"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231008214700"", ""headline"": ""3 Artificial Intelligence Stocks That Could Outperform the \u2018Godfather of AI\u2019"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231009081300"", ""headline"": ""Will more bidders emerge or CVR ever be paid in Mirati takeover deal?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231009123500"", ""headline"": ""Merck & Co. Inc. stock rises Monday, still underperforms market"", ""summary"": ""Shares of Merck & Co. Inc. inched 0.60% higher to $104.50 Monday, on what proved to be an all-around positive trading session for the stock market, with the...""}, {""date"": ""20231009153005"", ""headline"": ""Merck: Right On Time"", ""summary"": ""Merck is slowly executing a pivot into adjacent areas of oncology, immunology, and beyond. Read more to see why MRK stock is a Hold.""}, {""date"": ""20231010013200"", ""headline"": ""Merck: KEYNOTE-671 trial meets dual primary endpoint of OS"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231010021200"", ""headline"": ""Merck succeeds in Phase 3 trial for Keytruda in lung cancer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231010024700"", ""headline"": ""Merck: Phase 3 Keytruda Study Hits Second Goal in Non-Small Cell Lung Cancer"", ""summary"": ""By Colin Kellaher Merck &amp; Co. on Tuesday said a Phase 3 study of its Keytruda cancer drug met the second of its dual primary endpoints as a perioperative...""}, {""date"": ""20231010025600"", ""headline"": ""Merck reports positive results for blockbuster cancer drug in treating non-small cell lung cancer"", ""summary"": ""Keytruda showed a 'statistically significant and clinically meaningful improvement' in overall survival in a late-stage trial.""}, {""date"": ""20231010031500"", ""headline"": ""Oncotelic Therapeutics' (OTCQB: OTLC) Lead Immunotherapy Candidate For Treating Deadly Cancers, OT-101, Could Hold Potential Applications In Multiple Multi-Billion Dollar Markets"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231010041300"", ""headline"": ""Merck phase 3 Keytruda trial meets primary overall survival endpoint"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231010063000"", ""headline"": ""Merck Announces Pivotal KEYNOTE-671 Trial Meets Dual Primary Endpoint of Overall Survival (OS) in Resectable Stage II, IIIA or IIIB Non-Small Cell Lung Cancer (NSCLC)"", ""summary"": ""RAHWAY, N.J., October 10, 2023--Merck Announces Pivotal KEYNOTE-671 Trial Meets Dual Primary Endpoint of Overall Survival (OS) in Resectable Stage II, IIIA or IIIB NSCLC""}, {""date"": ""20231010073200"", ""headline"": ""Merck's Lead Cancer Drug Meets Primary Goal In Certain Type Of Lung Cancer Patients"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231010084500"", ""headline"": ""BioXcel Therapeutics Shares Rise 14% After Positive Trial Data for Cancer Treatment"", ""summary"": ""By Chris Wack BioXcel Therapeutics shares were up 14% to $3.13 after the company reported positive overall survival data from its Phase 2 trial of BXCL701,...""}, {""date"": ""20231010123500"", ""headline"": ""Merck & Co. Inc. stock underperforms Tuesday when compared to competitors"", ""summary"": ""Shares of Merck & Co. Inc. sank 0.85% to $103.61 Tuesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500...""}, {""date"": ""20231010221500"", ""headline"": ""Evobrutinib, CNS-Penetrant BTKi, Has Shown Sustained Clinical Benefit Up to Five Years in People with RMS"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231010231400"", ""headline"": ""EMD Electronics Celebrates Opening of New Arizona Factory, Contributing to the State's Growing Semiconductor Industry"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231011063521"", ""headline"": ""AQR Capital Management: AUM, Performance, Stock Picks"", ""summary"": ""In this article, we looked at Cliff Asness\u2019 investment philosophy and outlook on the US stock market. We also reviewed Asness\u2019 AQR Capital Management\u2019s assets under management, performance and stock picks. You can skip our detailed discussion of AQR Capital Management and go straight to AQR Capital Management\u2019s Top 5 Stock Picks. Following record-breaking returns [\u2026]""}, {""date"": ""20231011070031"", ""headline"": ""With 78% institutional ownership, Merck & Co., Inc. (NYSE:MRK) is a favorite amongst the big guns"", ""summary"": ""Key Insights Institutions' substantial holdings in Merck implies that they have significant influence over the...""}, {""date"": ""20231011101500"", ""headline"": ""Merck's (MRK) Keytruda Early-Stage NSCLC Study Shows OS Benefit"", ""summary"": ""Merck's (MRK) phase III study on Keytruda shows a statistically significant overall survival benefit for patients with stage II, IIIA or IIIB NSCLC.""}, {""date"": ""20231011123500"", ""headline"": ""Merck & Co. Inc. stock falls Wednesday, underperforms market"", ""summary"": ""Shares of Merck & Co. Inc. sank 0.14% to $103.46 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the S&P...""}, {""date"": ""20231011125831"", ""headline"": ""Morgan Stanley Maintains Merck (MRK) Equal-Weight Recommendation"", ""summary"": """"}, {""date"": ""20231011210000"", ""headline"": ""Buy McKesson Stock. Ozempic Can Lift Drug Distributors Too."", ""summary"": ""McKesson\u2019s business is relatively simple. It buys drugs from manufacturers and then distributes them to pharmacies. It's more difficult than it sounds.""}, {""date"": ""20231012015400"", ""headline"": ""Marks Electrical half-year revenue climbs but suffers margin pressure"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231012040000"", ""headline"": ""Better Passive Income Snowball: SCHD Or DIVO?"", ""summary"": ""We compare two potential core ETFs for building a passive income snowball. Click here to learn which one is a better fit for the investing strategy.""}, {""date"": ""20231012063200"", ""headline"": ""Stocks to watch out in the Health Care sector as earnings close in"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231012064900"", ""headline"": ""Stocks to watch in the Health Care sector as earnings close in"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231012100746"", ""headline"": ""25 US Cities with Cleanest Air and Water"", ""summary"": ""In this article, we will discuss the 25 US cities with cleanest air and water. If you want to skip our discussion on the overall environmental conditions in the US, you can go directly to the 5 US Cities with Cleanest Air and Water. According to IQAir US, the air quality in the United States [\u2026]""}, {""date"": ""20231012123500"", ""headline"": ""Merck & Co. Inc. stock rises Thursday, outperforms market"", ""summary"": ""Shares of Merck & Co. Inc. inched 0.13% higher to $103.59 Thursday, on what proved to be an all-around poor trading session for the stock market, with the...""}, {""date"": ""20231012165251"", ""headline"": ""15 Worst Performing Dow Stocks YTD"", ""summary"": ""In this article, we discuss 15 worst performing Dow stocks year-to-date. If you want to skip our detailed discussion on stock market performance overall, head directly to 5 Worst Performing Dow Stocks YTD. In a July report by J.P. Morgan, it was stated that global economic growth is expected to slow down in the latter [\u2026]""}, {""date"": ""20231012175018"", ""headline"": ""(MRK) Rises As Market Takes a Dip: Key Facts"", ""summary"": ""In the latest trading session, Merck (MRK) closed at $103.59, marking a +0.13% move from the previous day.""}, {""date"": ""20231012213800"", ""headline"": ""See Which Of The Latest 13F Filers Holds Merck & Co"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231012220500"", ""headline"": ""Catalyst watch: Tesla earnings, Jerome Powell speech, UAW drama and Baidu event"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231012234100"", ""headline"": ""Analysts Are Bullish on Top Healthcare Stocks: Terns Pharmaceuticals (TERN), BridgeBio Pharma (BBIO)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231013025100"", ""headline"": ""Merck adopts opinion recommending approval of Keytruda"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231013034500"", ""headline"": ""Merck Receives Positive EU CHMP Opinion for KEYTRUDA\u00ae (pembrolizumab) Plus Chemotherapy as First-Line Treatment for HER2-Negative Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Expressing PD-L1 (CPS \u22651)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231013035600"", ""headline"": ""Merck's Keytruda combo gets EMA panel backing for expanded use in gastric cancer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231013051400"", ""headline"": ""Merck receives positive EU opinion for Keytruda to treat cancer forms"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231013074500"", ""headline"": ""Merck Receives Positive EU CHMP Opinion for KEYTRUDA\u00ae (pembrolizumab) Plus Chemotherapy as First-Line Treatment for HER2-Negative Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma\nExpressing PD-L1 (CPS \u22651)"", ""summary"": ""RAHWAY, N.J., October 13, 2023--Merck Receives Positive CHMP Opinion for KEYTRUDA Plus Chemotherapy as First-Line Treatment for HER2-Negative Advanced Gastric Cancer""}, {""date"": ""20231013123500"", ""headline"": ""Merck & Co. Inc. stock rises Friday, outperforms market"", ""summary"": ""Shares of Merck & Co. Inc. inched 0.41% higher to $104.01 Friday, on what proved to be an all-around mixed trading session for the stock market, with the Dow...""}, {""date"": ""20231015000007"", ""headline"": ""Merck to open \u00a31bn London research centre with plea for government support of industry"", ""summary"": ""Drugmaker praises country\u2019s scientific expertise but says it must address conflicts in areas such as drug pricing""}, {""date"": ""20231015015000"", ""headline"": ""ClearBridge Appreciation Strategy Q3 2023 Portfolio Manager Commentary"", ""summary"": ""We believe 2023\u00e2\u0080\u0099s market increase is a rally in a multiyear bear market and that we need to retain a conservative tilt to our portfolio.""}, {""date"": ""20231015133000"", ""headline"": ""7 Safe Stocks to Steady Your Portfolio in 2024"", ""summary"": ""With the high-flying equities sector suddenly going soft in the second half, investors may want to consider safe stocks. These ideas might not be the first choice among market participants. Maybe they\u2019re too boring or seemingly not relevant to present circumstances. Still, some surprises may be in order. To better qualify which ideas are the steady stocks to trust, I turned to TipRanks\u2019 Top Smart Score Stocks indicator. Measuring the viability of publicly traded securities based on eight factors""}]","{""assetTurnoverTTM"": 0.5541, ""bookValue"": 41246, ""cashRatio"": 0.37260760370659046, ""currentRatio"": 1.3836, ""ebitPerShare"": 2.2569, ""eps"": 1.8637, ""ev"": 286476.8, ""fcfMargin"": 0.427, ""fcfPerShareTTM"": 5.1935, ""grossMargin"": 0.7349, ""inventoryTurnoverTTM"": 2.7183, ""longtermDebtTotalAsset"": 0.3183, ""longtermDebtTotalCapital"": 0.4464, ""longtermDebtTotalEquity"": 0.8236, ""netDebtToTotalCapital"": 0.345, ""netDebtToTotalEquity"": 0.6365, ""netMargin"": 0.2973, ""operatingMargin"": 0.36, ""payoutRatioTTM"": 0.5157, ""pb"": 6.309, ""peTTM"": 56.472, ""pfcfTTM"": 19.7633, ""pretaxMargin"": 0.3521, ""psTTM"": 4.3872, ""ptbv"": 11.8031, ""quickRatio"": 1.1182, ""receivablesTurnoverTTM"": 5.9684, ""roaTTM"": 0.0431, ""roeTTM"": 0.1067, ""roicTTM"": 0.0602, ""rotcTTM"": 0.094, ""salesPerShare"": 6.2694, ""sgaToSale"": 0.2651, ""tangibleBookValue"": 22047, ""totalDebtToEquity"": 0.8451, ""totalDebtToTotalAsset"": 0.3266, ""totalDebtToTotalCapital"": 0.458, ""totalRatio"": 1.6299, ""period"": ""2023-09-30""}"
40,2023-10-15,101.32329559326172,2023-10-22,100.01789855957031,-0.012883483764006387,D2,"[{""date"": ""20230322142251"", ""headline"": ""Stock Market Today: Stock Market News And Analysis"", ""summary"": ""Check the Stock Market Today column to spot changes in market trend and track the best stocks to buy and watch.""}, {""date"": ""20231015000007"", ""headline"": ""Merck to open \u00a31bn London research centre with plea for government support of industry"", ""summary"": ""Drugmaker praises country\u2019s scientific expertise but says it must address conflicts in areas such as drug pricing""}, {""date"": ""20231015015000"", ""headline"": ""ClearBridge Appreciation Strategy Q3 2023 Portfolio Manager Commentary"", ""summary"": ""We believe 2023\u00e2\u0080\u0099s market increase is a rally in a multiyear bear market and that we need to retain a conservative tilt to our portfolio.""}, {""date"": ""20231015133000"", ""headline"": ""7 Safe Stocks to Steady Your Portfolio in 2024"", ""summary"": ""With the high-flying equities sector suddenly going soft in the second half, investors may want to consider safe stocks. These ideas might not be the first choice among market participants. Maybe they\u2019re too boring or seemingly not relevant to present circumstances. Still, some surprises may be in order. To better qualify which ideas are the steady stocks to trust, I turned to TipRanks\u2019 Top Smart Score Stocks indicator. Measuring the viability of publicly traded securities based on eight factors""}, {""date"": ""20231015220000"", ""headline"": ""EMD Serono to Present Latest Research from Oncology Portfolio at ESMO 2023"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231015235200"", ""headline"": ""Healthcare Portfolio Focus Stocks"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231016004500"", ""headline"": ""ClearBridge Appreciation ESG Strategy Q3 2023 Portfolio Manager Commentary"", ""summary"": ""The ClearBridge Appreciation ESG Strategy outperformed its benchmark in the third quarter, driven by positive stock selection. Click here to read the full fund letter.""}, {""date"": ""20231016014700"", ""headline"": ""Merck: EC approves KEYTRUDA as adjuvant treatment for NSCLC"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231016020300"", ""headline"": ""FDA approves Merck's Keytruda for treatment of resectable NSCLC"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231016022500"", ""headline"": ""FDA grants expanded approval for Merck's lung cancer drug Keytruda"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231016022900"", ""headline"": ""Merck (NYSE:MRK) Requests UK Government to Support Pharma"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231016023700"", ""headline"": ""Merck (NYSE:MRK) Urges UK Government to Support Pharma"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231016030300"", ""headline"": ""Merck's Keytruda gets approval in EU for expanded use in lung cancer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231016030621"", ""headline"": ""Worried About a Recession? This Pharma Stock Could Be the Safe Haven You Need."", ""summary"": ""When you\u2019re concerned about an economic downturn, a relatively safe solution is to stick with famous names like Merck (NYSE:MRK). I recommend holding MRK stock, reinvesting the dividend payments and sleeping soundly at night. Believe me, I fully understand the importance of low-volatility investments in 2023\u2019s fourth quarter. Interest rates could stay higher for longer, and the stock market\u2019s high flyers may be vulnerable to a sharp pullback. That\u2019s why prudent investors should look at tried-and""}, {""date"": ""20231016042000"", ""headline"": ""IN BRIEF: EU approves Merck's Keytruda as lung cancer treatment"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231016064428"", ""headline"": ""AbbVie: Successfully Navigating Humira's Patent Cliff With 4% Yield And 270% DGR Since 2014"", ""summary"": ""Despite declining Humira sales, AbbVie remains resilient, focusing on new therapies, M&A, and R&D for sustained growth. Find out why ABBV stock is a Hold.""}, {""date"": ""20231016064500"", ""headline"": ""European Commission Approves KEYTRUDA\u00ae (pembrolizumab) as Adjuvant Treatment for Adults With Non-Small Cell Lung Cancer at High Risk of Recurrence Following Complete Resection and Platinum-Based Chemotherapy"", ""summary"": ""RAHWAY, N.J., October 16, 2023--EC Approves KEYTRUDA as Adjuvant Treatment for Adults With NSCLC at High Risk of Recurrence Following Complete Resection & Platinum-Based Chemotherapy""}, {""date"": ""20231016074700"", ""headline"": ""Promising Oncology and Vaccine Catalysts Drive Buy Rating for Merck & Company: An Analysis of Daina Graybosch\u2019s Recommendation"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231016075600"", ""headline"": ""Maintaining Buy Rating for Merck & Co.: Unaffected by Pfizer\u2019s Revenue Cut and Anticipated Growth in Non-COVID Business"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231016082600"", ""headline"": ""My Dividend Growth Portfolio - Q3 2023 Summary"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231016100021"", ""headline"": ""Is Merck & Co., Inc. (NYSE:MRK) Trading At A 48% Discount?"", ""summary"": ""Key Insights Using the 2 Stage Free Cash Flow to Equity, Merck fair value estimate is US$199 Current share price of...""}, {""date"": ""20231016104700"", ""headline"": ""CHMP Endorses Merck's (MRK) Keytruda Expansion in Gastric Cancer"", ""summary"": ""If approved, Merck's (MRK) Keytruda will be approved for a second indication in advanced gastric or GEJ cancer.""}, {""date"": ""20231016105657"", ""headline"": ""Health Care Select Sector Fund ETF: Riding The Healthcare Boom"", ""summary"": ""Health Care Select Sector SPDR Fund ETF tracks performance of US healthcare sector. It has a diverse portfolio of holdings. Find out why XLV ETF is a Buy.""}, {""date"": ""20231016123500"", ""headline"": ""Merck & Co. Inc. stock rises Monday, still underperforms market"", ""summary"": ""Shares of Merck & Co. Inc. inched 0.12% higher to $104.14 Monday, on what proved to be an all-around favorable trading session for the stock market, with the...""}, {""date"": ""20231016152500"", ""headline"": ""Merck Gets FDA Approval for Resectable Lung Cancer Treatment With Keytruda and Chemotherapy"", ""summary"": ""By Ben Glickman Merck received approval from the Food and Drug Administration for the use of blockbuster cancer drug Keytruda to treat certain types of...""}, {""date"": ""20231016190000"", ""headline"": ""FDA Approves KEYTRUDA\u00ae (pembrolizumab) for Treatment of Patients With Resectable (T\u22654 cm or N+) NSCLC in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as a Single Agent as Adjuvant Treatment After Surgery"", ""summary"": ""RAHWAY, N.J., October 16, 2023--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA, Merck\u2019s anti-PD-1 therapy, for the treatment of patients with resectable (tumors \u22654 centimeters [cm] or node positive) non-small cell lung cancer (NSCLC) in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery.""}, {""date"": ""20231016190211"", ""headline"": ""UPDATE 3-Merck's Keytruda gets FDA nod for expanded use in lung cancer"", ""summary"": ""The U.S. Food and Drug Administration on Monday approved the expanded use of Merck & Co's blockbuster immunotherapy Keytruda in early-stage patients with non-small cell lung cancer who can get their tumors removed surgically.  The U.S. health regulator's approval extends Keytruda's use in combination with chemotherapy as a treatment given before surgery to shrink the size of the tumor in patients.  The U.S. drugmaker is aiming to widen use of Keytruda, used as a second line of treatment in some cancer patients, into earlier lines of treatment.""}, {""date"": ""20231016231700"", ""headline"": ""Merck & Co's Keytruda gets FDA approval for lung cancer treatment"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231017014700"", ""headline"": ""Merck receives positive EU CHMP opinion for PREVYMIS"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231017023300"", ""headline"": ""FDA Approves Merck's Top Selling Drug, Keytruda For Expanded Use In Lung Cancer Indication"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231017033200"", ""headline"": ""Kineta announces first patient dosed in Phase 1/2 VISTA-101 trial of KVA12123"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231017033900"", ""headline"": ""IN BRIEF: Merck gains positive EU opinion to Prevymis in CMV disease"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231017040300"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Omnicell (OMCL), Black Diamond Therapeutics (BDTX) and Merck & Company (MRK)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231017041100"", ""headline"": ""Analysts\u2019 Top Healthcare Picks: Black Diamond Therapeutics (BDTX), Ultragenyx Pharmaceutical (RARE)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231017043000"", ""headline"": ""Merck price target lowered to $127 from $128 at Guggenheim"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231017055100"", ""headline"": ""Merck cytomegalovirus therapy endorsed for approval in EU"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231017064500"", ""headline"": ""Merck Receives Positive EU CHMP Opinion for PREVYMIS\u00ae for Prevention of CMV Disease in High-Risk Adult Kidney Transplant Recipients and Extended 200-Day Dosing in Adult HSCT Recipients at Risk for Late CMV Infection and Disease"", ""summary"": ""RAHWAY, N.J., October 17, 2023--Merck Receives Positive EU CHMP Opinion for PREVYMIS\u00ae for Prevention of CMV Disease in High-Risk Adult Kidney Transplant Recipients""}, {""date"": ""20231017072336"", ""headline"": ""UPDATE 1-EU regulator backs use of Merck's viral infection drug"", ""summary"": ""Merck & Co said on Tuesday the European Union medicines regulator recommended a marketing authorisation for the company's drug Prevymis to treat a type of infection in adult kidney transplant recipients at high risk.  The drugmaker says Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA) also recommended the approval for extending dosing of the drug to 200 days from 100 days, following a type of transplant in adult patients.""}, {""date"": ""20231017123500"", ""headline"": ""Merck & Co. Inc. stock outperforms competitors on strong trading day"", ""summary"": ""Shares of Merck & Co. Inc. inched 0.03% higher to $104.17 Tuesday, on what proved to be an all-around mixed trading session for the stock market, with the...""}, {""date"": ""20231018110100"", ""headline"": ""Merck (MRK) Gets CHMP Nod for Expanded Use of Antiviral Drug"", ""summary"": ""CHMP gives a positive opinion to Merck (MRK) for the expanded use of Prevymis to help prevent CMV disease in high-risk kidney transplant patients.""}, {""date"": ""20231018123500"", ""headline"": ""Merck & Co. Inc. stock outperforms competitors despite losses on the day"", ""summary"": ""Shares of Merck & Co. Inc. slipped 2.09% to $101.99 Wednesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500...""}, {""date"": ""20231018235300"", ""headline"": ""Looking At Merck & Co's Recent Unusual Options Activity"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231019060300"", ""headline"": ""Peering Into Merck & Co's Recent Short Interest"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231019061800"", ""headline"": ""Dow drops nearly 100 points on losses in shares of Merck, Amgen"", ""summary"": ""Shares of Merck and Amgen are posting losses Thursday morning, dragging the Dow Jones Industrial Average into negative territory. The Dow was most recently...""}, {""date"": ""20231019064200"", ""headline"": ""Eli Lilly, Novo among notable decliners in pharma weakness"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231019065700"", ""headline"": ""Merck to pay up to $22B in cancer drug deal with Daiichi Sankyo"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231019071500"", ""headline"": ""BioNTech starts another Phase 2 trial for mRNA-based cancer shot"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231019103100"", ""headline"": ""Dow's 100-point fall led by losses in Travelers, Caterpillar shares"", ""summary"": ""The Dow Jones Industrial Average is declining Thursday afternoon with shares of Travelers and Caterpillar delivering the stiffest headwinds for the...""}, {""date"": ""20231019123500"", ""headline"": ""Merck & Co. Inc. stock underperforms Thursday when compared to competitors"", ""summary"": ""Shares of Merck & Co. Inc. shed 1.53% to $100.43 Thursday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500...""}, {""date"": ""20231019180800"", ""headline"": ""Daiichi Sankyo shares jump on multibillion-dollar drug development deal with Merck"", ""summary"": ""Daiichi Sankyo shares rose sharply after the Japanese drugmaker announced a multibillion dollar deal with Merck to jointly develop and commercialize three...""}, {""date"": ""20231019193000"", ""headline"": ""Daiichi Sankyo and Merck Announce Global Development and Commercialization Collaboration for Three Daiichi Sankyo DXd ADCs"", ""summary"": ""BASKING RIDGE, N.J. & RAHWAY, N.J., October 19, 2023--Daiichi Sankyo (TSE: 4568) and Merck (known as MSD outside of the United States and Canada) (NYSE: MRK) have entered into a global development and commercialization agreement for three of Daiichi Sankyo\u2019s DXd antibody drug conjugate (ADC) candidates: patritumab deruxtecan (HER3-DXd), ifinatamab deruxtecan (I-DXd) and raludotatug deruxtecan (R-DXd). The companies will jointly develop and potentially commercialize these ADC candidates worldwide""}, {""date"": ""20231019210600"", ""headline"": ""TOP NEWS: Daiichi Sankyo soars on USD22 billion Merck cancer drug deal"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231019220200"", ""headline"": ""Catalyst Watch: Tech earnings blitz, Qualcomm event and Stellantis reveals"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231019220400"", ""headline"": ""Friday Sector Leaders: Healthcare, Consumer Products"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231019220600"", ""headline"": ""Merck, Daiichi Sankyo Ink Commercialization Deal for Up to $22 Billion"", ""summary"": ""Merck and  Daiichi Sankyo  agreed to jointly develop and commercialize three potential cancer treatments in a deal worth up to $22 billion.  Merck and Daiichi Sankyo will develop and commercialize three antibody drug conjugate candidates\u2014patritumab deruxtecan, ifinatamab deruxtecan and raludotatug deruxtecan\u2014worldwide.  Daiichi Sankyo will retain exclusive rights in Japan.""}, {""date"": ""20231019230000"", ""headline"": ""Bond Prices Are Slumping Again. Consider These Dividend ETFs Instead."", ""summary"": ""Morningstar has identified four dividend funds that hold quality companies and have a proven record.""}, {""date"": ""20231019231100"", ""headline"": ""Investor Risk Sentiment Wavers Amid War, Interest Rate Concerns; Tesla Earnings Disappoint: The Week In The Markets"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231020001700"", ""headline"": ""Merck assumed with Buy from Neutral at UBS"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231020013600"", ""headline"": ""Merck & Company\u2019s Stock: A Buy Recommendation due to Favorable Collaborations and Promising ADC Portfolio"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231020015700"", ""headline"": ""Merck (NYSE:MRK) Joins Hands with Daichi Sankyo to Develop Cancer Drugs"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231020021217"", ""headline"": ""Morgan Stanley raised to Peerperform, Merck a Buy at UBS: 4 big analyst picks"", ""summary"": ""Wolfe Research upgraded Morgan Stanley (NYSE:MS) to Peerperform from Underperform.""}, {""date"": ""20231020031000"", ""headline"": ""Merck announces results from KEYNOTE-671 trial at ESMO Congress"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231020032600"", ""headline"": ""Merck announces results from KEYNOTE-811 trial at ESMO Congress"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231020032900"", ""headline"": ""Merck announces results from KEYNOTE-756 trial at ESMO Congress"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231020034700"", ""headline"": ""7 Healthcare Stocks to invest in for a Healthy Future"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231020041300"", ""headline"": ""Merck\u2019s Keytruda shows positive results in confirmatory trial as treatment for rare form of esophageal cancer"", ""summary"": ""Merck & Co. said Friday a late-stage trial of its blockbuster cancer drug Keytruda plus trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy...""}, {""date"": ""20231020050200"", ""headline"": ""Merck announces results from Phase 3 KEYNOTE-A18 trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231020051400"", ""headline"": ""CVS Health pulls some cough-and-cold treatments with ingredient deemed ineffective by doctors"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231020052100"", ""headline"": ""Merck, Daiichi Sankyo announce development and commercialization collaboration"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231020061600"", ""headline"": ""Merck study shows Keytruda can help lower death risk from cervical cancer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231020061600"", ""headline"": ""Merck upgraded to Buy at UBS citing upside to consensus"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231020080000"", ""headline"": ""KEYTRUDA\u00ae (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as Single Agent After Surgery Reduced Risk of Death by 28% Versus Pre-Operative Chemotherapy in Resectable Stage II, IIIA or IIIB Non-Small Cell Lung Cancer (NSCLC)"", ""summary"": ""RAHWAY, N.J., October 20, 2023--KEYTRUDA Plus Chemo Before Surgery & Continued as Single Agent After Surgery Reduced Risk of Death by 28% Vs Pre-Operative Chemo in Resectable NSCLC""}, {""date"": ""20231020080100"", ""headline"": ""KEYTRUDA\u00ae (pembrolizumab) Plus Trastuzumab and Chemotherapy Significantly Improved Progression-Free Survival (PFS) Versus Trastuzumab and Chemotherapy in First-Line HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma"", ""summary"": ""RAHWAY, N.J., October 20, 2023--KEYTRUDA Plus Trastuzumab and Chemo Significantly Improved PFS Versus Trastuzumab and Chemo in First-Line HER2+ Advanced Gastric or GEJ Cancer""}, {""date"": ""20231020080200"", ""headline"": ""Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Plus Chemotherapy Showed Statistically Significant Improvement in Pathological Complete Response (pCR) Rate as Neoadjuvant Therapy Versus Chemotherapy in High-Risk, Early-Stage ER+/HER2- Breast Cancer"", ""summary"": ""RAHWAY, N.J., October 20, 2023--Neoadjuvant KEYTRUDA Plus Chemo Showed Statistically Significant Improvement in pCR Rate Vs Chemo in High-Risk, Early-Stage ER+/HER2- Breast Cancer""}, {""date"": ""20231020082600"", ""headline"": ""Buy Rating Assigned to Merck & Co.: Strategic Collaboration for Anti-Cancer ADCs Promises Revenue Diversification and Long-Term Value"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231020093037"", ""headline"": ""Merck Q3 2023 Earnings Preview: Keytruda LOE Continues To Dominate Narrative"", ""summary"": ""Keytruda, Merck's immuno-oncology drug, continues to drive significant revenue growth. Read more to see a detailed analysis on MRK stock.""}, {""date"": ""20231020100000"", ""headline"": ""Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Plus Concurrent Chemoradiotherapy Significantly Improved Progression-Free Survival (PFS) Versus Concurrent Chemoradiotherapy Alone in Newly Diagnosed, High-Risk Locally Advanced Cervical Cancer"", ""summary"": ""RAHWAY, N.J., October 20, 2023--Merck\u2019s KEYTRUDA Plus Concurrent Chemoradiotherapy Significantly Improved PFS in Newly Diagnosed, High-Risk Locally Advanced Cervical Cancer""}, {""date"": ""20231020121900"", ""headline"": ""NEW YORK MARKET CLOSE: Tech suffers as rate nerves, Middle East weighs"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231020123500"", ""headline"": ""Merck & Co. Inc. stock outperforms market on strong trading day"", ""summary"": ""Shares of Merck & Co. Inc. rose 2.23% to $102.67 Friday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""20231020130200"", ""headline"": ""Merck (MRK) Inks Deal With Daiichi to Develop Cancer Drugs"", ""summary"": ""Per the terms, Merck (MRK) and Daiichi Sankyo will develop and market three ADC drugs to treat multiple types of cancer. Following the execution, Merck will make an upfront payment of $4 billion.""}, {""date"": ""20231020163022"", ""headline"": ""AT&T, Merck-Daiichi Sankyo, Klaviyo: Top Stocks"", ""summary"": ""Scotiabank analysts upgrade AT&T (T) stock from \""Sector Perform\"" to \""Sector Outperform.\"" Merck (MRK) strikes a deal worth up to $22 billion with Japanese pharmaceutical company Daiichi Sankyo (4568.T) to jointly develop an antibody drug for cancer treatment. Lastly, Klaviyo (KVYO) closes Friday lower below its IPO debut price of $30 per share. Yahoo Finance's Julie Hyman and Josh Lipton highlight several of Friday's trending sticks after the closing bell. For more expert insight and the latest market action,\u00a0click here\u00a0to watch this full episode of Yahoo Finance Live.""}, {""date"": ""20231021043300"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Exelixis (EXEL), American Well (AMWL) and Merck & Company (MRK)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231021084500"", ""headline"": ""Merck\u2019s WELIREG\u00ae (belzutifan) Significantly Improved Progression-Free Survival and Objective Response Rates Versus Everolimus in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)"", ""summary"": ""RAHWAY, N.J., October 21, 2023--Merck\u2019s WELIREG\u00ae Significantly Improved PFS and Objective Response Rates Versus Everolimus in Certain Previously Treated Patients With Advanced RCC""}, {""date"": ""20231021234200"", ""headline"": ""Merck announces results from Phase 3 KEYNOTE-A39 trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231022031200"", ""headline"": ""Merck announces results from Phase 3 LITESPARK-005 trial investigating WELIREG"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231022031900"", ""headline"": ""Earnings week ahead: Amazon, Microsoft, Alphabet, Meta, Ford, GM and more"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231022103000"", ""headline"": ""KEYTRUDA\u00ae (pembrolizumab) Plus Padcev\u00ae (enfortumab vedotin-ejfv) Reduced Risk of Death by More Than Half Versus Chemotherapy in Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer"", ""summary"": ""RAHWAY, N.J., October 22, 2023--KEYTRUDA Plus Padcev (enfortumab vedotin-ejfv) Reduced Risk of Death by More Than Half Vs. Chemotherapy in Patients With Previously Untreated la/mUC""}, {""date"": ""20231022171100"", ""headline"": ""Immutep Shares Jump 13% on Lung-Cancer Combination Trial Data"", ""summary"": ""By Stuart Condie SYDNEY--Immutep shares are on course for their best day since June after the Australia-listed developer of cancer treatments presented...""}]",{}
41,2023-10-22,100.01789855957031,2023-10-29,100.16402435302734,0.0014609964372527262,U1,"[{""date"": ""20231021234200"", ""headline"": ""Merck announces results from Phase 3 KEYNOTE-A39 trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231022031200"", ""headline"": ""Merck announces results from Phase 3 LITESPARK-005 trial investigating WELIREG"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231022031900"", ""headline"": ""Earnings week ahead: Amazon, Microsoft, Alphabet, Meta, Ford, GM and more"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231022103000"", ""headline"": ""KEYTRUDA\u00ae (pembrolizumab) Plus Padcev\u00ae (enfortumab vedotin-ejfv) Reduced Risk of Death by More Than Half Versus Chemotherapy in Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer"", ""summary"": ""RAHWAY, N.J., October 22, 2023--KEYTRUDA Plus Padcev (enfortumab vedotin-ejfv) Reduced Risk of Death by More Than Half Vs. Chemotherapy in Patients With Previously Untreated la/mUC""}, {""date"": ""20231022171100"", ""headline"": ""Immutep Shares Jump 13% on Lung-Cancer Combination Trial Data"", ""summary"": ""By Stuart Condie SYDNEY--Immutep shares are on course for their best day since June after the Australia-listed developer of cancer treatments presented...""}, {""date"": ""20231022212800"", ""headline"": ""Seagen/ Astellas succeed in Phase 3 trial for bladder cancer therapy"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231022215100"", ""headline"": ""Check Out What Whales Are Doing With MRK"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231022221700"", ""headline"": ""Amazon, Alphabet, Meta, Intel Q3 Earnings This Week: Will Mega-Caps Shatter Forecasts And Revive Market?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231022235300"", ""headline"": ""Merck, Seagen, Astellas hail \""groundbreaking\"" data for bladder cancer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231023002700"", ""headline"": ""Hold Rating on Merck & Company: Assessing Growth Potential Through Collaborative Oncology Ventures"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231023010400"", ""headline"": ""Merck says Welireg data shows reduction is disease progression"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231023020911"", ""headline"": ""Daiichi Sankyo: Positive Long-Term Outlook With High Market Expectations"", ""summary"": ""Daiichi Sankyo is a Japanese pharmaceutical company known for its flagship products Lixiana and Enhertu. Click here to read my analysis of DSKYF stock.""}, {""date"": ""20231023024100"", ""headline"": ""Astellas Pharma upgraded to Buy from Hold at Jefferies"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231023030700"", ""headline"": ""Promising Collaborations and Emerging Treatments Reinforce Buy Rating for Merck & Company: An Analysis"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231023031600"", ""headline"": ""Cantor Fitzgerald Sticks to Their Buy Rating for Merck & Company (MRK)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231023033600"", ""headline"": ""Merck & Company\u2019s Stock Receives a Buy Rating: Analysis of Growth Opportunities and Strategic Partnerships"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231023033937"", ""headline"": ""Merck discontinues some cancer drug development with China's Sichuan Kelun"", ""summary"": ""Chinese drugmaker Sichuan Kelun Pharmaceutical Co said on Monday that Merck & Co Inc was abandoning the joint development of two candidate cancer drugs which have yet to start clinical trials.  Representatives for Merck did not immediately respond to a Reuters request for comment.  The move comes days after Merck said it would pay Daiichi Sankyo $5.5 billion to jointly develop three of its candidate cancer drugs in a deal that could be worth up to $22 billion for the Japanese firm.""}, {""date"": ""20231023050258"", ""headline"": ""Daiichi Sankyo: Merck Partnership Poises Both Companies For ADC Expansion"", ""summary"": ""Daiichi Sankyo (DSNKY) collaboration with Merck on 3 antibody-drug conjugates offers financial security and potential success. Read more on this partnership.""}, {""date"": ""20231023063500"", ""headline"": ""Pivotal Week Coming Up: Big Tech Earnings, Geopolitics, Technicals, Treasury Yield..."", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231023070022"", ""headline"": ""Those who invested in Merck (NYSE:MRK) five years ago are up 76%"", ""summary"": ""When you buy and hold a stock for the long term, you definitely want it to provide a positive return. Furthermore...""}, {""date"": ""20231023073210"", ""headline"": ""Merck & Co. Inc. (MRK) Merck & Co. Announced Collaboration with Daiichi Sankyo and ESMO Investor Event (Transcript)"", ""summary"": ""Merck & Co. Inc.""}, {""date"": ""20231023101000"", ""headline"": ""Charles River (CRL) Offers Access to Preclinical Cancer Research"", ""summary"": ""Charles River (CRL) contributes to 84 percent of the FDA-approved cancer medicines and provides partners with 16 oncology prospects.""}, {""date"": ""20231023115648"", ""headline"": ""Cantor Fitzgerald Reiterates Merck (MRK) Overweight Recommendation"", ""summary"": """"}, {""date"": ""20231023121000"", ""headline"": ""NetScientific investee claims promising results in biomarker study"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231024014500"", ""headline"": ""Merck expected to report higher Q3 revenue, despite drop in COVID-19 drug sales"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231024044400"", ""headline"": ""VTV: A Great ETF for Value Investors"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231024044500"", ""headline"": ""VTV: A Must-Watch ETF for Value Investors"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231024080000"", ""headline"": ""Merck Senior Vice President Sarah Aiosa Named to Most Powerful Latinas List"", ""summary"": ""NORTHAMPTON, MA / ACCESSWIRE / October 24, 2023 / We're proud to celebrate Sarah M. Aiosa, SVP and president, Latin America, for being recognized as one of The Association of Latino Professionals for Americas' 2023 Most Powerful Latinas! Sarah was ...""}, {""date"": ""20231024110259"", ""headline"": ""12 Defensive Healthcare Dividend Stocks To Invest In"", ""summary"": ""In this article, we discuss 12 defensive healthcare dividend stocks to invest in. You can skip our detailed analysis of the healthcare sector and dividend stocks, and go directly to read 5 Defensive Healthcare Dividend Stocks To Invest In. The healthcare sector has undergone significant evolution over the years, especially after the pandemic. Advances in [\u2026]""}, {""date"": ""20231024123500"", ""headline"": ""Merck & Co. Inc. stock falls Tuesday, underperforms market"", ""summary"": ""Shares of Merck & Co. Inc. dropped 0.31% to $103.03 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P...""}, {""date"": ""20231024210800"", ""headline"": ""Merck\u2019s Oncology Strategy: Pembrolizumab Success and Promising ADC Pipeline \u2013 A Buy Recommendation"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231024212100"", ""headline"": ""Merck & Company: A Buy Rating Driven by Oncology Portfolio Diversification and Strategic Collaborations"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231025032500"", ""headline"": ""Notable companies reporting before tomorrow's open"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231025041552"", ""headline"": ""10 Best Dialysis and Kidney Disease Stocks to Buy"", ""summary"": ""In this article, we will take a look at the 10 best dialysis and kidney disease stocks to buy. To see more such companies, go directly to 5 Best Dialysis and Kidney Disease Stocks to Buy. According to the National Kidney Foundation, millions of people die every year due to kidney failures because they do not [\u2026]""}, {""date"": ""20231025042809"", ""headline"": ""20 Countries with Lowest Rates of Cancer"", ""summary"": ""In this article, we will be taking a look at the 20 countries with lowest rates of cancer. If you want to skip our analysis of the oncology industry, then head straight to 5 Countries with Lowest Rates of Cancer. Cancer\u2014 a disease in which some of the body\u2019s cells grow uncontrollably and spread to [\u2026]""}, {""date"": ""20231025045158"", ""headline"": ""10 Most Effective Methods of Birth Control and Biggest Brands In This Space"", ""summary"": ""In this article, we shall discuss the 10 most effective methods of birth control and biggest brands in this space. To skip our detailed analysis of the contraceptives industry and the FemTech revolution in 2023, go directly and see 5 Most Effective Methods of Birth Control. According to a market report by Precedence Research, the [\u2026]""}, {""date"": ""20231025072000"", ""headline"": ""Travelers, Microsoft share gains contribute to Dow's 85-point climb"", ""summary"": ""Shares of Travelers and Microsoft are trading higher Wednesday morning, lifting the Dow Jones Industrial Average into positive territory. The Dow was most...""}, {""date"": ""20231025073000"", ""headline"": ""KEYTRUDA\u00ae (pembrolizumab) Plus LENVIMA\u00ae (lenvatinib) is Available for the First-Line Treatment of Adult Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC)"", ""summary"": ""Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai announced today that KEYTRUDA\u00ae, an anti-PD-1 therapy, in combination with LENVIMA\u00ae, the multiple receptor tyrosine kinase inhibitor discovered by Eisai, is reimbursed under the Alberta, British Columbia, Nova Scotia, Ontario, Quebec, and Saskatchewan drug plans with respective clinical criteria and conditions for adult patients with advanced (not amenable to curative surgery or radiation) or metastatic renal cell car""}, {""date"": ""20231025074000"", ""headline"": ""Merck ends trial for oral Alzheimer\u2019s candidate amid liver toxicity cases"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231025105900"", ""headline"": ""Is a Surprise Coming for Merck & Co. (MRK) This Earnings Season?"", ""summary"": ""Merck & Co. (MRK) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.""}, {""date"": ""20231025114737"", ""headline"": ""Amazon earnings, Merck reports, Southwest Airlines: 3 things to watch"", ""summary"": ""Investing.com -- Stocks weakened, led by a sinking Nasdaq after Alphabet (NASDAQ:GOOGL)'s miss on revenue expectations from its cloud operations.""}, {""date"": ""20231025123500"", ""headline"": ""Merck & Co. Inc. stock rises Wednesday, outperforms market"", ""summary"": ""Shares of Merck & Co. Inc. inched 0.58% higher to $103.63 Wednesday, on what proved to be an all-around poor trading session for the stock market, with the...""}, {""date"": ""20231025132700"", ""headline"": ""Merck Raises Sales Outlook After Earnings Beat"", ""summary"": ""Pharmaceutical stocks have generally fallen, partly because of regulatory concerns, but also because high interest rates have made the companies dividends...""}, {""date"": ""20231025172448"", ""headline"": ""Amazon and Ford earnings, U.S. GDP: What to Watch"", ""summary"": ""Yahoo Finance Live anchor Josh Lipton previews the top industry headlines for Thursday, October 26, including Amazon (AMZN) and Ford (F) earnings among many others, as well as the latest reading of the U.S. Gross Domestic Product. For more expert insight and the latest market action,\u00a0click here\u00a0to watch this full episode of Yahoo Finance Live.""}, {""date"": ""20231025203900"", ""headline"": ""GLOBAL BRIEFING: Dollar crosses JPY150; StanChart profit down 54%"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231025233500"", ""headline"": ""What You Missed On Wall Street On Thursday"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231026004700"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS), Merck & Company (MRK) and Integra Lifesciences (IART)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231026013100"", ""headline"": ""Merck reports Q3 adjusted EPS $2.13, consensus $1.84"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231026013200"", ""headline"": ""Merck cuts FY23 adjusted EPS view to $1.33-$1.38 from $2.95-$3.05"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231026013500"", ""headline"": ""Merck Non-GAAP EPS of $2.13 beats by $0.18, revenue of $16B beats by $730M"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231026021000"", ""headline"": ""Merck lifts 2023 outlook amid strong sales for COVID-19 pill"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231026022100"", ""headline"": ""Merck in charts: Pharmaceutical sales up 10% Y/Y, led by KEYTRUDA and GARDASIL"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231026023200"", ""headline"": ""Merck third-quarter results beat estimates, boosted by cancer drug and vaccine growth"", ""summary"": ""Drugmaker raises full-year sales outlook but cuts earnings guidance as it digests recent deals""}, {""date"": ""20231026024300"", ""headline"": ""Nasdaq Futures Plunge As Meta Warns Of Q4 Softness: GDP Data, Amazon Earnings On Investors' Radar Amid Market Mayhem"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231026024800"", ""headline"": ""Merck: Q3 Earnings Snapshot"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231026030500"", ""headline"": ""The Passive Income Snowball Path To Wealth: VYM Vs. DGRW"", ""summary"": ""WisdomTree US Quality Dividend Growth ETF and Vanguard High Dividend Yield ETF are 2 popular dividend growth ETFs. Read our take on which is the better buy right now.""}, {""date"": ""20231026031700"", ""headline"": ""TOP NEWS: Merck hails Daiichi Sankyo partnership but will take charge"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231026033500"", ""headline"": ""Merck 3Q Profit Rose as Sales of Breast Cancer Treatment Jumped"", ""summary"": ""By Jeffrey T. Lewis Merck's profit increased in the third quarter after sales of cancer treatments and vaccines boosted sales in the period. The Rahway,...""}, {""date"": ""20231026040600"", ""headline"": ""5 stocks to watch on Thursday: Ford, Meta, Comcast and more"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231026063000"", ""headline"": ""Merck 3rd-quarter profit tops expectations on COVID pill surprise"", ""summary"": ""Merck & Co on Thursday reported higher-than-expected third-quarter sales and profit on surprisingly strong demand for  its COVID-19 treatment, primarily in Japan.  Sales of Merck's top-selling cancer immunotherapy Keytruda rose 17% to $6.34 billion for the quarter, while Gardasil, its vaccine to prevent cancers caused by the human papillomavirus (HPV) rose 13% to $2.59 billion.  Molnupiravir was initially hailed as a potential breakthrough when few treatment options were available, but was soon eclipsed by Pfizer's rival treatment Paxlovid, which had more impressive data, and it fell out of favor.""}, {""date"": ""20231026063000"", ""headline"": ""Merck Announces Third-Quarter 2023 Financial Results"", ""summary"": ""RAHWAY, N.J., October 26, 2023--Merck Announces Third-Quarter 2023 Financial Results""}, {""date"": ""20231026063316"", ""headline"": ""Merck quarterly profit tops expectations on COVID pill surprise"", ""summary"": ""(Reuters) -Merck & Co on Thursday reported higher-than-expected results in the third quarter on surprisingly strong demand for its COVID-19 treatment, primarily in Japan, and raised its annual sales forecast for the therapy.  Sales of molnupiravir, the COVID-19 antiviral pill sold under brand name Lagevrio, jumped 47% to $640 million in the quarter, crushing Wall Street estimates of $120 million, according to LSEG data.  Molnupiravir was initially hailed as a potential breakthrough when few treatment options were available, but was soon eclipsed by Pfizer's rival treatment Paxlovid, which had more impressive data.""}, {""date"": ""20231026065800"", ""headline"": ""What You Missed On Wall Street This Morning"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231026070900"", ""headline"": ""MRK May 2024 Options Begin Trading"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231026080528"", ""headline"": ""UPDATE 1-Merck quarterly profit tops expectations on COVID pill surprise"", ""summary"": ""Merck & Co on Thursday reported higher-than-expected results in the third quarter on surprisingly strong demand for its COVID-19 treatment, primarily in Japan, and raised its annual sales forecast for the therapy.  Molnupiravir was initially hailed as a potential breakthrough when few treatment options were available, but was soon eclipsed by Pfizer's rival treatment Paxlovid, which had more impressive data.  Paxlovid dominates the out-of-hospital COVID-treatment market in the United States, and in the EU, the regulator recommended against use of Merck's drug.""}, {""date"": ""20231026080837"", ""headline"": ""12 Best Dow Jones Dividend Stocks According to Hedge Funds"", ""summary"": ""In this article, we discuss 12 best Dow Jones dividend stocks according to hedge funds. You can skip our detailed analysis of dividend stocks and their performance, and go directly to read 5 Best Dow Jones Dividend Stocks According to Hedge Funds. The Dow Jones Industrial Average, often simply referred to as the Dow, is [\u2026]""}, {""date"": ""20231026082900"", ""headline"": ""US Stocks Sink, VIX Soars As Overheated Economy, Mixed Earnings Complicate Fed's Action: What's Driving Markets Thursday?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231026085700"", ""headline"": ""US Stocks Sink, VIX Soars As Overheated Economy, Mixed Earnings Complicate Fed's Path: What's Driving Markets Thursday?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231026095648"", ""headline"": ""Merck & Co., Inc. 2023 Q3 - Results - Earnings Call Presentation"", ""summary"": ""The following slide deck was published by Merck & Co., Inc.""}, {""date"": ""20231026104304"", ""headline"": ""Merck & Co., Inc. (MRK) Q3 2023 Earnings Call Transcript"", ""summary"": ""Merck & Co., Inc. (NYSE:NYSE:MRK) Q3 2023 Earnings Conference Call October 26, 2023 9:00 AM ETCompany ParticipantsPeter Dannenbaum - Vice President,...""}, {""date"": ""20231026121400"", ""headline"": ""NEW YORK MARKET CLOSE: Tech slips again despite robust economic growth"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231026123500"", ""headline"": ""Merck & Co. Inc. stock outperforms competitors on strong trading day"", ""summary"": ""Shares of Merck & Co. Inc. rallied 1.85% to $105.55 Thursday, on what proved to be an all-around dismal trading session for the stock market, with the S&P...""}, {""date"": ""20231026135100"", ""headline"": ""Health Care Down Amid Mixed Earnings -- Health Care Roundup"", ""summary"": ""Health-care companies fell amid mixed earnings. Merck shares rose after the Big Pharma concern reported third-quarter results that topped analysts'...""}, {""date"": ""20231026211900"", ""headline"": ""Merck & Company: A Buy Recommendation Based on Consistent Outperformance and Promising Future Growth Potential"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231026220300"", ""headline"": ""Catalyst Watch: Apple earnings, Fed policy meeting, jobs report"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231027001800"", ""headline"": ""Merck upgraded to Outperform from Market Perform at BMO Capital"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231027010100"", ""headline"": ""Pfizer, Merck COVID-19 drugs moving to commercial market on Nov. 1: report"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231027020200"", ""headline"": ""Analysts Conflicted on These Healthcare Names: Blueprint Medicines (BPMC), Abbott Labs (ABT) and Merck & Company (MRK)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231027034100"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Dexcom (DXCM), Aclaris Therapeutics (ACRS) and Merck & Company (MRK)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231027035000"", ""headline"": ""GLOBAL BROKER RATINGS: BofA cuts Mercedes-Benz to 'neutral'"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231027051119"", ""headline"": ""Moderna: Looking Beyond Covid, The Pipeline Is Promising"", ""summary"": ""Investors should consider accumulating Moderna stock due to its promising pipeline and significant upside potential, despite short-term setbacks. Click here to read my analysis.""}, {""date"": ""20231027055300"", ""headline"": ""Chevron, JPMorgan Chase share losses lead Dow's 100-point drop"", ""summary"": ""Behind negative returns for shares of Chevron and JPMorgan Chase, the Dow Jones Industrial Average is falling Friday morning. Shares of Chevron and JPMorgan...""}, {""date"": ""20231027070059"", ""headline"": ""Merck (NYSE:MRK) Seems To Use Debt Quite Sensibly"", ""summary"": ""Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...""}, {""date"": ""20231027072900"", ""headline"": ""3 Deeply Undervalued Growth Stocks"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231027082700"", ""headline"": ""Dow down nearly 200 points on losses for shares of Chevron, Verizon"", ""summary"": ""Shares of Chevron and Verizon are trading lower Friday afternoon, dragging the Dow Jones Industrial Average into negative territory. The Dow was most...""}, {""date"": ""20231027092800"", ""headline"": ""Chevron, JPMorgan Chase share losses contribute to Dow's 286-point drop"", ""summary"": ""Shares of Chevron and JPMorgan Chase are trading lower Friday afternoon, sending the Dow Jones Industrial Average into negative territory. Shares of Chevron...""}, {""date"": ""20231027093300"", ""headline"": ""Company News for Oct 27, 2023"", ""summary"": ""Companies in The News Are: MRK, UPS, IBM, CBRE""}, {""date"": ""20231027100122"", ""headline"": ""Roblox upgraded, Bristol Myers downgraded: Wall Street's top analyst calls"", ""summary"": ""Roblox upgraded, Bristol Myers downgraded: Wall Street's top analyst calls""}, {""date"": ""20231027123500"", ""headline"": ""Merck & Co. Inc. stock falls Friday, underperforms market"", ""summary"": ""Shares of Merck & Co. Inc. slipped 2.59% to $102.82 Friday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500...""}, {""date"": ""20231027162238"", ""headline"": ""Morgan Stanley Maintains Merck (MRK) Equal-Weight Recommendation"", ""summary"": """"}, {""date"": ""20231027162238"", ""headline"": ""BMO Capital Upgrades Merck (MRK)"", ""summary"": """"}, {""date"": ""20231027214000"", ""headline"": ""Week In Review: Hansoh Sells Ex-China ADC Rights To GSK In $1.6 Billion Deal"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231028053000"", ""headline"": ""5 Buy Rated Stocks For November 2023"", ""summary"": ""S&P 500 has fallen 10% since August 1st, providing opportunities to buy high-quality stocks at discounted prices. Explore more details here.""}, {""date"": ""20231028152627"", ""headline"": ""Merck & Co., Inc. (NYSE:MRK) Q3 2023 Earnings Call Transcript"", ""summary"": ""Merck & Co., Inc. (NYSE:MRK) Q3 2023 Earnings Call Transcript October 26, 2023 Merck & Co., Inc. beats earnings expectations. Reported EPS is $2.13, expectations were $1.95. Operator: [Started Abruptly] \u2026 Merck & Co. Q3 Sales and Earnings Conference Call. At this time, all participants are in a listen-only mode until the question-and-answer session of [\u2026]""}, {""date"": ""20231029053600"", ""headline"": ""Merck & Company (MRK) Receives a Buy from Truist Financial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231029070500"", ""headline"": ""Pharma, PBMs spar over rising drug costs amid public scrutiny"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]",{}
42,2023-10-29,100.16402435302734,2023-11-05,100.70956420898438,0.005446465030541026,U1,"[{""date"": ""20231029053600"", ""headline"": ""Merck & Company (MRK) Receives a Buy from Truist Financial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231029070500"", ""headline"": ""Pharma, PBMs spar over rising drug costs amid public scrutiny"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231029224600"", ""headline"": ""Apple, AMD, Palantir Earnings On Deck This Week As Market Seeks Positive Catalysts In Fed Decision Week"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231030052541"", ""headline"": ""11 Best Immunotherapy Stocks To Buy Now"", ""summary"": ""In this article, we discuss 11 of the best immunotherapy stocks to buy now. If you want to skip our detailed discussion on the cancer and oncology industry, head directly to the 5 Best Immunotherapy Stocks To Buy Now. The global oncology landscape is continually transforming, driven by persistent efforts to explore, create, and deliver [\u2026]""}, {""date"": ""20231030123500"", ""headline"": ""Merck & Co. Inc. stock falls Monday, underperforms market"", ""summary"": ""Shares of Merck & Co. Inc. dropped 0.14% to $102.68 Monday, on what proved to be an all-around great trading session for the stock market, with the S&P 500...""}, {""date"": ""20231030163554"", ""headline"": ""13 Most Undervalued Pharma Stocks To Buy According To Analysts"", ""summary"": ""In this piece, we will take a look at the 13 most undervalued pharmaceutical stocks to buy according to analysts. If you want to skip our overview of the pharma industry, then check out 5 Most Undervalued Pharma Stocks To Buy. The pharmaceutical industry is one of the biggest in the world and one that [\u2026]""}, {""date"": ""20231030212100"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Dexcom (DXCM), AbbVie (ABBV) and Merck & Company (MRK)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231030221100"", ""headline"": ""Analysts\u2019 Opinions Are Mixed on These Healthcare Stocks: Abcam (ABCM), Viridian Therapeutics (VRDN) and Merck & Company (MRK)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231030233600"", ""headline"": ""Merck & Co. Inc. stock rises Tuesday, still underperforms market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231031012000"", ""headline"": ""Daiichi Sankyo ups revenue and profit, boosts quarterly dividend"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231031020100"", ""headline"": ""2 No-Brainer AI Stocks to Buy and One to Run Away From"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231031041800"", ""headline"": ""Jim Cramer Says Hold Onto This Tech Stock, But 'You're Not Going To Make A Lot Of Money In It Right Now, Because That Was A Really Terrible Last Quarter'"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231031090018"", ""headline"": ""Merck & Co., Inc.'s (NYSE:MRK) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?"", ""summary"": ""Merck (NYSE:MRK) has had a rough three months with its share price down 2.5%. But if you pay close attention, you might...""}, {""date"": ""20231031112510"", ""headline"": ""Analyzing The Acquisition Potential Of ImmunoGen"", ""summary"": ""ImmunoGen has an approved drug, a modest pipeline with a catalyst upcoming, and a market cap of around $3.6 billion. Find out why IMGN stock is a Buy.""}, {""date"": ""20231031211100"", ""headline"": ""Healthcare Playbook: Hardly Defensive With A Covid Hangover In Biotech"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231101013600"", ""headline"": ""Merck reports KEYNOTE-564 trial met its key overall survival secondary endpoint"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231101015700"", ""headline"": ""Merck therapy shows improved survival in certain kidney cancer patients"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231101020500"", ""headline"": ""Merck: FDA approves Keytruda in combination with gemcitabine and cisplatin"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231101045300"", ""headline"": ""Merck wins FDA approval for Keytruda in biliary tract cancer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231101060000"", ""headline"": ""Dow's 100-point rally highlighted by gains for Microsoft, Boeing shares"", ""summary"": ""Led by positive growth for shares of Microsoft and Boeing, the Dow Jones Industrial Average is trading up Wednesday morning. Shares of Microsoft and Boeing...""}, {""date"": ""20231101063000"", ""headline"": ""KEYTRUDA\u00ae (pembrolizumab) Significantly Improved Overall Survival (OS) Versus Placebo as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma (RCC) Following Nephrectomy"", ""summary"": ""RAHWAY, N.J., November 01, 2023--KEYTRUDA Significantly Improved OS Versus Placebo as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma (RCC) Following Nephrectomy""}, {""date"": ""20231101064500"", ""headline"": ""FDA Approves Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Plus Gemcitabine and Cisplatin as Treatment for Patients With Locally Advanced Unresectable or Metastatic Biliary Tract Cancer"", ""summary"": ""RAHWAY, N.J., November 01, 2023--FDA Approves Merck\u2019s KEYTRUDA\u00ae Plus Gemcitabine and Cisplatin as Treatment for Patients With Locally Advanced Unresectable or Metastatic BTC""}, {""date"": ""20231101065000"", ""headline"": ""Merck to Participate in the UBS BioPharma Conference"", ""summary"": ""RAHWAY, N.J., November 01, 2023--Merck to Participate in the UBS BioPharma Conference""}, {""date"": ""20231101080300"", ""headline"": ""Dow's 100-point rally led by gains in Microsoft, Intel stocks"", ""summary"": ""Powered by strong returns for shares of Microsoft and Intel, the Dow Jones Industrial Average is climbing Wednesday afternoon. The Dow was most recently...""}, {""date"": ""20231101081800"", ""headline"": ""A Look Into Merck & Co Inc's Price Over Earnings"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231101082300"", ""headline"": ""Merck & Co says Keytruda to treat biliary cancer approved by US FDA"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231101085700"", ""headline"": ""Merck's Blockbuster Cancer Drug Keytruda Secures FDA Approval For Biliary Tract Cancer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231101123500"", ""headline"": ""Merck & Co. Inc. stock rises Wednesday, still underperforms market"", ""summary"": ""Shares of Merck & Co. Inc. inched 0.15% higher to $102.85 Wednesday, on what proved to be an all-around great trading session for the stock market, with the...""}, {""date"": ""20231102050000"", ""headline"": ""Pfizer: Value Investment Opportunity After Recent Price Decline"", ""summary"": ""Pfizer still generates significant gross profit and has a strong revenue growth rate. Read why I feel PFE stock presents a value investment opportunity now.""}, {""date"": ""20231102081800"", ""headline"": ""Merck & Company: A Promising Investment Driven by Diversification and Innovative Pipeline"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231102084000"", ""headline"": ""10 Health Care Stocks Whale Activity In Today's Session"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231102123500"", ""headline"": ""Merck & Co. Inc. stock remains steady Thursday, underperforms market"", ""summary"": ""Shares of Merck & Co. Inc. were unchanged Thursday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""20231102163700"", ""headline"": ""Q3 Earnings Season Scorecard and Analyst Reports for Merck, Bank of America & AMD"", ""summary"": ""Today's Research Daily features the Q3 earnings season scorecard and new research reports on Merck (MRK), Bank of America (BAC), AMD (AMD) and others.""}, {""date"": ""20231103022800"", ""headline"": ""Merck price target raised to $135 from $130 at Citi"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231103024000"", ""headline"": ""Actinium Pharmaceuticals names Lynn Bodarky as Chief Business Officer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231103030500"", ""headline"": ""Werewolf Therapeutics jumps on early-sage data from lead program"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231103032100"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Nuvation Bio (NUVB) and Generation Bio (GBIO)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231103043200"", ""headline"": ""Moderna upgraded at HSBC; says bearish thesis has played out"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231103094600"", ""headline"": ""The Zacks Analyst Blog Highlights Merck, Bank of America, AMD, Netflix and Union Pacific"", ""summary"": ""Merck, Bank of America, AMD, Netflix and Union Pacific are part of the Zacks top Analyst Blog.""}, {""date"": ""20231103123500"", ""headline"": ""Merck & Co. Inc. stock rises Friday, still underperforms market"", ""summary"": ""Shares of Merck & Co. Inc. inched 0.52% higher to $103.38 Friday, on what proved to be an all-around great trading session for the stock market, with the S&P...""}, {""date"": ""20231104090000"", ""headline"": ""3 Trustworthy Blue-Chip Stocks to Buy Now"", ""summary"": ""As economic uncertainty rises, blue-chip stocks to buy can provide stability for the prudent investor. Typically, these are resilient and established businesses with a track record of steady performance. In addition, in prior downturns, they have preserved capital relative to the market. In today\u2019s financial markets, you must bolster your portfolio with blue-chip stocks. Rising interest rates, unsustainable U.S. debt, and conflicts in the Middle East and Ukraine all pose significant risks. There""}, {""date"": ""20231104214000"", ""headline"": ""Mizuho's Top Stock Picks For November Revealed"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]",{}
43,2023-11-05,100.70956420898438,2023-11-12,98.77096557617188,-0.019249399478977747,D2,"[{""date"": ""20231104214000"", ""headline"": ""Mizuho's Top Stock Picks For November Revealed"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231106023600"", ""headline"": ""Portage Biotech presents updates on its iNKT, adenosine programs at SITC"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231106024300"", ""headline"": ""Merck highlights list of healthcare stocks among Mizuho's top picks"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231106040000"", ""headline"": ""Acurx Undervalued And Set For Potential M&A With Next-Gen C. Diff Treatment"", ""summary"": ""Acurx is a promising antibiotic company with perfect Phase 2a data in treating C. difficile infection. Find out why ACXP stock is a Buy.""}, {""date"": ""20231106051300"", ""headline"": ""Walt Disney Co. names PepsiCo's Hugh Johnston as chief financial officer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231106060500"", ""headline"": ""Eli Lilly chief scientific officer \u2018extremely optimistic\u2019 that major new Alzheimer\u2019s breakthrough is coming\u00a0"", ""summary"": ""Dr. Daniel Skovronsky believes a big leap in Alzheimer\u2019s disease treatment may be just around the corner\u2013and that an overlooked class of medicines could...""}, {""date"": ""20231106071300"", ""headline"": ""Risk On For Biotech - Time To Trade The Small Caps"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231106090009"", ""headline"": ""Insiders At Merck Sold US$5.5m In Stock, Alluding To Potential Weakness"", ""summary"": ""In the last year, many Merck & Co., Inc. ( NYSE:MRK ) insiders sold a substantial stake in the company which may have...""}, {""date"": ""20231106104453"", ""headline"": ""IHE: You Better Like Eli Lilly And Johnson & Johnson To Buy This"", ""summary"": ""The iShares U.S. Pharmaceuticals ETF offers targeted exposure to the pharmaceutical industry with a concentrated portfolio. Read more about IHE here.""}, {""date"": ""20231106112812"", ""headline"": ""November Dogs Of The Dow: 3 Buyable, 4 Watchable"", ""summary"": ""Learn about the Dow Jones Industrial Average and the top-performing stocks in November. Click to see our exclusive list of dividend stocks we consider buyable now.""}, {""date"": ""20231106113500"", ""headline"": ""Merck & Co. Inc. stock outperforms competitors on strong trading day"", ""summary"": ""Shares of Merck & Co. Inc. inched 0.93% higher to $104.34 Monday, on what proved to be an all-around positive trading session for the stock market, with the...""}, {""date"": ""20231107113500"", ""headline"": ""Merck & Co. Inc. stock falls Tuesday, underperforms market"", ""summary"": ""Shares of Merck & Co. Inc. sank 0.33% to $104.00 Tuesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500...""}, {""date"": ""20231107211900"", ""headline"": ""BioXcel Therapeutics Reveals Survival Data From Prostate Cancer Combo Therapy Trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231107222800"", ""headline"": ""Merck initiated with a Buy at Deutsche Bank"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231108014100"", ""headline"": ""Grab these 2 funds with rich 11%-12% yields while you can"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231108025000"", ""headline"": ""BioXcel spikes after mid-stage data for prostate cancer drug"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231108064500"", ""headline"": ""Merck to Participate in the Jefferies London Healthcare Conference"", ""summary"": ""RAHWAY, N.J., November 08, 2023--Merck to Participate in the Jefferies London Healthcare Conference""}, {""date"": ""20231108110100"", ""headline"": ""Ligand Reports Third Quarter 2023 Financial Results"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231108113500"", ""headline"": ""Merck & Co. Inc. stock rises Wednesday, outperforms market"", ""summary"": ""Shares of Merck & Co. Inc. inched 0.38% higher to $104.40 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the...""}, {""date"": ""20231109010300"", ""headline"": ""10 Analysts Have This to Say About Merck & Co"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231109010809"", ""headline"": ""Deutsche warms to Merck; Ralph Lauren snags a buy rating: 4 big analyst picks"", ""summary"": ""Here is your Pro Recap of the biggest analyst picks you may have missed since yesterday: a Buy initiation at Merck, and upgrades at Ralph Lauren, TopBuild, and Valaris.  Deutsche Bank initiated coverage on Merck (NYSE:MRK) with a Buy rating and a price target of $115.00, as reported in real time on InvestingPro.  Analysts noted that Merck's Keytruda drug has become a central element for oncology treatment regimens and is likely to continue being a growth driver until at least fiscal year 2028.""}, {""date"": ""20231109015700"", ""headline"": ""GLOBAL BROKER RATINGS: Wells Fargo raises Adyen; HSBC likes AB InBev"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231109025845"", ""headline"": ""Merck: Investing In Excellence"", ""summary"": ""Merck's diverse portfolio, including its flagship drug Keytruda, positions it for future growth. See why I think MRK stock is still a strong buy.""}, {""date"": ""20231109072200"", ""headline"": ""Eli Lilly declines a day after FDA nod for weight loss therapy"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231109073937"", ""headline"": ""Deutsche Bank Initiates Coverage of Merck (MRK) with Buy Recommendation"", ""summary"": """"}, {""date"": ""20231109075200"", ""headline"": ""Fortunes Can Be Made With Bristol-Myers Squibb"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231109075830"", ""headline"": ""Zoetis: High-Quality Compounder With A Reasonable Price After Earnings"", ""summary"": ""Zoetis operates in 2 main categories: livestock, which is growing slowly, and the faster-growing companion market for pets. Find out why ZTS stock is a Buy.""}, {""date"": ""20231109092617"", ""headline"": ""7 Safe Stocks to Buy if You Think Q3\u2019s Gangbuster Growth Won\u2019t Last"", ""summary"": ""At first glance, the proposal to dive into safe stocks to buy might appear overly conservative. As NPR recently pointed out, the U.S. GDP grew 4.9% in the third quarter, catalyzed by stronger-than-expected consumer spending. While stunning, the good times might not last. For one thing, experts warn that the economy is unlikely to sustain the current blistering pace. In particular, higher interest rates \u2013 which obviously impose elevated borrowing costs \u2013 may crimp upside. Pointing to the slowdown""}, {""date"": ""20231109094200"", ""headline"": ""Dow's nearly 250-point fall led by losses in shares of Amgen, Home Depot"", ""summary"": ""Shares of Amgen and Home Depot are posting losses Thursday afternoon, sending the Dow Jones Industrial Average into negative territory. Shares of Amgen and...""}, {""date"": ""20231109113500"", ""headline"": ""Merck & Co. Inc. stock outperforms competitors despite losses on the day"", ""summary"": ""Shares of Merck & Co. Inc. shed 1.93% to $102.38 Thursday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500...""}, {""date"": ""20231109123700"", ""headline"": ""Top Analyst Reports for McDonald's, ConocoPhillips & RTX"", ""summary"": ""Today's Research Daily features new research reports on 16 major stocks, including McDonald's Corporation (MCD), ConocoPhillips (COP) and RTX Corporation (RTX).""}, {""date"": ""20231109213000"", ""headline"": ""Cantor biotech/biopharma analysts hold analyst/industry conference call"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231110014600"", ""headline"": ""Merck announces CHMP opinion recommending approval of Keytruda"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231110020700"", ""headline"": ""Qualcomm, Merck And 2 Other Stocks Insiders Are Selling"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231110021300"", ""headline"": ""IO Biotech completes enrollment in Phase 3 trial of advanced melanoma"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231110023300"", ""headline"": ""Merck's Keytruda gets CHMP nod for combo therapy of biliary tract cancer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231110030500"", ""headline"": ""Merck Gets CHMP Backing for Keytruda in Biliary Tract Cancer"", ""summary"": ""By Colin Kellaher Merck &amp; Co. on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended expanded approval...""}, {""date"": ""20231110032700"", ""headline"": ""WHO\u2019s new COVID guidelines see fewer patients requiring hospitalization"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231110041800"", ""headline"": ""Looking Into Merck & Co's Recent Short Interest"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231110063700"", ""headline"": ""10 Health Care Stocks Whale Activity In Today's Session"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231110070000"", ""headline"": ""7 Biotech Stocks to Buy for Big-Time Gains"", ""summary"": ""This is an amazing week to consider biotech stocks. Big news by the U.S. Food & Drug Administration (which we\u2019ll get to momentarily) shows the benefits and outsized gains you can enjoy by choosing the right biotech stock. Biotech companies have the potential to be big winners because of their very nature. They\u2019re at the forefront of scientific innovation and push the boundaries of medical research, drug development, and healthcare solutions. By investing in biotech stocks, you support and potent""}, {""date"": ""20231110074000"", ""headline"": ""Merck Receives Positive EU CHMP Opinion for KEYTRUDA\u00ae (pembrolizumab) Plus Gemcitabine and Cisplatin as First-Line Treatment for Locally Advanced Unresectable or Metastatic Biliary Tract Cancer"", ""summary"": ""RAHWAY, N.J., November 10, 2023--Merck Receives EU CHMP Opinion for KEYTRUDA Plus Gemcitabine and Cisplatin as First-Line Treatment for Locally Advanced Unresectable or Metastatic BTC""}, {""date"": ""20231110113500"", ""headline"": ""Merck & Co. Inc. stock falls Friday, underperforms market"", ""summary"": ""Shares of Merck & Co. Inc. slumped 0.97% to $101.39 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P...""}, {""date"": ""20231111060034"", ""headline"": ""Merck & Co., Inc. (NYSE:MRK) is favoured by institutional owners who hold 77% of the company"", ""summary"": ""Key Insights Given the large stake in the stock by institutions, Merck's stock price might be vulnerable to their...""}, {""date"": ""20231111071020"", ""headline"": ""Merck & Co., Inc. (MRK) Presents at UBS BioPharma Conference (Transcript)"", ""summary"": ""Merck & Co., Inc. (NYSE:NYSE:MRK) UBS BioPharma Conference November 8, 2023 12:00 PM ETCompany ParticipantsJannie Oosthuizen - President, U.S.""}, {""date"": ""20231112004732"", ""headline"": ""High-Quality Dividend Growth Near 52-Week Lows: Pfizer Is Phenomenal"", ""summary"": ""Pfizer appears to be a good investment opportunity due to its high quality, future growth projections, and sustainable dividend. Explore more details here.""}, {""date"": ""20231112170615"", ""headline"": ""Passive Income Snowball: How Does VYM Stack Up Against 6 Competing ETFs?"", ""summary"": ""Vanguard High Dividend Yield Index Fund ETF is a well-diversified, low-cost dividend growth fund for passive income. Find out why VYM is a Hold.""}]",{}
44,2023-11-12,98.77096557617188,2023-11-19,99.12167358398438,0.0035507196448538725,U1,"[{""date"": ""20231112004732"", ""headline"": ""High-Quality Dividend Growth Near 52-Week Lows: Pfizer Is Phenomenal"", ""summary"": ""Pfizer appears to be a good investment opportunity due to its high quality, future growth projections, and sustainable dividend. Explore more details here.""}, {""date"": ""20231112170615"", ""headline"": ""Passive Income Snowball: How Does VYM Stack Up Against 6 Competing ETFs?"", ""summary"": ""Vanguard High Dividend Yield Index Fund ETF is a well-diversified, low-cost dividend growth fund for passive income. Find out why VYM is a Hold.""}, {""date"": ""20231112220600"", ""headline"": ""Barrow, Hanley, Mewhinney & Strauss Adjusts Portfolio, Major Moves in Dollar General Corp"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231112231955"", ""headline"": ""OUSA: Attractive Quality, Average Performance"", ""summary"": ""OUSA ETF holds 100 dividend stocks selected and weighted based on profitability, dividend quality, leverage and volatility. Read why I'm neutral on the fund.""}, {""date"": ""20231113051235"", ""headline"": ""Nike, Merck Among 13 Companies To Announce Annual Dividend Increases In H2 Of November"", ""summary"": ""13 companies are set to announce annual dividend increases in the second half of November. Click here to read what investors need to know.""}, {""date"": ""20231113113500"", ""headline"": ""Merck & Co. Inc. stock outperforms competitors on strong trading day"", ""summary"": ""Shares of Merck & Co. Inc. rallied 1.07% to $102.47 Monday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones...""}, {""date"": ""20231113145611"", ""headline"": ""10 Healthcare Focused Hedge Funds and 10 Top Stock Picks"", ""summary"": ""In this article, we discuss 10 healthcare focused hedge funds and 10 top stock picks. You can skip our detailed analysis of the performance of healthcare focused hedge funds and go directly to read 10 Healthcare Focused Hedge Funds and 5 Top Stock Picks. Hedge funds resort to defensive stocks when faced with economic growth uncertainty [\u2026]""}, {""date"": ""20231113160344"", ""headline"": ""Robert Bruce's Investment Strategy Leads to Notable Changes in Portfolio, Highlighting Merck ..."", ""summary"": ""Insight into the Latest 13F Filing Reveals Key Stock Adjustments by Value Investing Firm Bruce & Co""}, {""date"": ""20231113190505"", ""headline"": ""13 Cheap Blue Chip Stocks To Buy"", ""summary"": ""In this piece, we will take a look at the 13 cheap blue chip stocks to buy. To skip our overview of the blue chip sector and the latest news about the stock market, take a look at the 5 Cheap Blue Chip Stocks To Buy. Within the American stock market, the Dow Jones Industrial [\u2026]""}, {""date"": ""20231113191238"", ""headline"": ""The 3 Best Defensive Stocks for Uncertain Times"", ""summary"": ""Investment is not just the art of finding potential multi-bagger stocks. There is a lot of thinking and strategizing involved in creating a portfolio that beats the index, delivers regular cash flows, and ensures capital preservation in challenging market conditions. To ensure capital preservation, some of the best defensive stocks need to be included in the portfolio. In general, defensive stocks can be defined as names that have a low beta. Further, defensive stocks are invariably blue-chip st""}, {""date"": ""20231114020700"", ""headline"": ""Natera enters oncology research agreement with Merck"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231114025700"", ""headline"": ""Agilent gastric cancer assay wins FDA nod"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231114030000"", ""headline"": ""MilliporeSigma Launches ChemisTwin\u2122, First Ever Digital Reference Material Platform for Analytical Testing"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231114030400"", ""headline"": ""Kahn Brothers Adjusts Holdings with Notable Moves in BP PLC and CSX Corp"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231114043500"", ""headline"": ""Merck to use Natera's database for oncology drug research"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231114053000"", ""headline"": ""Earnings Estimates Are Falling. These Two Companies Are Shouldering the Blame."", ""summary"": ""Investors appear to be taking the shifting picture in stride, partly because much of the responsibility appears to fall on Pfizer and Merck.""}, {""date"": ""20231114061900"", ""headline"": ""Merck: Tracking Well Above The Industry"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231114073000"", ""headline"": ""EMD Serono Announces Plans for New U.S. Healthcare Headquarters in Boston\u2019s Seaport District"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231114113500"", ""headline"": ""Merck & Co. Inc. stock underperforms Tuesday when compared to competitors"", ""summary"": ""Shares of Merck & Co. Inc. slid 0.29% to $102.17 Tuesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500...""}, {""date"": ""20231114123001"", ""headline"": ""The S&P 500 Has Two Companies to Thank for the Slide in Earnings Estimates"", ""summary"": ""Wall Street analysts often trim their estimates for S&P 500 earnings during the first month of a quarter. This time, the cuts have been deeper than usual. Investors don't seem particularly rattled. That may be because just two companies\u2014Pfizer and Merck\u2014accounted for half of the decline in quarterly profit estimates from Oct.""}, {""date"": ""20231114232100"", ""headline"": ""FDA reviewers reportedly question efficacy of Merck cough drug"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231115034100"", ""headline"": ""UBS highlights 14 stocks on its list of high-conviction names"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231115071500"", ""headline"": ""Alkermes separates cancer drug business as new company Mural"", ""summary"": ""Now independent Mural Oncology will focus on advancing a pipeline of engineered cytokines for cancer, while Alkermes has recast itself as a \u201cpure-play\u201d neuroscience company.""}, {""date"": ""20231115071800"", ""headline"": ""Pfizer, Merck said to be behind cuts to Q4 earnings views"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231115072331"", ""headline"": ""US FDA staff flags concerns on Merck's chronic cough drug"", ""summary"": ""U.S. Food and Drug Administration'sreviewers on Wednesday flagged concerns that data on Merck'schronic cough drug might not be sufficient to provemeaningful benefit, according to documents released...""}, {""date"": ""20231115113500"", ""headline"": ""Merck & Co. Inc. stock falls Wednesday, underperforms market"", ""summary"": ""Shares of Merck & Co. Inc. shed 0.80% to $101.35 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the S&P...""}, {""date"": ""20231115202400"", ""headline"": ""Pembrolizumab with chemo approved for HER2-negative gastric or GEJ adenocarcinoma"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231115212600"", ""headline"": ""Cantor Fitzgerald Sticks to Its Buy Rating for Merck & Company (MRK)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231115234100"", ""headline"": ""FDA approves Merck's Keytruda plus chemotherapy as first-line treatment"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231116005000"", ""headline"": ""FDA Approves Bristol-Myers' Lung Cancer Drug Acquired Via $4B Turning Point Deal: Competes With Roche, Merck, AstraZeneca"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231116025505"", ""headline"": ""Merck & Co., Inc. (MRK) Presents at Jefferies London Healthcare Conference (Transcript)"", ""summary"": ""Merck & Co., Inc. (NYSE:NYSE:MRK) Jefferies London Healthcare Conference November 16, 2023 5:00 AM ETCompany ParticipantsCaroline Litchfield - Chief...""}, {""date"": ""20231116035700"", ""headline"": ""Pfizer: Undervalued At Peak Pessimism in the Post-COVID-19 Era"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231116042000"", ""headline"": ""Marks Electrical half-year profit declines despite strong sales"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231116062400"", ""headline"": ""MRK July 2024 Options Begin Trading"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231116063300"", ""headline"": ""Merck's Gefapixant Under FDA Lens: Advisory Committee To Discuss Chronic Cough Drug's Future"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231116113500"", ""headline"": ""Merck & Co. Inc. stock rises Thursday, outperforms market"", ""summary"": ""Shares of Merck & Co. Inc. inched 0.63% higher to $101.99 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the...""}, {""date"": ""20231116125200"", ""headline"": ""Merck\u2019s Keytruda gets approval to treat certain types of gastric cancer"", ""summary"": ""Merck said late Thursday that the Food and Drug Administration has approved its star cancer drug Keytruda as treatment for some adult gastrointestinal...""}, {""date"": ""20231116174000"", ""headline"": ""FDA Approves Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Plus Chemotherapy as First-Line Treatment for Locally Advanced Unresectable or Metastatic HER2-Negative Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma"", ""summary"": ""RAHWAY, N.J., November 16, 2023--FDA Approves Merck\u2019s KEYTRUDA Plus Chemo as First-Line Treatment for Locally Advanced Unresectable or Metastatic HER2-Negative Gastric or GEJ Cancer""}, {""date"": ""20231116200800"", ""headline"": ""Senator's Bearish Tesla Bet Under Scrutiny As He Buys Put Options Ahead Of Elon Musk-Led Company's Q3 Results That Set Stock Slide In Motion"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231116234900"", ""headline"": ""FDA panel votes 12-1 against Merck's gefapixant, Reuters reports"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231117000800"", ""headline"": ""Merck gets FDA nod for Keytruda in stomach cancer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231117001100"", ""headline"": ""Bayer's Legal Victory Against Merck: Delaware Court Rules In Company's Favor Regarding Talc Lawsuits"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231117012503"", ""headline"": ""Merck : FDA approves Keytruda for gastric cancer"", ""summary"": ""Merck announced on Friday that the U.S. Food and Drug Administration had approved Keytruda for the first-line treatment of cancers of the stomach and esogastric junction.The pharmaceutical group...""}, {""date"": ""20231117024600"", ""headline"": ""FDA Approves Merck's Blockbuster Cancer Drug For Type Of Gastric Cancer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231117032400"", ""headline"": ""4 stocks to watch on Friday: Zoom, ChargePoint, Li Auto and more"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231117041842"", ""headline"": ""FDA Approves Merck's KEYTRUDA Plus Chemotherapy as First-Line Treatment for Locally Advanced Unresectable or Metastatic HER2-Negative Gastric or Gastroesophageal Junction Adenocarcinoma"", ""summary"": ""RAHWAY - Merck , known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration has approved KEYTRUDA, Merck's anti-PD-1 therapy, in combination...""}, {""date"": ""20231117044500"", ""headline"": ""Cantor biotech/biopharma analysts hold analyst/industry conference call"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231117061300"", ""headline"": ""AstraZeneca: Growth Is Still A Better Choice"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231117071000"", ""headline"": ""5 Top Growth Stocks to Buy Now, According to Analysts \u2013 November 2023"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231117082700"", ""headline"": ""Merck & Co says Keytruda combination receives US FDA approval"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231117110738"", ""headline"": ""US FDA panel votes against Merck's chronic cough drug"", ""summary"": ""The U.S. health regulator's adviserson Friday did not recommend Merck's drug for thetreatment of chronic cough. The FDA panel voted 12 to 1 that the data presented does notdemonstrate...""}, {""date"": ""20231117112900"", ""headline"": ""Merck (MRK) Gets FDA Nod for Keytruda Expansion in Gastric Cancer"", ""summary"": ""Following this approval, Merck's (MRK) Keytruda is approved for seven gastrointestinal cancers. Overall, the drug is approved for 38 indications in the country.""}, {""date"": ""20231117113500"", ""headline"": ""Merck & Co. Inc. stock underperforms Friday when compared to competitors"", ""summary"": ""Shares of Merck & Co. Inc. dropped 0.24% to $101.75 Friday, on what proved to be an all-around great trading session for the stock market, with the S&P 500...""}, {""date"": ""20231117124503"", ""headline"": ""Merck : Provides Update on FDA Advisory Committee Meeting Evaluating Gefapixant"", ""summary"": ""November 17, 2023 5:31 pm ET RAHWAY, N.J., Nov. 17, 2023 - Merck , known as MSD outside of the United States and Canada, today announced the outcome of the U.S. Food and Drug...""}, {""date"": ""20231118072700"", ""headline"": ""Merck's Latest Drug For Chronic Cough Faces FDA Pushback"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231119060200"", ""headline"": ""M&A, GLP-1s to dominate healthcare themes in 2024 as COVID fades: survey"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231119094337"", ""headline"": ""Ken Griffin Stock Portfolio: Top 10 Stock Picks"", ""summary"": ""In this piece, we will take a look at the top ten stock picks of Ken Griffin and his hedge fund Citadel Investment Group. If you want to skip our introduction to the billionaire hedge fund boss and his firm, then take a look at Ken Griffin Stock Portfolio: Top 5 Stock Picks. Ken Griffin\u2019s [\u2026]""}]",{}
45,2023-11-19,99.12167358398438,2023-11-26,99.23857116699219,0.0011793342341901436,U1,"[{""date"": ""20231119060200"", ""headline"": ""M&A, GLP-1s to dominate healthcare themes in 2024 as COVID fades: survey"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231119094337"", ""headline"": ""Ken Griffin Stock Portfolio: Top 10 Stock Picks"", ""summary"": ""In this piece, we will take a look at the top ten stock picks of Ken Griffin and his hedge fund Citadel Investment Group. If you want to skip our introduction to the billionaire hedge fund boss and his firm, then take a look at Ken Griffin Stock Portfolio: Top 5 Stock Picks. Ken Griffin\u2019s [\u2026]""}, {""date"": ""20231119201100"", ""headline"": ""Analysts Conflicted on These Healthcare Names: Fresenius Medical Care (FMS), Solid Biosciences (SLDB) and Merck & Company (MRK)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231119223700"", ""headline"": ""Merck & Co. Inc. stock rises Monday, outperforms market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231119225100"", ""headline"": ""Merck disappointed as FDA panel refuses to recommend gefapixant"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231119233500"", ""headline"": ""Three Solid Stocks That Still Have Plenty Of Growth Left"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231120021800"", ""headline"": ""Merck fails to win over FDA panel for cough therapy"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231120064500"", ""headline"": ""Merck to Participate in the 6th Annual Evercore ISI HealthCONx Conference"", ""summary"": ""RAHWAY, N.J., November 20, 2023--Merck to Participate in the 6th Annual Evercore ISI HealthCONx Conference""}, {""date"": ""20231120200000"", ""headline"": ""A Golden Age of Vaccines Is Here. What It Means for You."", ""summary"": ""Pharmaceutical companies are currently developing vaccines for a range of purposes, from preventing disease to treating cancers.""}, {""date"": ""20231120203400"", ""headline"": ""Noteworthy Tuesday Option Activity: MRK, MDT, MA"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231120212600"", ""headline"": ""Merck & Company (MRK) Gets a Buy from Cantor Fitzgerald"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231120223600"", ""headline"": ""Merck & Co. Inc. stock underperforms Tuesday when compared to competitors"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231120231600"", ""headline"": ""These ten stocks, not just from tech, are the key to next year\u2019s S&P 500 earnings growth"", ""summary"": ""Here are the companies that are expected to drive the bulk of earnings growth next year for the S&P 500.""}, {""date"": ""20231120233144"", ""headline"": ""Merck: A Dividend Growth Stock Worth Considering"", ""summary"": ""Merck reports positive quarterly earnings and consistent dividend growth over 12 years. Read why MRK stock is well-positioned for potential future success.""}, {""date"": ""20231121004700"", ""headline"": ""Merck to acquire Caraway Therapeutics for up to $610M"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231121010200"", ""headline"": ""Merck to acquire Caraway Therapeutics for $610M"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231121015056"", ""headline"": ""Merck & Co To Acquire Caraway Therapeutics"", ""summary"": ""Merck & Co Inc: * MERCK TO ACQUIRE CARAWAY THERAPEUTICS, INC. * MERCK & CO INC: PROPOSED DEAL FOR TOTAL POTENTIAL CONSIDERATION OF UP TO$610MILLION * MERCK...""}, {""date"": ""20231121015129"", ""headline"": ""Merck to acquire Caraway Therapeutics for up to $610 mln"", ""summary"": ""Merck & Co will acquireCaraway Therapeutics for a total potential consideration of upto $610 million, the companies said on Tuesday. ...""}, {""date"": ""20231121021300"", ""headline"": ""Merck paying $610 million for Caraway Therapeutics"", ""summary"": ""Merck & Co. Inc. said Tuesday it agreed to pay up to $610 million to acquire Caraway Therapeutics, a preclinical biopharmaceutical company pursuing new...""}, {""date"": ""20231121031803"", ""headline"": ""Merck : agreement to acquire Caraway Therapeutics"", ""summary"": ""Merck announced on Tuesday that it had reached a definitive agreement to acquire the US biopharmaceutical company Caraway Therapeutics for up to $610 million.Under the terms of the agreement, the US...""}, {""date"": ""20231121042100"", ""headline"": ""IN BRIEF: Merck & Co inks deal to buy investee Caraway Therapeutics"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231121063700"", ""headline"": ""J&J, Merck, Bristol Myers CEOs asked to testify before Senate panel on drug prices"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231121064500"", ""headline"": ""Merck to Acquire Caraway Therapeutics, Inc."", ""summary"": ""RAHWAY, N.J., & CAMBRIDGE, Mass., November 21, 2023--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Caraway Therapeutics, Inc. announced today that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Caraway Therapeutics for a total potential consideration of up to $610 million, including an undisclosed upfront payment as well as contingent milestone payments. The upfront payment will be expensed by Merck in t""}, {""date"": ""20231121072000"", ""headline"": ""Merck to buy private biotech Caraway in neuroscience deal"", ""summary"": ""In a deal worth up to $610 million, Merck will gain a pipeline of neuroscience and rare disease programs from a startup it previously backed.""}, {""date"": ""20231121072043"", ""headline"": ""UPDATE 1-Merck to acquire Caraway Therapeutics for up to $610 mln"", ""summary"": ""Merck & Co will acquire Caraway Therapeutics for a total potential consideration of up to $610 million, the companies said on Tuesday, to build on its treatment pipeline of nervous system-related diseases.  Merck, through a subsidiary, will acquire all outstanding shares of Caraway for an undisclosed upfront payment and earnout milestones linked to the development of certain drugs Caraway has in the pipeline.  Drug developer Caraway's drug pipeline includes experimental treatment of genetically defined neurodegenerative and rare diseases, including Parkinson's disease.""}, {""date"": ""20231121161515"", ""headline"": ""Tracking Jeremy Grantham's GMO Capital Portfolio - Q3 2023 Update"", ""summary"": ""Jeremy Grantham's 13F portfolio value declined by 2% to $21.17B in Q3 2023. Microsoft, UnitedHealth, Alphabet, J&J, and Meta Platforms are top holdings.""}, {""date"": ""20231121201800"", ""headline"": ""Top gainers and laggards in S&P, DJI, and NDX on Wednesday"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231121223600"", ""headline"": ""Merck & Co. Inc. stock falls Wednesday, underperforms market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231122010300"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (AXSM), Merck & Company (MRK) and Twist Bioscience (TWST)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231122011900"", ""headline"": ""Strategic Acquisition of Caraway Therapeutics Bolsters Merck\u2019s Portfolio: An In-depth Analysis and Buy Rating Recommendation"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231122035900"", ""headline"": ""GSK: Undervalued At Peak Pessimism"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231122040000"", ""headline"": ""Merck: Keytruda Patent Expiry Nears With Replacement Yet To Be Found"", ""summary"": ""For now, Merck's prospects have somewhat dimmed, with management engaging on expensive partnerships to boost its pipelines. Learn why we rate MRK stock a hold.""}, {""date"": ""20231122053804"", ""headline"": ""Merck: Not The Time To Be Adding"", ""summary"": ""Merck's stock has seen a sustained pattern of lower highs and lower lows. Read why MRK stock remains a hold for us at present.""}, {""date"": ""20231122055700"", ""headline"": ""Merck's Caraway Deal: Analyst Says \""Timely, Anchored By Novel Programs & Management Team\"""", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231122073800"", ""headline"": ""Top gainers and laggards in S&P, DJI, and NDX Today - CNBC"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231122121502"", ""headline"": ""20 Healthiest States in the US in 2023"", ""summary"": ""In this article, we will look into the 20 healthiest states in the US in 2023. If you want to skip our detailed analysis, you can go directly to the 5 Healthiest States in the US in 2023. Health Status of the US According to the OECD Health at a Glance 2023 report, The United [\u2026]""}, {""date"": ""20231122213824"", ""headline"": ""Merck Will Keep Your Retirement Income Healthy"", ""summary"": ""Merck presents a compelling investment opportunity with its strong growth prospects, low forward P/E ratio, and upcoming dividend hike. Read more on MRK here.""}, {""date"": ""20231123160253"", ""headline"": ""Stability Seekers: 7 Low-Volatility Stocks for Uncertain Times"", ""summary"": ""At first blush, focusing on low-volatility stocks may appear an overly pessimistic strategy. After all, the benchmark S&P 500 gained almost 8% in the trailing month. On a year-to-date basis, the venerable index is up nearly 19%, very close to its record high. Nevertheless, it doesn\u2019t hurt to prepare for negative outcomes. Yes, thinking positively carries a desirable premium in society. However, that\u2019s not how this works on Wall Street. Mister Market gives two you-know-whats about investors\u2019 feel""}, {""date"": ""20231124113500"", ""headline"": ""Merck & Co. Inc. stock rises Friday, outperforms market"", ""summary"": ""Shares of Merck & Co. Inc. inched 0.19% higher to $101.87 Friday, on what proved to be an all-around great trading session for the stock market, with the S&P...""}, {""date"": ""20231124222010"", ""headline"": ""MannKind: Continues To Kick The Can Down The Road For Investors"", ""summary"": ""MannKind (MNKD) needs to decide if Afrezza will be a reliable source of revenue or a drag on future revenues. Click here to read more.""}, {""date"": ""20231125070024"", ""headline"": ""Merck (NYSE:MRK) shareholders have earned a 9.4% CAGR over the last five years"", ""summary"": ""When you buy and hold a stock for the long term, you definitely want it to provide a positive return. Furthermore...""}, {""date"": ""20231125090000"", ""headline"": ""SCHD: Time To Be Really Greedy"", ""summary"": ""Learn why SCHD may have reached peak pessimism in October, making it an opportunity for investors to be greedy and capitalize on its recovery.""}, {""date"": ""20231125162254"", ""headline"": ""11 Best Fortune 500 Dividend Stocks To Buy Now"", ""summary"": ""In this article, we discuss 11 best Fortune 500 dividend stocks to buy now. You can skip our detailed analysis of large-cap dividend stocks and their performance in the past, and go directly to read 5 Best Fortune 500 Dividend Stocks To Buy Now. The Fortune 500 is an annual list compiled and published by [\u2026]""}]",{}
46,2023-11-26,99.23857116699219,2023-12-03,100.7874984741211,0.015608117780358421,U2,"[{""date"": ""20231126212900"", ""headline"": ""Biden Plans to Boost Drug Production Using Cold-War Era Law"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231127054410"", ""headline"": ""Mastercard, Pfizer Among 18 Companies To Announce Dividend Increases In December"", ""summary"": ""2H of November saw announcements of annual dividend increases from 9 companies. 16 other companies will announce annual increases before Christmas. Read more here.""}, {""date"": ""20231127065300"", ""headline"": ""Biotech And Healthcare Portfolio Playbook For December 2023/24"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231127071500"", ""headline"": ""President Biden to use 1950 law to boost essential drug production"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231127113500"", ""headline"": ""Merck & Co. Inc. stock falls Monday, underperforms market"", ""summary"": ""Shares of Merck & Co. Inc. sank 0.43% to $101.43 Monday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""20231127205100"", ""headline"": ""PFAS's Forever Problem: Ohio Lawsuit Against Chemical Companies Fizzles Out"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231127210900"", ""headline"": ""Merck raises dividend by 5.5% to $0.77"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231128005000"", ""headline"": ""Merck's pneumococcal vaccine shows superior immunogenicity"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231128021300"", ""headline"": ""Merck pneumococcal shot shows superior immunogenicity in late-stage trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231128024200"", ""headline"": ""Vaxcyte appoints Lee to board of directors"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231128041602"", ""headline"": ""Merck : promising results for pneumococcal vaccine"", ""summary"": ""Merck today announced the results of a Phase 3 trial evaluating V116, its investigational 21-valent pneumococcal conjugate vaccine specifically designed to protect adults. In adults aged 50 and over ,...""}, {""date"": ""20231128060800"", ""headline"": ""Merck Highlights Data On New Vaccine, Compares 'Tolerability And Safety' To Pfizer's"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231128064500"", ""headline"": ""Merck\u2019s V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed to Protect Adults, Demonstrated Superior Immunogenicity for 10 of 11 Unique Serotypes Compared to PCV20 in Adults 50 Years of Age and Older"", ""summary"": ""RAHWAY, N.J., November 28, 2023--Merck\u2019s V116 an Investigational 21-valent PCV Demonstrated Superior Immunogenicity for 10 of 11 Unique Serotypes Compared to PCV20 in Adults 50+""}, {""date"": ""20231128071900"", ""headline"": ""Merck raises quarterly dividend to 77c from 73c per share"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231128074200"", ""headline"": ""Coherus cancer drug undercuts Merck's Keytruda"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231128081700"", ""headline"": ""Merck Declares Dividend for the First Quarter of 2024, Payable on January 8, 2024"", ""summary"": ""Merck announced that the Board of Directors has declared a quarterly dividend of $0.77 per share of the company?s common stock for the first quarter of 2024. Payment will be made on January 8, 2024,...""}, {""date"": ""20231128082300"", ""headline"": ""Merck raises quarterly dividend to 77 cents vs. 73 cents"", ""summary"": ""Merck & Co. Inc. said Tuesday its board has raised its quarterly dividend to 77 cents. The dividend was previously 73 cents. The new dividend is payable Jan....""}, {""date"": ""20231128084000"", ""headline"": ""Merck Raises Quarterly Dividend 5.5% To 77c"", ""summary"": ""By Ben Glickman Merck &amp; Co. raised its quarterly dividend 5.5% on Tuesday. The Rahway, N.J.-based pharmaceutical company lifted its payout to 77 cents a...""}, {""date"": ""20231128085602"", ""headline"": ""Merck Raises Quarterly Dividend 5.5% To 77 Cents"", ""summary"": ""By Ben Glickman Merck & Co. raised its quarterly dividend 5.5% on Tuesday. The Rahway, N.J.-based pharmaceutical company lifted its payout to 77 cents a share from 73 cents a share. ...""}, {""date"": ""20231128113500"", ""headline"": ""Merck & Co. Inc. stock underperforms Tuesday when compared to competitors"", ""summary"": ""Shares of Merck & Co. Inc. slid 1.23% to $100.18 Tuesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500...""}, {""date"": ""20231128131700"", ""headline"": ""Merck Announces First-Quarter 2024 Dividend"", ""summary"": ""RAHWAY, N.J., November 28, 2023--Merck Announces First-Quarter 2024 Dividend""}, {""date"": ""20231129031400"", ""headline"": ""Vanguard Health Care Fund's Strategic Moves: Spotlight on Ono Pharmaceutical Co Ltd"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231129032700"", ""headline"": ""Amazon Web Services, Accenture aid Merck move its IT infrastructure to AWS"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231129040600"", ""headline"": ""Analyst Ratings for Merck & Co"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231129041615"", ""headline"": ""Merck's V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed to Protect Adults, Demonstrated Superior Immunogenicity for 10 of 11 Unique Serotypes Compared to PCV20 in Adults 50 Years of Age and Older"", ""summary"": ""RAHWAY - Merck , known as MSD outside of the United States and Canada, today announced results from STRIDE-3, a Phase 3 trial evaluating V116, the company's investigational 21-valent pneumococcal...""}, {""date"": ""20231129060600"", ""headline"": ""Video: Daily Dividend Report: MRK,MSFT,UNP,MKC,ENB"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231129062526"", ""headline"": ""Why I Made Big Changes To My Dividend Growth Portfolio"", ""summary"": ""How to make significant changes to your portfolio, for when buying a new house and selling stocks for cash? Click here to read about my strategy.""}, {""date"": ""20231129074400"", ""headline"": ""Spyre gains as TD Cowen starts at Outperform on anti-TL1A potential"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231129080011"", ""headline"": ""We Think Merck (NYSE:MRK) Can Stay On Top Of Its Debt"", ""summary"": ""David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...""}, {""date"": ""20231129082600"", ""headline"": ""Merck's (MRK) Pneumococcal Jab Shows Upbeat Responses in Study"", ""summary"": ""Positive data from Merck's (MRK) phase III study on V116, an investigational, 21-valent pneumococcal conjugate vaccine, supports the immunogenicity of V116 compared to standard of care.""}, {""date"": ""20231129090000"", ""headline"": ""AWS and Accenture Help Merck Use Cloud Technology to Reduce Drug Discovery Time and Accelerate Clinical Trial Development"", ""summary"": ""LAS VEGAS, November 29, 2023--At AWS re:Invent, Amazon Web Services, Inc. (AWS), an Amazon.com, Inc. company (NASDAQ: AMZN), today announced it is working with Accenture (NYSE: ACN) to help Merck (NYSE: MRK), known as MSD outside of the U.S. and Canada, to move a substantial portion of its IT infrastructure to AWS as part of the company\u2019s multiyear cloud migration.""}, {""date"": ""20231129105859"", ""headline"": ""12 Best Quality Stocks To Buy Now"", ""summary"": ""In this piece, we will take a look at the 12 best quality stocks to buy now. If you want to skip our analysis of stock quality and want to jump ahead to the top five stocks in this list, then take a look at the 5 Best Quality Stocks To Buy Now. When it [\u2026]""}, {""date"": ""20231129113500"", ""headline"": ""Merck & Co. Inc. stock rises Wednesday, outperforms market"", ""summary"": ""Shares of Merck & Co. Inc. inched 0.95% higher to $101.13 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the...""}, {""date"": ""20231129211600"", ""headline"": ""Cantor Fitzgerald Sticks to Their Buy Rating for Merck & Company (MRK)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231129230700"", ""headline"": ""Seagen, Astellas and Merck announce FDA grants priority review to Padcev BLA"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231129235000"", ""headline"": ""FDA to decide on approving Keytruda/Padcev combo therapy by May 9"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231130021900"", ""headline"": ""AbbVie to acquire cancer drugmaker ImmunoGen for $10B cash (update)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231130062700"", ""headline"": ""AbbVie-ImmunoGen buyout deal lifts ADC-focused biotechs"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231130071900"", ""headline"": ""Price Over Earnings Overview: Merck & Co"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231130112424"", ""headline"": ""For DSI, Ethics Is Not A Drag"", ""summary"": ""Valuation and growth metrics for the iShares MSCI KLD 400 Social ETF are underwhelming, but quality is above-par. Read more to see our analysis on DSI.""}, {""date"": ""20231130113019"", ""headline"": ""Merck & Co., Inc. (MRK) Management Presents at 6th Annual Evercore ISI HealthCONx Conference (Transcript)"", ""summary"": ""Merck &amp; Co., Inc. (NYSE:NYSE:MRK) 6th Annual Evercore ISI HealthCONx Conference Transcript November 30, 2023 1:20 PM ETExecutivesDr.""}, {""date"": ""20231130113500"", ""headline"": ""Merck & Co. Inc. stock underperforms Thursday when compared to competitors despite daily gains"", ""summary"": ""Shares of Merck & Co. Inc. advanced 1.33% to $102.48 Thursday, on what proved to be an all-around great trading session for the stock market, with the S&P...""}, {""date"": ""20231130115530"", ""headline"": ""17 Ideal Pre-Crash Recovery December Divi-Dogs"", ""summary"": ""Discover the top pre-crash-recovery stocks of 2023 in financial services, healthcare, and real estate sectors. Click for our top dividend picks in several sectors.""}, {""date"": ""20231130170000"", ""headline"": ""FDA Grants Priority Review to Merck\u2019s Application for KEYTRUDA\u00ae (pembrolizumab) Plus Padcev\u00ae (enfortumab vedotin-ejfv) for the First-Line Treatment of Patients With Locally Advanced or Metastatic Urothelial Cancer"", ""summary"": ""RAHWAY, N.J., November 30, 2023--FDA Grants Priority Review to Merck\u2019s Application for KEYTRUDA Plus Padcev for the First-Line Treatment of Patients With Advanced Urothelial Cancer""}, {""date"": ""20231201014500"", ""headline"": ""Dividend Roundup: Merck, TD Bank, Kohl\u2019s, Haliburton, and more"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231201031603"", ""headline"": ""Merck : priority review in bladder cancer"", ""summary"": ""Merck announced on Friday that the FDA had granted priority review to its marketing application for Keytruda in bladder cancer.The American biopharmaceutical group explains that the FDA's decision...""}, {""date"": ""20231201050300"", ""headline"": ""Salesforce, Boeing share gains contribute to Dow's 100-point climb"", ""summary"": ""Buoyed by strong returns for shares of Salesforce and Boeing, the Dow Jones Industrial Average is climbing Friday morning. Shares of Salesforce and Boeing...""}, {""date"": ""20231201113500"", ""headline"": ""Merck & Co. Inc. stock rises Friday, outperforms market"", ""summary"": ""Shares of Merck & Co. Inc. inched 0.96% higher to $103.46 Friday, on what proved to be an all-around favorable trading session for the stock market, with the...""}, {""date"": ""20231202040000"", ""headline"": ""Which ETF May Disappoint Retirees The Most, SCHD Or VYM?"", ""summary"": ""Schwab's US Dividend Equity ETF (SCHD) and Vanguard's High Dividend Yield Index Fund ETF (VYM) have struggled in the past year. Explore the alternatives here.""}, {""date"": ""20231202040000"", ""headline"": ""5 Relatively Secure And Cheap Dividend Stocks To Invest In - December 2023"", ""summary"": ""Discover five large-cap dividend-paying companies with discounts to their historical norms, selected from over 7,500 U.S. traded companies. Click for our picks!""}, {""date"": ""20231202072000"", ""headline"": ""Week In Review: Tang Capital Offers $465 Million For LianBio Plus 80% Of Any Licenses/Divestments"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231202072743"", ""headline"": ""Merck (NYSE:MRK) Is Increasing Its Dividend To $0.77"", ""summary"": ""Merck & Co., Inc. ( NYSE:MRK ) will increase its dividend on the 8th of January to $0.77, which is 5.5% higher than...""}, {""date"": ""20231202230032"", ""headline"": ""Abbott Laboratories: A 'Must-Have' In A Defensive Dividend Growth Portfolio"", ""summary"": ""Abbott Laboratories had a difficult last three years, with its stock price trading sideways as sales driven by COVID-19 plummeted. Read more on ABT stock here.""}, {""date"": ""20231202233000"", ""headline"": ""Week In Review: Tang Capital Offers $465M For LianBio Plus 80% Of Any Licenses/Divestments"", ""summary"": ""Tang Capital offering $465M for LianBio Plus 80% of any Licenses/Divestments is ChinaBio's lead news this week. Click here to read more.""}, {""date"": ""20231203021023"", ""headline"": ""Dividend Champion, Contender, And Challenger Highlights: Week Of December 3"", ""summary"": ""A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Read more to see the update for the week of December 3.""}, {""date"": ""20231203064231"", ""headline"": ""Billionaire Ken Fisher\u2019s 10 Stock Picks with Huge Upside Potential"", ""summary"": ""In this article, we discuss billionaire Ken Fisher\u2019s 10 stock picks with huge upside potential. To skip Fisher\u2019s comments on current economic conditions and details about his Q3 bets, go directly to Billionaire Ken Fisher\u2019s 5 Stock Picks with Huge Upside Potential. Ken Fisher runs one of the largest and most successful hedge funds in [\u2026]""}]",{}
47,2023-12-03,100.7874984741211,2023-12-10,101.07000732421875,0.002803014802180037,U1,"[{""date"": ""20231202230032"", ""headline"": ""Abbott Laboratories: A 'Must-Have' In A Defensive Dividend Growth Portfolio"", ""summary"": ""Abbott Laboratories had a difficult last three years, with its stock price trading sideways as sales driven by COVID-19 plummeted. Read more on ABT stock here.""}, {""date"": ""20231202233000"", ""headline"": ""Week In Review: Tang Capital Offers $465M For LianBio Plus 80% Of Any Licenses/Divestments"", ""summary"": ""Tang Capital offering $465M for LianBio Plus 80% of any Licenses/Divestments is ChinaBio's lead news this week. Click here to read more.""}, {""date"": ""20231203021023"", ""headline"": ""Dividend Champion, Contender, And Challenger Highlights: Week Of December 3"", ""summary"": ""A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Read more to see the update for the week of December 3.""}, {""date"": ""20231203064231"", ""headline"": ""Billionaire Ken Fisher\u2019s 10 Stock Picks with Huge Upside Potential"", ""summary"": ""In this article, we discuss billionaire Ken Fisher\u2019s 10 stock picks with huge upside potential. To skip Fisher\u2019s comments on current economic conditions and details about his Q3 bets, go directly to Billionaire Ken Fisher\u2019s 5 Stock Picks with Huge Upside Potential. Ken Fisher runs one of the largest and most successful hedge funds in [\u2026]""}, {""date"": ""20231204011900"", ""headline"": ""Merck a Top Socially Responsible Dividend Stock With 3.0% Yield (MRK)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231204025109"", ""headline"": ""December Dogs Of The Dow: 3 Buyable, 5 Watchable"", ""summary"": ""Some of these Dow Industrials are too pricey and reveals only skinny dividends. Read here about 3 of the 5 lowest-priced Dogs of the Dow which are ready to buy.""}, {""date"": ""20231204033900"", ""headline"": ""Merck to Pay at Least $70 Mln for Rights to Abbisko Joint-Tumor Drug"", ""summary"": ""By David Sachs Merck has a deal worth at least $70 million with Abbisko Therapeutics to commercialize a drug to treat joint tumors. The German pharmaceutical...""}, {""date"": ""20231204054900"", ""headline"": ""(MRK) - Analyzing Merck & Co's Short Interest"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231204130434"", ""headline"": ""Pfizer: This Year's Disaster Should Set The Stage For A Strong 2024"", ""summary"": ""Read about Pfizer's challenges in 2023, including decreased demand for COVID-19 vaccines and antiviral products, a destructive tornado, and a weight-loss treatment.""}, {""date"": ""20231204201600"", ""headline"": ""Buy Rating for Merck & Co. on Strong Prospects for New Pneumococcal Vaccine V116"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231205003700"", ""headline"": ""Vaxcyte's pneumococcal shot shows safety profile comparable to Pfizer's Prevnar 20"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231205003956"", ""headline"": ""Macroeconomic Factors Pulled Merck & Co. (MRK) in Q3"", ""summary"": ""Carillon Tower Advisers, an investment management company, released its \u201cCarillon Eagle Mid Cap Growth Fund\u201d third quarter 2023 investor letter. A copy of the same can be downloaded here. After a robust first half of the year, the S&P 500 Index declined 3.3% in the third quarter, leaving the market up 13.1% through the first nine [\u2026]""}, {""date"": ""20231205020400"", ""headline"": ""Curis signs agreement for emavusertib/pembrolizumab combination melanoma study"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231205043300"", ""headline"": ""Incyte's Bullish Outlook: A Surprising Strength You Shouldn't Overlook"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231205044204"", ""headline"": ""5 Stocks That Recently Increased Their Dividend"", ""summary"": ""Dividend growth stocks consistently increase dividend year after year with 5-year growth rate of 10% or more. Find out 5 stocks that recently increased dividend.""}, {""date"": ""20231205054900"", ""headline"": ""Video: Dow Analyst Moves: MRK"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231205055000"", ""headline"": ""Broker Darlings of the Dow: Merck Ranks As a Top 15 Analyst Pick"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231205064933"", ""headline"": ""25 States with the Lowest Life Expectancy in the US"", ""summary"": ""In this article, we will look into the 25 states with the lowest life expectancy in the US. If you want to skip our detailed analysis, you can go directly to the 5 States with the Lowest Life Expectancy in the US. Health Outlook of the United States According to the OECD Health at a [\u2026]""}, {""date"": ""20231205090000"", ""headline"": ""MilliporeSigma Launches First Ever AI Solution to Integrate Drug Discovery and Synthesis"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231205113200"", ""headline"": ""Merck trial for evobrutinib does not meet primary endpoint"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231205113500"", ""headline"": ""Merck & Co. Inc. stock outperforms market on strong trading day"", ""summary"": ""Shares of Merck & Co. Inc. rallied 1.11% to $106.23 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500...""}, {""date"": ""20231205200700"", ""headline"": ""Merck MS Drug Fails to Meet Target of Late-Stage Trials"", ""summary"": ""By David Sachs Merck's multiple sclerosis drug evobrutinib didn't meet a key goal in late-stage trials. The German pharmaceutical company's phase 3 clinical...""}, {""date"": ""20231205213500"", ""headline"": ""German stocks rise after ending at a record high"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231206001000"", ""headline"": ""Amgen: Relative Valuation Remains Unattractive"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231206003400"", ""headline"": ""White House to back controversial patent ploy to fight drug costs, STAT says"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231206020900"", ""headline"": ""LONDON MARKET MIDDAY: Stocks rise amid dovish Fed, ECB expectations"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231206021000"", ""headline"": ""Merck a Top 25 Dividend Giant With 2.90% Yield (MRK)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231206032000"", ""headline"": ""Seagen's breast cancer drug shows positive results in combination therapy trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231206060048"", ""headline"": ""Merck & Co., Inc.'s (NYSE:MRK) Stock's On An Uptrend: Are Strong Financials Guiding The Market?"", ""summary"": ""Merck's (NYSE:MRK) stock is up by a considerable 6.0% over the past week. Given that the market rewards strong...""}, {""date"": ""20231206065200"", ""headline"": ""LONDON MARKET CLOSE: Stocks in Europe boosted by dovish rhetoric"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231206094200"", ""headline"": ""5 Dividend Stocks That Recently Increased Their Payouts"", ""summary"": ""My favorite stocks to invest in are those that continuously increase their dividend. Merck & Co (NYSE: MRK) is one stock that I like a lot that has been growing its dividend at a solid clip for a number of years.""}, {""date"": ""20231206111347"", ""headline"": ""Hedge Funds are Betting on These 14 Sliding Stocks"", ""summary"": ""In this article, we will take a look at the hedge funds that are betting on these 14 sliding stocks. To see more such companies, go directly to Hedge Funds are Betting on These 5 Sliding Stocks. Stocks jumped on December 6 after the release of yet another welcome data point for the Federal Reserve, [\u2026]""}, {""date"": ""20231206113500"", ""headline"": ""Merck & Co. Inc. stock falls Wednesday, underperforms market"", ""summary"": ""Shares of Merck & Co. Inc. dropped 0.56% to $105.63 Wednesday, on what proved to be an all-around rough trading session for the stock market, with the S&P...""}, {""date"": ""20231207000700"", ""headline"": ""Merck reports Phase 2 results of coformulation for lung cancer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231207004900"", ""headline"": ""Merck discontinues trial evaluating Keytruda combination in NSCLC"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231207005700"", ""headline"": ""Merck coformulation fails to meet key goal in lung cancer trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231207010945"", ""headline"": ""Merck's lung cancer drug combo fails to meet trial goal"", ""summary"": ""Merck said on Thursday itsexperimental therapy in combination with Keytruda to treat atype of lung cancer in previously treated patients did not reachstatistical significance in a mid-stage...""}, {""date"": ""20231207013100"", ""headline"": ""Merck halts lung cancer trial for Keytruda combo after failure in main goal"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231207020000"", ""headline"": ""Merck says trial shows improvement to progression-free survival"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231207031000"", ""headline"": ""Merck & Co to stop phase 3 trial probing Keytruda on lung cancer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231207032402"", ""headline"": ""Merck discontinues lung cancer clinical trial"", ""summary"": ""On Thursday, Merck announced the discontinuation of a Phase 3 clinical trial of its flagship immunotherapy Keytruda in squamous and metastatic non-small cell lung cancer.The biopharmaceutical group...""}, {""date"": ""20231207033900"", ""headline"": ""Double Flops For Merck's Lung Cancer Studies"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231207042200"", ""headline"": ""Video: Dow Movers: MRK, AAPL"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231207045600"", ""headline"": ""January 2024 Options Now Available For Merck (MRK)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231207060000"", ""headline"": ""Merck Announces Findings from Phase 2 KeyVibe-002 Trial Evaluating an Investigational Coformulation of Vibostolimab and Pembrolizumab in Previously Treated Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC)"", ""summary"": ""RAHWAY, N.J., December 07, 2023--Merck Announces Findings from Ph 2 KeyVibe-002 Trial Evaluating Investigational Coformulation Vibostolimab/Pembrolizumab in Previously Treated mNSCLC""}, {""date"": ""20231207063500"", ""headline"": ""Morning Brew: AI Hype Boosts Tech Stocks; AMD and Google Shine"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231207064500"", ""headline"": ""Merck Announces KEYLYNK-008 Trial Evaluating KEYTRUDA\u00ae (pembrolizumab) Plus LYNPARZA\u00ae (olaparib) for Patients With Metastatic Squamous Non-Small Cell Lung Cancer to Stop for Futility"", ""summary"": ""RAHWAY, N.J., December 07, 2023--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that it will stop the Phase 3 KEYLYNK-008 trial evaluating KEYTRUDA, Merck\u2019s anti-PD-1 therapy, in combination with maintenance LYNPARZA, a PARP inhibitor, for the treatment of patients with metastatic squamous non-small cell lung cancer (NSCLC). Merck is discontinuing the study based on the recommendation of an independent Data Monitoring Committee (DMC), which reviewed data""}, {""date"": ""20231207073300"", ""headline"": ""Merck Scraps Phase 3 Keytruda-Lynparza Lung Cancer Study"", ""summary"": ""Merck & Co. is ending a late-stage study of the combination of Keytruda and Lynparza in certain lung cancer patients due to an expected failure of the trial.""}, {""date"": ""20231207091601"", ""headline"": ""13 Best S&P 500 Dividend Stocks To Buy"", ""summary"": ""In this article, we discuss 13 best S&P 500 dividend stocks to buy. You can skip our detailed analysis of dividend stocks and their performance over the years, and go directly to read 5 Best S&P 500 Dividend Stocks To Buy. In the market conditions of 2022, when the S&P 500 Index dropped by over [\u2026]""}, {""date"": ""20231207100000"", ""headline"": ""Rare Stock Picks In November 2023 - From 31 Discerning Analysts"", ""summary"": ""Welcome to another installment of our monthly Rare Stock Picks article, where we highlight investment picks you may have missed. Explore more details here.""}, {""date"": ""20231207111400"", ""headline"": ""NEW YORK MARKET CLOSE: Stocks up despite eyes on US jobs report"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231207113500"", ""headline"": ""Merck & Co. Inc. stock falls Thursday, underperforms market"", ""summary"": ""Shares of Merck & Co. Inc. slipped 1.66% to $103.88 Thursday, on what proved to be an all-around positive trading session for the stock market, with the S&P...""}, {""date"": ""20231207121400"", ""headline"": ""Health Care Slips on Rotation Into Rate-Sensitive Sectors -- Health Care Roundup"", ""summary"": ""Health-care companies fell as traders rotated into sectors with more to gain from a shift in Federal Reserve policy. Drug giant Merck &amp; Co. pulled the...""}, {""date"": ""20231207133310"", ""headline"": ""15 Upcoming Dividend Increases"", ""summary"": ""Discover the top up-and-coming companies set to raise their dividends in December.""}, {""date"": ""20231207211800"", ""headline"": ""Merck (MRK) Shares Cross 3% Yield Mark"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231207232600"", ""headline"": ""Hold Rating on Merck Amid Uncertainty Over TIGIT Program\u2019s Efficacy"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231208004800"", ""headline"": ""Merck, Eisai provide update on Phase 3 LEAP-001 trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231208012800"", ""headline"": ""Merck Keytruda combo fails in late-stage trial for uterine cancer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231208015347"", ""headline"": ""Merck-Eisai's cancer therapy combo fails in late-stage study"", ""summary"": ""Merck said on Friday itsexperimental combination therapy being developed with partnerEisai to treat a type of cancer in the lining of theuterus failed to meet the main goals in a late-stage...""}, {""date"": ""20231208020600"", ""headline"": ""Merck, Eisai: Keytruda/Lenvima Combo Fails in 1st-Line Endometrial Cancer Study"", ""summary"": ""By Colin Kellaher Merck &amp; Co. and Eisai on Friday said a late-stage study of the cancer drugs Keytruda plus Lenvima as a first-line treatment in certain...""}, {""date"": ""20231208021547"", ""headline"": ""Merck-Eisai's uterine cancer therapy combo fails first-line treatment trial"", ""summary"": ""Merck said a combinationtherapy being developed with partner Eisai failed alate-stage trial testing it as a first-line treatment for a typeof cancer in the uterus lining, the two companies said...""}, {""date"": ""20231208022102"", ""headline"": ""Merck, Eisai : Keytruda/Lenvima Combo Fails in 1st-Line Endometrial Cancer Study"", ""summary"": ""By Colin Kellaher Merck & Co. and Eisai on Friday said a late-stage study of the cancer drugs Keytruda plus Lenvima as a first-line treatment in certain patients with endometrial cancer missed...""}, {""date"": ""20231208023300"", ""headline"": ""Merck, Eisai Report Yet Another Failure For Keytruda Plus Lenvima Combo Trial, This Time In Endometrial Cancer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231208025600"", ""headline"": ""Merck and Eisai combination endometrial cancer treatment fails to meet goals in clinical trial"", ""summary"": ""Merck & Co. Inc. and Eisai Co. Ltd. said Friday that a late-stage trial of Merck\u2019s blockbuster cancer treatment Keytruda in combination with Eisai\u2019s drug...""}, {""date"": ""20231208032910"", ""headline"": ""Merck : study in endometrial carcinoma fails"", ""summary"": ""Merck and Eisai report that the phase III LEAP-001 trial evaluating their Keytruda-Lenvima combination failed to meet its primary endpoints as a first-line treatment for patients with advanced or...""}, {""date"": ""20231208033000"", ""headline"": ""ALX Oncology shares jump 9% after Jefferies upgrade"", ""summary"": ""ALX Oncology Holdings Inc. shares climbed 9% premarket on Friday after Jefferies analysts upgraded the stock to buy, from hold. The stock is \u201cvery cheap,\u201d...""}, {""date"": ""20231208040030"", ""headline"": ""Merck suffers bad week as three Keytruda combination trials fail"", ""summary"": ""The three setbacks for Merck demonstrate the challenges drug developers face in improving on Keytruda, which has brought in at least $18 billion so far this year for its maker.""}, {""date"": ""20231208041922"", ""headline"": ""Merck Announces KEYLYNK-008 Trial Evaluating KEYTRUDA Plus LYNPARZA for Patients with Metastatic Squamous Non-Small Cell Lung Cancer to Stop for Futility"", ""summary"": ""RAHWAY - Merck , known as MSD outside of the United States and Canada, today announced that it will stop the Phase 3 KEYLYNK-008 trial evaluating KEYTRUDA, Merck's anti-PD-1 therapy, in combination...""}, {""date"": ""20231208041924"", ""headline"": ""Merck Announces Findings from Phase 2 KeyVibe-002 Trial Evaluating an Investigational Coformulation of Vibostolimab and Pembrolizumab in Previously Treated Patients with Metastatic Non-Small Cell Lung Cancer"", ""summary"": ""RAHWAY - Merck , known as MSD outside of the United States and Canada, today announced full results from the non-registrational Phase 2 KeyVibe-002 trial evaluating vibostolimab/pembrolizumab, an...""}, {""date"": ""20231208061400"", ""headline"": ""Biotech Deals Are Heating Up. Why 2024 Could Be Even Hotter for M&A."", ""summary"": ""The year-end spurt of biopharma mergers and acquisitions bodes well for the sector in 2024.""}, {""date"": ""20231208064500"", ""headline"": ""Merck and Eisai Provide Update on Phase 3 LEAP-001 Trial Evaluating (pembrolizumab) Plus LENVIMA\u00ae (lenvatinib) as First-Line Treatment for Patients with Advanced or Recurrent Endometrial Carcinoma"", ""summary"": ""RAHWAY, N.J., & NUTLEY, N.J., December 08, 2023--Merck and Eisai Provide Update on LEAP-001 Trial Evaluating KEYTRUDA + LENVIMA as First-Line Treatment for Advanced or Recurrent Endometrial Carcinoma""}, {""date"": ""20231208094500"", ""headline"": ""Company News for Dec 8, 2023"", ""summary"": ""Companies In The Article Are: CIEN,MRK,VRNT,OXM""}, {""date"": ""20231208103221"", ""headline"": ""SPMO: Simple And Efficient Momentum ETF"", ""summary"": ""Invesco S&P 500 Momentum has a unique investment strategy, strong performance, and superior quality. Click here to read an analysis on SPMO ETF now.""}, {""date"": ""20231208113500"", ""headline"": ""Merck & Co. Inc. stock outperforms competitors despite losses on the day"", ""summary"": ""Shares of Merck & Co. Inc. dropped 0.13% to $103.75 Friday, on what proved to be an all-around great trading session for the stock market, with the S&P 500...""}, {""date"": ""20231208114400"", ""headline"": ""Merck's (MRK) Keytruda-Lynparza Combo Fails Lung Cancer Study"", ""summary"": ""After a late-stage study fails to show any improvement in its primary endpoints, Merck (MRK) decides to stop evaluating the Keytruda-Lynparza combination in metastatic squamous NSCLC.""}, {""date"": ""20231209040000"", ""headline"": ""How To Invest $100,000 Today In A Sleep Well Portfolio"", ""summary"": ""The economic cycles have always been with us. But the frequency of boom and bust cycles has certainly increased in the last couple of decades. Read more here.""}, {""date"": ""20231209071653"", ""headline"": ""Income Investors Should Know That Merck & Co., Inc. (NYSE:MRK) Goes Ex-Dividend Soon"", ""summary"": ""Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be...""}, {""date"": ""20231210032239"", ""headline"": ""Dividend Champion, Contender, And Challenger Highlights: Week Of December 10"", ""summary"": ""A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Read more to see the December 10 weekly update.""}, {""date"": ""20231210054103"", ""headline"": ""United Therapeutics: Cheap With Litigation Headwinds"", ""summary"": ""United Therapeutics' treprostinil products are also facing challenges from generics and clinical aspirants. Read why I'm neutral on UTHR stock.""}, {""date"": ""20231210114030"", ""headline"": ""12 Healthcare Stocks Billionaires Like the Most"", ""summary"": ""In this article, we will take a look at the 12 healthcare stocks billionaires like the most. To skip our analysis of the recent market trends and activity, you can go directly to see the 5 Healthcare Stocks Billionaires Like the Most. The healthcare sector includes companies ranging from pharmaceuticals, medical equipment and device manufacturers, [\u2026]""}, {""date"": ""20231210130746"", ""headline"": ""12 Dow Stocks Billionaires Like The Most"", ""summary"": ""In this piece, we will take a look at the 12 Dow stocks that billionaires like the most. If you don\u2019t want to learn more about the Dow Jones Industrial Average (DJIA), its history, and recent performance, then skip ahead to 5 Dow Stocks Billionaires Like The Most. In its current form today, the Dow [\u2026]""}]",{}
48,2023-12-10,101.07000732421875,2023-12-17,103.13631439208984,0.02044431501071009,U3,"[{""date"": ""20231210032239"", ""headline"": ""Dividend Champion, Contender, And Challenger Highlights: Week Of December 10"", ""summary"": ""A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Read more to see the December 10 weekly update.""}, {""date"": ""20231210054103"", ""headline"": ""United Therapeutics: Cheap With Litigation Headwinds"", ""summary"": ""United Therapeutics' treprostinil products are also facing challenges from generics and clinical aspirants. Read why I'm neutral on UTHR stock.""}, {""date"": ""20231210114030"", ""headline"": ""12 Healthcare Stocks Billionaires Like the Most"", ""summary"": ""In this article, we will take a look at the 12 healthcare stocks billionaires like the most. To skip our analysis of the recent market trends and activity, you can go directly to see the 5 Healthcare Stocks Billionaires Like the Most. The healthcare sector includes companies ranging from pharmaceuticals, medical equipment and device manufacturers, [\u2026]""}, {""date"": ""20231210130746"", ""headline"": ""12 Dow Stocks Billionaires Like The Most"", ""summary"": ""In this piece, we will take a look at the 12 Dow stocks that billionaires like the most. If you don\u2019t want to learn more about the Dow Jones Industrial Average (DJIA), its history, and recent performance, then skip ahead to 5 Dow Stocks Billionaires Like The Most. In its current form today, the Dow [\u2026]""}, {""date"": ""20231210233200"", ""headline"": ""Biotech Is Coming Back, Can The Run Last?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231211004900"", ""headline"": ""Merck Animal Health receives positive CVMP opinion for injectable BRAVECTO"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231211005100"", ""headline"": ""Merck, Moderna initiat INTerpath-002 phase 3 study of V940"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231211012000"", ""headline"": ""Merck, Moderna begin new Phase 3 trial for mRNA-based cancer therapy"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231211014402"", ""headline"": ""A Milestone: The S&P 500's 4,600 Level On The Bull Plateau"", ""summary"": ""The S&P 500 reaches new highs as the strong bull plateau continues, extending its duration and offering opportunities for gains to traders. Click here for more.""}, {""date"": ""20231211022702"", ""headline"": ""Merck, Moderna Expand Phase 3 Keytruda/V940 Combo Work"", ""summary"": ""By Colin Kellaher Merck and Moderna have launched a second late-stage study of the combination of Merck's blockbuster cancer drug Keytruda with V940, an individualized neoantigen therapy they...""}, {""date"": ""20231211033603"", ""headline"": ""Merck : start of phase III clinical trial with Moderna"", ""summary"": ""Merck and Moderna announced on Monday the launch of their Phase III clinical trial to evaluate the combination of immunotherapy and messenger RNA technology in the treatment of lung cancer.The two...""}, {""date"": ""20231211045425"", ""headline"": ""Merck and Eisai Provide Update on Phase 3 LEAP-001 Trial Evaluating KEYTRUDA plus LENVIMA as First-Line Treatment for Patients with Advanced or Recurrent Endometrial Carcinoma"", ""summary"": ""RAHWAY - Merck , known as MSD outside of the United States and Canada, and Eisai today announced that the Phase 3 LEAP-001 trial evaluating KEYTRUDA, Merck's anti-PD-1 therapy, plus LENVIMA, the...""}, {""date"": ""20231211064500"", ""headline"": ""Merck Animal Health Receives Positive CVMP Opinion for an Injectable Formulation of BRAVECTO\u00ae (Fluralaner) for Use in Dogs"", ""summary"": ""RAHWAY, N.J., December 11, 2023--Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced that the European Medicines Agency\u2019s Committee for Veterinary Medicinal Products (CVMP) issued a positive opinion for BRAVECTO\u00ae (fluralaner) 150 mg/ml powder and solvent for suspension for injection for dogs. The CVMP recommends the product for approval for the treatment and persistent killing of f""}, {""date"": ""20231211064500"", ""headline"": ""Merck and Moderna Initiate INTerpath-002, a Phase 3 Study Evaluating V940 (mRNA-4157) in Combination with KEYTRUDA\u00ae (pembrolizumab) for Adjuvant Treatment of Patients with Certain Types of Resected Non-Small Cell Lung Cancer"", ""summary"": ""RAHWAY, N.J. & CAMBRIDGE, Mass., December 11, 2023--Merck and Moderna Initiate INTerpath-002 Evaluating V940 (mRNA-4157) in Combination with KEYTRUDA for Certain Types of Resected NSCLC""}, {""date"": ""20231211072013"", ""headline"": ""UPDATE 1-Moderna, Merck begin late-stage study for mRNA cancer therapy"", ""summary"": ""Moderna and Merck & Co said on Monday they have started a late-stage trial of their experimental personalized mRNA cancer treatment in combination with blockbuster drug Keytruda for patients with a type of lung cancer.  Moderna and Merck started a late-stage study in July testing the combination therapy in patients with melanoma, the most deadly form of skin cancer.""}, {""date"": ""20231211074900"", ""headline"": ""Merck & Company: A Strong Buy on Diverse Portfolio and Promising Pipeline"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231211075600"", ""headline"": ""Merck reports mixed updates for cancer treatment, Keytruda"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231211094600"", ""headline"": ""AbbVie and Big Pharma Have Floundered. How That Could Change in 2024."", ""summary"": ""Goldman Sachs still sees headwinds for the sector next year, but AbbVie could be an outlier.""}, {""date"": ""20231211113500"", ""headline"": ""Merck & Co. Inc. stock rises Monday, outperforms market"", ""summary"": ""Shares of Merck & Co. Inc. inched 0.60% higher to $104.37 Monday, on what proved to be an all-around great trading session for the stock market, with the S&P...""}, {""date"": ""20231211115900"", ""headline"": ""Merck's (MRK) Keytruda, Lenvima Endometrial Cancer Study Fails"", ""summary"": ""The combination of Merck's (MRK) Keytruda and Eisai's Lenvima for the first-line treatment of advanced/recurrent endometrial carcinoma fails to meet dual primary endpoints in late-stage study.""}, {""date"": ""20231211160800"", ""headline"": ""Top Research Reports for Merck, Equinor & Illinois Tool Works"", ""summary"": ""Today's Research Daily features new research reports on 16 major stocks, including Merck & Co., Inc. (MRK), Equinor ASA (EQNR) and Illinois Tool Works Inc. (ITW).""}, {""date"": ""20231212010300"", ""headline"": ""C4 Therapeutics announces license, research collab with Merck"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231212012224"", ""headline"": ""Merck and Moderna Initiate INTerpath-002, a Phase 3 Study Evaluating V940 in Combination with KEYTRUDA for Adjuvant Treatment of Patients with Certain Types of Resected Non-Small Cell Lung Cancer"", ""summary"": ""RAHWAY - Merck , known as MSD outside of the United States and Canada, and Moderna, Inc. , today announced the initiation of INTerpath-002, a pivotal Phase 3 randomized clinical trial evaluating V940...""}, {""date"": ""20231212012225"", ""headline"": ""Merck Animal Health Receives Positive CVMP Opinion for an Injectable Formulation of BRAVECTO for Use in Dogs"", ""summary"": ""RAHWAY - Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA , today announced that the European Medicines...""}, {""date"": ""20231212013800"", ""headline"": ""C4 Therapeutics stock rallies on Merck deal to develop cancer antibodies"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231212013800"", ""headline"": ""Merck price target lowered by $2 at Morgan Stanley, here's why"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231212023000"", ""headline"": ""Moderna CEO to lead sales and marketing as commercial chief departs"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231212032200"", ""headline"": ""Morning Brew: CPI Data Surprises Ahead of Fed Decision, Epic Wins Antitrust Case Against Google"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231212041800"", ""headline"": ""Why Is C4 Therapeutics (CCCC) Stock Up 72% Today?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231212051200"", ""headline"": ""C4 Therapeutics Shares Jump 77% After Licensing Deal With Merck"", ""summary"": ""By Chris Wack C4 Therapeutics shares were up 77% to $2.09 after the company entered into an exclusive license and collaboration agreement with Merck to...""}, {""date"": ""20231212062500"", ""headline"": ""Wall Street Lunch: No Big Surprises With CPI"", ""summary"": ""November CPI arrives about in line, gives Fed some room to push back on rate cuts. Oracle tumbles on cloud concerns. Chevron doesn't expect hostilities in South America.""}, {""date"": ""20231212065600"", ""headline"": ""Eli Lilly: The Party Is Over"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231212091100"", ""headline"": ""The Zacks Analyst Blog Highlights Merck, Equinor, Illinois Tool Works, Arthur J. Gallagher and Atlassian"", ""summary"": ""Merck, Equinor, Illinois Tool Works, Arthur J. Gallagher and Atlassian are part of the Zacks top Analyst Blog.""}, {""date"": ""20231212113500"", ""headline"": ""Merck & Co. Inc. stock falls Tuesday, underperforms market"", ""summary"": ""Shares of Merck & Co. Inc. slid 0.01% to $104.36 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500...""}, {""date"": ""20231212131700"", ""headline"": ""Moderna (MRNA), Merck Start 2nd Late-Study on Cancer Therapy"", ""summary"": ""The second late-stage study will evaluate Moderna (MRNA)/Merck's investigational cancer combination therapy in certain lung cancer patients. A late-stage study in melanoma indication is ongoing.""}, {""date"": ""20231212221400"", ""headline"": ""Dow Jones Skyrockets To Record Heights, Shatters 37,000 Mark, Fueled By Fed's Dovish Stance"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231213050908"", ""headline"": ""Merck & Co Inc's Dividend Analysis"", ""summary"": ""Merck & Co Inc (NYSE:MRK) recently announced a dividend of $0.77 per share, payable on 2024-01-08, with the ex-dividend date set for 2023-12-14.  As investors look forward to this upcoming payment, the spotlight also shines on the company's dividend history, yield, and growth rates.  Using the data from GuruFocus, let's look into Merck & Co Inc's dividend performance and assess its sustainability.""}, {""date"": ""20231213053156"", ""headline"": ""Goldman Sachs Says These 3 Healthcare Giants Look Very Attractive Right Now"", ""summary"": ""Barring some outliers, the US large cap pharmaceutical group has underperformed the broader markets this year. In a setting characterized by formidable macro factors, such as economic growth trends and the trajectory of interest rates, Goldman Sachs\u2019 Chris Shibutani says the group has shown it is \u201cunstable on a defensive basis.\u201d That has led to the overall lackluster performance in the market and has resulted in \u201csteeper than average levels of relative valuation discounts.\u201d For instance, while n""}, {""date"": ""20231213063100"", ""headline"": ""UBS\u2019 Top Global Stocks"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231213080025"", ""headline"": ""Insiders At Merck Sold US$10m In Stock, Alluding To Potential Weakness"", ""summary"": ""The fact that multiple Merck & Co., Inc. ( NYSE:MRK ) insiders offloaded a considerable amount of shares over the past...""}, {""date"": ""20231213090200"", ""headline"": ""Dow's 150-point rally led by gains for shares of Walgreens Boots, Procter & Gamble"", ""summary"": ""Led by positive growth for shares of Walgreens Boots and Procter & Gamble, the Dow Jones Industrial Average is trading up Wednesday afternoon. The Dow is...""}, {""date"": ""20231213112958"", ""headline"": ""What Are The Best Stocks To Invest In Now? 2 Health Care Stocks To Watch"", ""summary"": ""Health care stocks to check out in the stock market now.""}, {""date"": ""20231213113500"", ""headline"": ""Merck & Co. Inc. stock rises Wednesday, outperforms market"", ""summary"": ""Shares of Merck & Co. Inc. rallied 2.64% to $107.11 Wednesday, on what proved to be an all-around great trading session for the stock market, with the S&P...""}, {""date"": ""20231213165500"", ""headline"": ""Merck Ranks No. 1 on Newsweek\u2019s List of America\u2019s Most Responsible Companies 2024"", ""summary"": ""RAHWAY, N.J. / ACCESSWIRE / December 13, 2023 / Merck (NYSE:MRK), known as MSD outside of the United States and Canada, has earned the top spot on Newsweek's annual list of America's Most Responsible Companies, ranking No. 1 overall for the first ...""}, {""date"": ""20231213203800"", ""headline"": ""Dow hits pause on record-setting rally, S&P 500 and Nasdaq struggle for direction"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231213212700"", ""headline"": ""Dow Jones aims for back-to-back record close after Fed pencils in 2024 rates cuts"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231213220700"", ""headline"": ""Moderna CEO Highlights Promising Cancer Vaccine Data: 'Think About The Number Of Lives That Can Be Impacted'"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231213221500"", ""headline"": ""Stock market today: Asian markets churn upward after the Dow ticks to another record high"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231213221500"", ""headline"": ""Stock market today: Wall Street rises again as the Dow ticks to another record"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231213223100"", ""headline"": ""What You Missed On Wall Street On Thursday"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231213223600"", ""headline"": ""MRNA Stock Surges as Moderna Teams Up With Merck to Fight Cancer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231213224605"", ""headline"": ""Merck Ranks No. 1 on Newsweek's List of America's Most Responsible Companies 2024"", ""summary"": ""RAHWAY, N.J.- Merck , known as MSD outside of the United States and Canada, has earned the top spot on Newsweek's annual list of America's Most Responsible Companies, ranking No. 1 overall for the...""}, {""date"": ""20231214003900"", ""headline"": ""Moderna, Merck announc e follow-up data on V940 with Keytruda"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231214005100"", ""headline"": ""Moderna\u2019s stock rallies 7.9% after announcing positive data in trial of melanoma treatment combined with Merck\u2019s Keytruda"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231214010200"", ""headline"": ""FDA approves Merck's Welireg for treatment of patients with advanced RCC"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231214013000"", ""headline"": ""Moderna Reports More Promising Data on Cancer Treatment. The Stock Jumps."", ""summary"": ""The personalized cancer vaccine is being used with a Merck immunotherapy drug to fight melanoma cancer.""}, {""date"": ""20231214013300"", ""headline"": ""Moderna, Merck post three-year data for mRNA-based skin cancer therapy"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231214014500"", ""headline"": ""Moderna CEO Bancel says melanoma vaccine could be available by 2025"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231214014800"", ""headline"": ""Moderna's stock buoyed by positive data in trial of melanoma treatment"", ""summary"": ""Moderna's stock was on track for its biggest one-day gain in more than a year.""}, {""date"": ""20231214015200"", ""headline"": ""Moderna\u2019s stock rallies after announcement of positive data from trial of melanoma treatment combined with Merck\u2019s Keytruda"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231214022000"", ""headline"": ""Moderna\u2019s (NASDAQ:MRNA) Positive Melanoma Trial Data Sparks Stock Surge"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231214030100"", ""headline"": ""Fly Intel: Pre-market Movers"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231214032000"", ""headline"": ""5 stocks to watch on Thursday: Moderna, Costco, Live Nation and more"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231214033000"", ""headline"": ""Why Is Moderna (MRNA) Stock Up 11% Today?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231214035300"", ""headline"": ""Dow climbs to fresh record as Fed rate-cut forecasts spur global markets rally"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231214042100"", ""headline"": ""Top contributors to the S&P 500 from the past 2 years - UBS"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231214043300"", ""headline"": ""Biggest stock movers today: Moderna, Foot Locker, Adobe, Ocular Therapeutix and more"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231214052600"", ""headline"": ""Leerink skeptical on sustainability of Moderna rally given eroding fundamentals"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231214063000"", ""headline"": ""Moderna And Merck Announce mRNA-4157 (V940) In Combination with Keytruda(R) (Pembrolizumab) Demonstrated Continued Improvement in Recurrence-Free Survival and Distant Metastasis-Free Survival in Patients with High-Risk Stage III/IV Melanoma Following Complete Resection Versus Keytruda at Three Years"", ""summary"": ""At a median planned follow-up of approximately three years, mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence or death by 49% (HR=0.510 [95% CI, 0.288-0.906]; one-sided nominal p=0.0095) and the risk of distant metastasis ...""}, {""date"": ""20231214063000"", ""headline"": ""Benefits of Moderna and Merck melanoma vaccine plus Keytruda extend to three years"", ""summary"": ""An experimental messenger RNA cancer vaccine developed by Moderna and Merck & Co paired with Merck's Keytruda cut the chance of recurrence or death from melanoma by half after three years, showing that benefits demonstrated a year ago have held up over time.  The combination of the personalized cancer vaccine and Merck's blockbuster immunotherapy cut the risk of recurrence or death of the most deadly skin cancer by 49% compared with Keytruda alone in the midstage trial, the companies said.""}, {""date"": ""20231214065800"", ""headline"": ""New Moderna cancer vaccine data spurs share rally"", ""summary"": ""Shares climbed by\u00a0double digits after new evidence led to speculation among analysts that Moderna and partner Merck could seek an approval before completing Phase 3 testing.""}, {""date"": ""20231214071600"", ""headline"": ""Moderna, Rivian rise; Apellis, Adobe fall, Thursday, 12/14/2023"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231214073300"", ""headline"": ""What You Missed On Wall Street This Morning"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231214075700"", ""headline"": ""S&P 500 clings to gain, Nasdaq turns negative and Dow hits pause on record-setting rally"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231214081848"", ""headline"": ""Merck-Moderna Vaccine Cuts Return of Skin Cancer by Half"", ""summary"": ""(Bloomberg) -- A personalized vaccine developed by Merck & Co. and Moderna Inc. helped prevent the recurrence of severe skin cancer for three years in promising new results from a study.Most Read from BloombergCitigroup Offers Partial Early Bonuses to Encourage Staff DeparturesWall Street Traders Go All-In on Great Monetary Pivot of 2024Elon Musk Is Planning a New University in AustinOwner of the Philippines\u2019 Largest Malls Says China Feud May Hurt BusinessesJPMorgan Is in a Fight Over Its Client""}, {""date"": ""20231214084545"", ""headline"": ""UPDATE 2-Benefits of Moderna and Merck melanoma vaccine plus Keytruda extend to three years"", ""summary"": ""An experimental messenger RNA cancer vaccine developed by Moderna and Merck & Co paired with Merck's Keytruda cut the chance of recurrence or death from melanoma by half after three years, showing that benefits demonstrated a year ago have held up over time.  Moderna shares rose 11.1% to $87.20 premarket, while Merck shares were up marginally at $106.70 before the bell.  The combination of the personalized cancer vaccine and Merck's blockbuster immunotherapy cut the risk of recurrence or death of the most deadly skin cancer by 49% compared with Keytruda alone in the midstage trial, the companies said.""}, {""date"": ""20231214095600"", ""headline"": ""Moderna Stock Surges After Positive Trial Results"", ""summary"": ""Moderna shares rose more than 15% after the company and partner Merck [disclosed positive trial results](https://www.merck.com/news/moderna-and-merck-announce-mrna-4157-v940-an-investigational-personalized-mrna-cancer-vaccine-in-combination-with-keytruda-pembrolizumab-met-primary-efficacy-endpoint-in-phase-2b-keynote-94/) for an experimental mRNA-based treatment for skin cancer.""}, {""date"": ""20231214113500"", ""headline"": ""Merck & Co. Inc. stock falls Thursday, underperforms market"", ""summary"": ""Shares of Merck & Co. Inc. slid 0.43% to $105.88 Thursday, on what proved to be an all-around great trading session for the stock market, with the S&P 500...""}, {""date"": ""20231214123051"", ""headline"": ""Moderna: Stock soars on cancer vaccine data; CEO Bancel takes on commercial role."", ""summary"": ""Shares of Moderna (MRNA) soared around 14% on Thursday on the news that a personalized cancer vaccine, in partnership with Merck (MRK), reduced the risk of late-stage melanoma by 49%""}, {""date"": ""20231214124626"", ""headline"": ""US FDA approves Merck's drug for kidney cancer"", ""summary"": ""The U.S. Food and Drug Administrationon Thursday approved Merck's drug belzutifan for a typeof kidney cancer. ...""}, {""date"": ""20231214125754"", ""headline"": ""Moderna CEO talks skin cancer vaccine"", ""summary"": ""Moderna (MRNA) shares surged Thursday following positive results from a mid-stage trial for its experimental cancer vaccine. The trial found the vaccine, when used in combination with Merck's (MRK) immunotherapy Keytruda, significantly reduced the risk of death or relapse for patients with advanced melanoma skin cancer. \""We are so happy for patients,\"" Moderna CEO St\u00e9phane Bancel told Yahoo Finance Live, noting the trial showed a roughly 50% survival rate, meaning one in two treated patients were able to live without a relapse. Bancel also highlighted other vaccines in Moderna's pipeline, including its treatment for Respiratory Syncytial Virus (RSV). For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live.""}, {""date"": ""20231214160201"", ""headline"": ""Moderna stock sees boost over skin cancer treatment trials"", ""summary"": ""Moderna (MRNA) shares have jumped by over 9% on Thursday in relation to positive trial results in Moderna and Merck's (MRK) collaborative skin cancer treatment that utilizes both a vaccine and the drug Keytruda. Additionally, Pfizer (PFE) disappointed investors this week over the pharmaceutical company's 2024 guidance. Yahoo Finance Health Reporter Anjalee Khemlani details the top stories and biggest drivers behind pharmaceutical stocks Thursday. For more expert insight and the latest market action, click\u00a0here\u00a0to watch this full episode of Yahoo Finance Live.""}, {""date"": ""20231214190000"", ""headline"": ""FDA Approves Merck\u2019s WELIREG\u00ae (belzutifan) for the Treatment of Patients With Advanced Renal Cell Carcinoma (RCC) Following a PD-1 or PD-L1 Inhibitor and a VEGF-TKI"", ""summary"": ""RAHWAY, N.J., December 15, 2023--WELIREG FDA Approval""}, {""date"": ""20231214211600"", ""headline"": ""Merck gets FDA approval for kidney cancer drug Welireg"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231214220000"", ""headline"": ""FDA found control lapses at Moderna plant, Reuters reports"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231214224100"", ""headline"": ""Merck gets US FDA nod for Welireg, as trial with Moderna bears fruit"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231214230200"", ""headline"": ""Merck announces FDA approval of KEYTRUDA plus Padcev"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231215002500"", ""headline"": ""FDA approves Keytruda/Padcev combo therapy for bladder cancer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231215025454"", ""headline"": ""FDA Approves Merck's WELIREG for the Treatment of Patients with Advanced Renal Cell Carcinoma Following a PD-1 or PD-L1 Inhibitor and a VEGF-TKI"", ""summary"": ""RAHWAY - Merck , known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration has approved WELIREG, an oral hypoxia-inducible factor-2 alpha ...""}, {""date"": ""20231215040003"", ""headline"": ""Merck : promising trial in melanoma care"", ""summary"": ""In this analysis conducted with a median follow-up of approximately three years, mRNA-4157 + Keytruda demonstrated a clinically significant improvement in recurrence-free survival , reducing the risk...""}, {""date"": ""20231215053718"", ""headline"": ""Trending tickers: Costco | Moderna | Rivian | H&M"", ""summary"": ""The latest investor updates on stocks that are trending on Friday.""}, {""date"": ""20231215061000"", ""headline"": ""FDA widens use of cancer drug Merck acquired for $1B"", ""summary"": ""Welireg, which Merck got through its purchase of Peloton Therapeutics, can now be used to treat an advanced form of kidney cancer, adding to an earlier clearance in a rare genetic disease.""}, {""date"": ""20231215105400"", ""headline"": ""IXJ: Healthcare Dashboard For December"", ""summary"": ""iShares Global Healthcare is a global alternative to Healthcare Select Sector SPDR Fund. Click here to read an analysis on IXJ ETF here.""}, {""date"": ""20231215113500"", ""headline"": ""Merck & Co. Inc. stock falls Friday, underperforms market"", ""summary"": ""Shares of Merck & Co. Inc. slumped 0.73% to $105.11 Friday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones...""}, {""date"": ""20231215122700"", ""headline"": ""Moderna (MRNA) Soars on Upbeat Data From Cancer Therapy Study"", ""summary"": ""Three-year follow up data from a mid-stage study shows that treatment with Moderna (MRNA)/Merck's cancer combination therapy reduces recurrence/death risk in certain melanoma patients by half.""}, {""date"": ""20231215123200"", ""headline"": ""FDA Expands Merck's (MRK) Welireg Label in Renal Cell Carcinoma"", ""summary"": ""Per Merck (MRK), the latest FDA approval to Welireg marks the first time a new treatment has been approved in a novel therapeutic class in advanced renal cell carcinoma since 2015.""}, {""date"": ""20231215123903"", ""headline"": ""Merck, Pfizer, Astellas Get FDA OK For Expanded Use Of Keytruda Plus Padcev"", ""summary"": ""By Ben Glickman Merck & Co., Pfizer and Astellas Pharma have received approval from the U.S. Food and Drug Administration for using Keytruda in combination with Padcev to treat a form of...""}, {""date"": ""20231215170000"", ""headline"": ""FDA Approves Expanded Indication for KEYTRUDA\u00ae (pembrolizumab) Plus Padcev\u00ae (enfortumab vedotin-ejfv) for the First-Line Treatment of Adult Patients With Locally Advanced or Metastatic Urothelial Cancer"", ""summary"": ""RAHWAY, N.J., December 15, 2023--FDA Approves Expanded Indication for KEYTRUDA Plus Padcev for the First-Line Treatment of Adult Patients With Locally Advanced or Metastatic UC""}, {""date"": ""20231215210500"", ""headline"": ""Contaminated Vaccines: FDA Reportedly Finds Cleaning And Expiry Lapses At Moderna's Massachusetts Facility"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231216123033"", ""headline"": ""12 Best Slow Growth Stocks To Buy According To Hedge Funds"", ""summary"": ""In this article, we will take a detailed look at the 12 Best Slow Growth Stocks To Buy According To Hedge Funds. For a quick overview of such stocks, read our article 5 Best Slow Growth Stocks To Buy According To Hedge Funds. It would be interesting to see how markets react to the latest events after a statement [\u2026]""}, {""date"": ""20231217054301"", ""headline"": ""SCHD: A Long-Term Dividend Play With Potential To Generate Additional 'Income'"", ""summary"": ""Discover SCHD, a low-cost ETF that offers diversification to dividend-paying stocks and has shown respectable returns for passive income investors.""}, {""date"": ""20231217062700"", ""headline"": ""3 Ways To Buy The Boeing Boom, Without Buying Boeing"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231217070056"", ""headline"": ""Merck & Co., Inc. (NYSE:MRK) is largely controlled by institutional shareholders who own 77% of the company"", ""summary"": ""Key Insights Institutions' substantial holdings in Merck implies that they have significant influence over the...""}, {""date"": ""20231217163447"", ""headline"": ""Tracking Prem Watsa's Fairfax Financial Holdings Portfolio - Q3 2023 Update"", ""summary"": ""Prem Watsa's 13F portfolio value decreased slightly to $1.86B this quarter. Click here to read more about Fairfax Financial's holdings and trades for Q3 2023.""}]",{}
49,2023-12-17,103.13631439208984,2023-12-24,105.67766571044922,0.024640703260909724,U3,"[{""date"": ""20231217054301"", ""headline"": ""SCHD: A Long-Term Dividend Play With Potential To Generate Additional 'Income'"", ""summary"": ""Discover SCHD, a low-cost ETF that offers diversification to dividend-paying stocks and has shown respectable returns for passive income investors.""}, {""date"": ""20231217070056"", ""headline"": ""Merck & Co., Inc. (NYSE:MRK) is largely controlled by institutional shareholders who own 77% of the company"", ""summary"": ""Key Insights Institutions' substantial holdings in Merck implies that they have significant influence over the...""}, {""date"": ""20231217163447"", ""headline"": ""Tracking Prem Watsa's Fairfax Financial Holdings Portfolio - Q3 2023 Update"", ""summary"": ""Prem Watsa's 13F portfolio value decreased slightly to $1.86B this quarter. Click here to read more about Fairfax Financial's holdings and trades for Q3 2023.""}, {""date"": ""20231217192358"", ""headline"": ""3 Ways To Buy The Boeing Boom, Without Buying Boeing"", ""summary"": ""Boeing stock has been soaring temporarily, but it may be too late to buy. Check out the three other stocks that should catch up with BA.""}, {""date"": ""20231218005500"", ""headline"": ""Merck announcesEC approves two new indications for KEYTRUDA in GI cancers"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231218010400"", ""headline"": ""Astellas, Merck, Pfizer celebrate US approval for Keytruda plus Padcev"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231218015037"", ""headline"": ""Merck - FDA Approves Expanded Indication for KEYTRUDA plus Padcev for the First-Line Treatment of Adult Patients with Locally Advanced or Metastatic Urothelial Cancer"", ""summary"": ""RAHWAY - Merck , known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration has approved KEYTRUDA, Merck's anti-PD-1 therapy, in combination with...""}, {""date"": ""20231218020000"", ""headline"": ""IN BRIEF: Astellas \""proud\"" as EU regulator recommends arpraziquantel"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231218044325"", ""headline"": ""13 Most Profitable Pharmaceutical Stocks Now"", ""summary"": ""In this article, we discuss the 13 most profitable pharmaceutical stocks to buy. You can skip our detailed analysis of the pharmaceutical sector and its outlook this year, and go directly to read the 5 Most Profitable Pharmaceutical Stocks Now. The healthcare sector encompasses a diverse range of companies, spanning pharmaceuticals, medical equipment and device [\u2026]""}, {""date"": ""20231218054003"", ""headline"": ""Merck : EU approves 2 new indications for Keytruda"", ""summary"": ""Merck announced today that the European Commission has approved two new indications for Keytruda in the treatment of gastrointestinal cancers. The first concerns the combination of Keytruda with...""}, {""date"": ""20231218061108"", ""headline"": ""XLV: Considering The Low-Maintenance Option To Navigate The Healthcare Sector"", ""summary"": ""XLV comprises major healthcare industry players and offers a convenient and cost-effective way to invest in the sector. Find out my analysis of XLV ETF.""}, {""date"": ""20231218064500"", ""headline"": ""European Commission Approves Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Plus Chemotherapy for New First-Line Indications in Advanced HER2-Negative Gastric or GEJ Adenocarcinoma in Tumors Expressing PD-L1 (CPS \u22651) and Advanced Biliary Tract Cancer"", ""summary"": ""RAHWAY, N.J., December 18, 2023--KEYTRUDA Approved in the EU for use in Gastric and Biliary Tract Cancers""}, {""date"": ""20231218113500"", ""headline"": ""Merck & Co. Inc. stock outperforms competitors on strong trading day"", ""summary"": ""Shares of Merck & Co. Inc. inched 0.88% higher to $106.04 Monday, on what proved to be an all-around mixed trading session for the stock market, with the S&P...""}, {""date"": ""20231218204900"", ""headline"": ""EU approves Merck's Keytruda to treat form of biliary tract cancer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231219005000"", ""headline"": ""Merck's new BLA for pneumococcal conjugate vaccine granted priority review"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231219021503"", ""headline"": ""Merck Gets FDA Priority Review For New Pneumococcal Vaccine"", ""summary"": ""By Will Feuer Merck said the Food and Drug Administration has accepted for priority review the company's V116 investigational pneumococcal conjugate vaccine. Merck said the FDA has set...""}, {""date"": ""20231219031602"", ""headline"": ""Merck : priority review for pneumococcal vaccine"", ""summary"": ""Merck announced Tuesday that the U.S. Food and Drug Administration has granted a priority review to the registration dossier for its pneumococcal conjugate vaccine.A priority review means that the...""}, {""date"": ""20231219032900"", ""headline"": ""Evaxion Biotech prices 9.73M shares at 54.4c in private placement"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231219064500"", ""headline"": ""FDA Grants Priority Review to Merck\u2019s New Biologics License Application for V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed to Protect Adults"", ""summary"": ""RAHWAY, N.J., December 19, 2023--FDA Grants Priority Review to Merck\u2019s New Biologics License Application for V116, an Investigational, 21-valent PCV Designed to Protect Adults""}, {""date"": ""20231219065500"", ""headline"": ""Merck gets FDA decision date for new pneumococcal vaccine"", ""summary"": ""The company\u2019s shot targets 21 strains of pneumococcal bacteria and, if approved, would compete with Pfizer\u2019s Prevnar 20.""}, {""date"": ""20231219102700"", ""headline"": ""Merck (MRK) Gets EU Nod for Expanded Use in Gastric Cancer"", ""summary"": ""Following these approvals, Merck's (MRK) Keytruda is approved for seven gastrointestinal cancers in the European Union. Overall, the drug is approved for 26 indications in the region.""}, {""date"": ""20231219110348"", ""headline"": ""13 Most Promising Growth Stocks According to Analysts"", ""summary"": ""In this piece, we will take a look at the 13 most promising growth stocks according to analysts. If you want to skip our coverage of the latest stock market news, then you can take a look at the 5 Most Promising Growth Stocks According to Analysts. The primary reason most folks are attracted to [\u2026]""}, {""date"": ""20231219113500"", ""headline"": ""Merck & Co. Inc. stock rises Tuesday, still underperforms market"", ""summary"": ""Shares of Merck & Co. Inc. inched 0.42% higher to $106.49 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with...""}, {""date"": ""20231219191108"", ""headline"": ""C4 Therapeutics: Merck News Does Not Make It A Buy Yet, But Upgrading To Hold"", ""summary"": ""C4 Therapeutics' partnership with Merck doubled its share price. Read why this is still not enough evidence for me to rate CCCC stock a Buy.""}, {""date"": ""20231219223100"", ""headline"": ""Merck says FDA issues CRL regarding gefapixant NDA"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231219230200"", ""headline"": ""FDA rejects Merck's application for chronic cough treatment gefapixant"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231220060000"", ""headline"": ""Consider These 3 SWAN Stocks To Collect Dividends Almost Monthly"", ""summary"": ""Discover three high-quality stocks that offer monthly dividend payments, making them a valuable addition to any investment portfolio. Click here to read more.""}, {""date"": ""20231220060513"", ""headline"": ""FDA Grants Priority Review to Merck's New Biologics License Application for V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed to Protect Adults"", ""summary"": ""RAHWAY - Merck , known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration has accepted for priority review a new Biologics License Application for...""}, {""date"": ""20231220064500"", ""headline"": ""Merck to Participate in the Goldman Sachs Healthcare C-Suite Unscripted Conference"", ""summary"": ""RAHWAY, N.J., December 20, 2023--Merck to Participate in the Goldman Sachs Healthcare C-Suite Unscripted Conference""}, {""date"": ""20231220113500"", ""headline"": ""Merck & Co. Inc. stock falls Wednesday, still outperforms market"", ""summary"": ""Shares of Merck & Co. Inc. slipped 1.06% to $105.36 Wednesday, on what proved to be an all-around rough trading session for the stock market, with the S&P...""}, {""date"": ""20231220113900"", ""headline"": ""FDA Accepts Merck's (MRK) BLA for 21-Valent Pneumococcal Jab"", ""summary"": ""The FDA grants priority review to Merck's (MRK) filing seeking approval for its 21-valent pneumococcal conjugate vaccine in adults. A final decision is expected in June 2024.""}, {""date"": ""20231220121302"", ""headline"": ""FDA Says Merck's Chronic Cough Treatment Didn't Show Substantial Evidence of Effectiveness"", ""summary"": ""By Ben Glickman Merck's candidate to treat chronic cough didn't show substantial evidence of effectiveness, according to the Food and Drug Administration. The Rahway, N.J.-based...""}, {""date"": ""20231220163000"", ""headline"": ""Merck Provides U.S. Regulatory Update on Gefapixant"", ""summary"": ""RAHWAY, N.J., December 20, 2023--Merck Provides U.S. Regulatory Update on Gefapixant""}, {""date"": ""20231220164655"", ""headline"": ""XLV Likely Back To Outperforming"", ""summary"": ""The Health Care Select Sector SPDR Fund ETF (XLV) historically outperformed the S&P 500 but underperformed this year.""}, {""date"": ""20231221015603"", ""headline"": ""Merck : negative response from FDA for gefapixant"", ""summary"": ""Merck announced last night that it had received a Complete Response Letter from the U.S. Food and Drug Administration regarding the New Drug Application for gefapixant as a treatment for chronic...""}, {""date"": ""20231221025500"", ""headline"": ""Merck's Chronic Cough Treatment Candidate Receives Second Time FDA Rejection"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231221064719"", ""headline"": ""SCD: Add Diversification To Your Portfolio With This High-Yielding Fund At A Discount"", ""summary"": ""LMP Capital and Income Fund offers a high yield of 9.94% and exposure to common stocks, making it appealing to income-focused investors. Read more here.""}, {""date"": ""20231221070500"", ""headline"": ""KEYTRUDA\u00ae (pembrolizumab) Plus LENVIMA\u00ae (lenvatinib) Receive Public Listing for Patients with Advanced Endometrial Carcinoma (EC) that is not MSI-H or dMMR"", ""summary"": ""Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai announce that KEYTRUDA\u00ae, Merck's anti-PD-1 therapy, plus LENVIMA\u00ae, an orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, is now reimbursed with clinical criteria and conditions under the British Columbia, Alberta, Saskatchewan, Ontario, Quebec, Nova Scotia, New Brunswick, and Newfoundland drug plans, for adult patients with advanced endometrial carcinoma (EC) that is not microsatellite""}, {""date"": ""20231221091205"", ""headline"": ""7 Best Dow Jones Stocks to Buy for Conservative Investors"", ""summary"": ""With the Federal Reserve seemingly open to the idea of interest rate cuts next year, the narrative for the best Dow Jones stocks for conservative investors appears overly cautious. Don\u2019t get me wrong \u2013 you generally can\u2019t go wrong with targeting individual securities under the venerable index. Still, if you\u2019re looking for growth opportunities, the Dow is a bit tame to put it diplomatically. Nevertheless, you\u2019ve got to ask yourself a question: how sure are you that the Fed will actually lower bor""}, {""date"": ""20231221113500"", ""headline"": ""Merck & Co. Inc. stock rises Thursday, still underperforms market"", ""summary"": ""Shares of Merck & Co. Inc. inched 0.98% higher to $106.39 Thursday, on what proved to be an all-around great trading session for the stock market, with the...""}, {""date"": ""20231221222200"", ""headline"": ""7 Small-Cap Stocks That Wall Street Loves for Good Reason"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231222033200"", ""headline"": ""IN BRIEF: Merck's patritumab deruxtecan given US FDA priority review"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231222044800"", ""headline"": ""Walgreens Boots, Amgen share gains contribute to Dow's 100-point jump"", ""summary"": ""Shares of Walgreens Boots and Amgen are trading higher Friday morning, sending the Dow Jones Industrial Average into positive territory. The Dow is trading...""}, {""date"": ""20231222063602"", ""headline"": ""For Those Investors Stuck On Yield, 2023 Was Opportunistic"", ""summary"": ""Discover the power of active stock picking and contrarian investing in today's volatile market. Click here to read what investors need to know.""}, {""date"": ""20231222080000"", ""headline"": ""Patritumab Deruxtecan Granted Priority Review in the U.S. for Certain Patients with Previously Treated Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer"", ""summary"": ""BASKING RIDGE, N.J. & RAHWAY, N.J., December 22, 2023--Daiichi Sankyo (TSE: 4568) and Merck (known as MSD outside of the United States and Canada) (NYSE: MRK) announced today that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the Biologics License Application (BLA) for patritumab deruxtecan (HER3-DXd) for the treatment of adult patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) previously treated with two or more""}, {""date"": ""20231222090548"", ""headline"": ""12 Best Undervalued Stocks to Buy According to Reddit"", ""summary"": ""In this article, we discuss the 12 best undervalued stocks to buy according to Reddit. If you want to read about some more undervalued stocks, go directly to 5 Best Undervalued Stocks to Buy According to Reddit. Retail investors who often discuss their investment strategies on platforms like Reddit have become a dominant market force [\u2026]""}, {""date"": ""20231222113500"", ""headline"": ""Merck & Co. Inc. stock outperforms market on strong trading day"", ""summary"": ""Shares of Merck & Co. Inc. rose 1.23% to $107.70 Friday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500...""}, {""date"": ""20231223070300"", ""headline"": ""SCHD: Dividend ETF That Delivers Consistent Dividend Growth"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231224062900"", ""headline"": ""Merck: One Of The Best - Unveiling The Trifecta Of Safety, Dividends, And Growth"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231224090000"", ""headline"": ""January Effect: 3 Under-the-Radar Stocks Poised for a New Year Jump"", ""summary"": ""As the world bids adieu to one year and eagerly ushers in the next, the financial landscape comes alive with whispers of a phenomenon known as the January Effect. It\u2019s a time when astute investors set their sights on uncovering hidden treasures poised for a leap into the spotlight of profitability. Amidst this captivating speculation, three enigmatic entities loom on the edge of anticipation. The first one, a retail juggernaut, exerts a strategic blend that caters to the demands of do-it-yoursel""}]",{}
50,2023-12-24,105.67766571044922,2023-12-31,106.97288513183594,0.012256321264093373,U2,"[{""date"": ""20231224090000"", ""headline"": ""January Effect: 3 Under-the-Radar Stocks Poised for a New Year Jump"", ""summary"": ""As the world bids adieu to one year and eagerly ushers in the next, the financial landscape comes alive with whispers of a phenomenon known as the January Effect. It\u2019s a time when astute investors set their sights on uncovering hidden treasures poised for a leap into the spotlight of profitability. Amidst this captivating speculation, three enigmatic entities loom on the edge of anticipation. The first one, a retail juggernaut, exerts a strategic blend that caters to the demands of do-it-yoursel""}, {""date"": ""20231224192404"", ""headline"": ""Merck: One Of The Best - Unveiling The Trifecta Of Safety, Dividends, And Growth"", ""summary"": ""Merck & Co. is a drug manufacturer that has outperformed the healthcare ETF and the S&P 500 over the past decade. Read more about MRK stock here.""}, {""date"": ""20231225023000"", ""headline"": ""Merck: An Excellent Dividend Grower With Strong Annual Total Return Potential"", ""summary"": ""Merck posted healthy sales and non-GAAP EPS growth in the third quarter. Learn why MRK stock appears slightly undervalued.""}, {""date"": ""20231225042000"", ""headline"": ""Merck: Smart Value For Potentially Strong Total Returns"", ""summary"": ""Merck remains undervalued with a strong set of growing drugs and new indications in its pipeline. Read more about MRK stock here.""}, {""date"": ""20231225050302"", ""headline"": ""Capital Gain/Loss On Holdings And Trading Gain/Loss With Cash Cows"", ""summary"": ""I highlight the importance of trade income, capital gains, dividend collection, and tax harvesting in my investment approach. Read more here.""}, {""date"": ""20231225073300"", ""headline"": ""Looking Into Merck & Co's Recent Short Interest"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231226010400"", ""headline"": ""JN.1 Omicron strain becomes dominant COVID variant in U.S."", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231226070600"", ""headline"": ""What the Options Market Tells Us About Merck & Co"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231226090000"", ""headline"": ""Rethinking Immunotherapy for Cancer: When Is the Best Time to Stop?"", ""summary"": ""Immune-boosting drugs extend cancer patients\u2019 lives and deliver billions in sales to drugmakers, but some patients might be getting more of the drugs than they need.""}, {""date"": ""20231226113500"", ""headline"": ""Merck & Co. Inc. stock underperforms Tuesday when compared to competitors"", ""summary"": ""Shares of Merck & Co. Inc. slipped 0.06% to $107.63 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P...""}, {""date"": ""20231227025000"", ""headline"": ""Fusion Pharma climbs as  radiopharmaceutical company flagged as potential merger target"", ""summary"": ""Targeted-oncology specialist draws upgrade at Raymond James after big premium paid is for Rayze Bio.""}, {""date"": ""20231227185924"", ""headline"": ""20 Most Expensive Drugs in the World"", ""summary"": ""In this article, we will take a look at the 20 most expensive drugs in the world. If you want to skip our discussion on the pharmaceutical industry, you can go directly to the 5 Most Expensive Drugs in the World. The health of the global population is being adversely affected due to numerous factors, [\u2026]""}, {""date"": ""20231227211000"", ""headline"": ""Pharma and biotech deal values spike 35% in 2023: report"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231227220700"", ""headline"": ""Market Today: Pharma and Biotech Deal Values Surge Amid Patent Cliffs"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231228022800"", ""headline"": ""Common Investing Mistake: Income Obsession (& More)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231228032600"", ""headline"": ""Pharmaceutical Giants Brace for Showdown as Medicare Drug Price Negotiations Are Poised For 2024"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231228045400"", ""headline"": ""Merck (MRK) Shares Cross Above 200 DMA"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231228054400"", ""headline"": ""Interesting MRK Put And Call Options For February 2024"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231228060020"", ""headline"": ""Merck & Co., Inc. (NYSE:MRK) Shares Could Be 50% Below Their Intrinsic Value Estimate"", ""summary"": ""Key Insights Using the 2 Stage Free Cash Flow to Equity, Merck fair value estimate is US$215 Merck is estimated to be...""}, {""date"": ""20231228071214"", ""headline"": ""Vaxcyte: Looking Fully Valued"", ""summary"": ""Vaxcyte is a rising star in the stock market with a promising pneumococcal vaccine. Click here to find out if PCVX stock is a good value here.""}, {""date"": ""20231228080000"", ""headline"": ""5 Biggest Lawsuits in 2023 That Could Hit Your Wallet"", ""summary"": ""From the resumption of student loan repayments to charges against the world's largest cryptocurrency exchange, several 2023 court cases could affect consumers.""}, {""date"": ""20231228104500"", ""headline"": ""Nike, 3M share gains contribute to Dow's 119-point jump"", ""summary"": ""Powered by positive gains for shares of Nike and 3M, the Dow Jones Industrial Average is climbing Thursday afternoon. Shares of Nike and 3M are contributing...""}, {""date"": ""20231228113500"", ""headline"": ""Merck & Co. Inc. stock outperforms competitors on strong trading day"", ""summary"": ""Shares of Merck & Co. Inc. inched 0.73% higher to $108.77 Thursday, on what proved to be an all-around positive trading session for the stock market, with...""}, {""date"": ""20231228212800"", ""headline"": ""Can Moderna shares rebound in 2024?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231229010800"", ""headline"": ""Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231229083628"", ""headline"": ""15 Best Dow Stocks To Buy Now"", ""summary"": ""In this article, we discuss the 15 best Dow stocks to buy now. If you want to skip our detailed analysis of these stocks, go directly to 5 Best Dow Stocks To Buy Now. The Dow Jones Industrial Average, also known as Dow Jones or Dow, is one of the oldest and most followed equity [\u2026]""}, {""date"": ""20231229084746"", ""headline"": ""11 Best Psychedelic Stocks to Buy in 2024"", ""summary"": ""In this article, we discuss 11 of the best psychedelic stocks to buy in 2024. If you want to see more stocks in this selection, check out 5 Best Psychedelic Stocks to Buy. Unlike substances like marijuana or cocaine, psychedelics are potent and serve as a form of gateway to an \u2018alternate reality\u2019 for those [\u2026]""}, {""date"": ""20231229113500"", ""headline"": ""Merck & Co. Inc. stock outperforms market on strong trading day"", ""summary"": ""Shares of Merck & Co. Inc. inched 0.23% higher to $109.02 Friday, on what proved to be an all-around dismal trading session for the stock market, with the...""}, {""date"": ""20231230214947"", ""headline"": ""Bristol-Myers Squibb's Winning Formula: Dividends, M&A, And Innovation"", ""summary"": ""Bristol-Myers Squibb is a well-known blue-chip stock with a dividend yield exceeding 4.6%. Read why I'm rating BMY stock a Buy at this point.""}, {""date"": ""20231231052603"", ""headline"": ""Chevron, Kimberly-Clark Among 14 Companies To Announce Dividend Increases In January"", ""summary"": ""Investors celebrate double-digit increases for Mastercard and Broadcom.""}, {""date"": ""20231231052841"", ""headline"": ""Dividend Champion, Contender, And Challenger Highlights: Week Of December 31"", ""summary"": ""Stay updated on dividend activity with this weekly summary for Dividend Champions, Contenders, and Challengers.""}, {""date"": ""20231231054821"", ""headline"": ""MDA Breakouts In Best Year Ever: New Picks For Week 1 - 2024"", ""summary"": ""Discover the remarkable success of the MDA Breakout model, with impressive annual returns and advancements in algorithm for enhanced results in 2024.""}]",{}
